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Abstract
Malignant Mesothelioma (MM) is an aggressive tumour of the lung pleura with very 
poor patient prognosis. MM is unresponsive to all treatment regimes and over the 
next 30 years an estimated 100,000 fatalities will occur from this disease in Western 
Europe alone. MM is an extremely fibrous tumour containing abundant amounts of 
extracellular matrix, including collagen. Cell-matrix interactions are important for 
tumour progression and MM cells synthesise collagen as well as transforming growth 
factor-beta (TGF-p), a key regulator of collagen production. Thiaproline, a proline 
analogue, was used to inhibit collagen production in MM cells in vitro and in vivo to 
test the hypothesis that collagen is important for MM growth. Murine MM cells 
(AC29) were incubated with increasing concentrations of thiaproline with and without 
TGF-pi (lng/ml) and incorporation of tritiated thymidine and hydroxyproline levels 
measured as an index of cell proliferation and collagen production (nM 
hydroxyproline/106 cells) respectively. The effect of thiaproline on tumour growth 
(median weight, mg [range]) was determined in syngeneic mice subcutaneously 
injected in the flank with 106 MM cells. In vitro, lOmM thiaproline significantly 
reduced cell proliferation by over 65% (control 27400±3200; thiaproline 8950±1000 
dpm/well, p<0.001) and basal and TGF-Pi-induced collagen production by over 50% 
(control 1.6±0.1; thiaproline 0.7±0.1, p<0.005) and 60% (TGF-Pi 3.8±0.2; TGF- 
pi+thiaproline 1.3±0.1, p<0.005) respectively. At 10 days after injection of cells, 
lOOmg/kg/day thiaproline reduced median tumour weight by over 80% (control 58 
[30-105]; thiaproline 10.5 [5-12], p<0.01) but no significant difference was seen at 18 
days. To summarise, thiaproline inhibited MM cell proliferation, collagen production 
and delayed tumour growth, suggesting an important role for collagen in MM growth.
MM also secretes TGF-p, which regulates cell growth and collagen production. MM 
cells produce 30 -  70 times more TGF-p than untransformed normal mesothelial 
cells. To investigate the role of specific TGF-p isoforms in MM cell proliferation and 
collagen production and to determine the relative importance in tumour growth, 
selective neutralising antibodies to TGF-p i and TGF-p2 were used in conjunction with 
a pan-specific TGF-p antibody which neutralised all TGF-P isoforms. Through the 
use of the neutralising antibodies it was determined that the predominant isoform
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produced by AC29 cells into conditioned medium was TGF-P2 . TGF-p and control 
antibodies had no effect on AC29 cell proliferation or collagen production in vitro. 
TGF-P and control antibodies (5mg/kg) were injected intraperitoneally into the 
murine flank model of MM tumour growth at three-day intervals until the end of the 
experiment, when the tumours were resected and weighed. TGF-p2 antibody 
administered in vivo significantly decreased median tumour weight compared with 
PBS and control antibody (PBS control 67.5 [27-114], control antibody 57 [35-193], 
TGF-p2 antibody 27 [5-51], pcO.OOl for both controls). Pan-specific antibody 
reduced median tumour weight compared to PBS control (PBS control 46.5 [25-109], 
control antibody 36 [19-107], pan-specific TGF-p antibody 30 [14-66], p<0.05 vs. 
PBS control). Antibodies against TGF-P 1 had no effect on tumour growth. Collagen 
analysis of the tumours revealed a significantly lower concentration of collagen in the 
pan-specific antibody treated tumours (PBS control 9.11±0.76, pan-specific TGF-p 
antibody 4.03±0.68 nM hydroxyproline / mg tumour, p<0.0001). Collectively, this 
thesis has clearly demonstrated that TGF-P-induced collagen production may be an 
important aspect of MM tumour growth, and inhibition of either collagen production 
or TGF-p activity can delay MM tumour growth with a resultant decrease in tumour 
collagen content. A dual approach targeting both collagen and TGF-p production 
may be of benefit in the treatment of this disease in which the current therapies are 
inadequate.
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$  Additionally, repeated exposure to asbestos in certain professions such as 
carpentry and plumbing in conjunction with the biopersistence of asbestos fibres 
in the lung also contributes to the rising incidence (Miller et a l 1999).
1.1 Malignant mesothelioma
Lung and pleural cancer are responsible for more deaths than any other malignancy in 
the developed world and claim the lives of approximately 42,000 in the UK each year 
(Rintoul and Sethi, 2002). More than 3% of these deaths are caused by malignant 
mesothelioma (MM),.an extremely aggressive tumour of the mesothelial lining of 
serosal surfaces, occurring primarily in the lung pleura and strongly associated with 
exposure to asbestos (first implicated by Wagner in 1960). MM is characterised by an 
extremely fibrous extracellular matrix (ECM) invading the pleural cavity and 
encasing the lungs, causing shortness of breath and respiratory difficulties.
Patient prognosis is exceptionally poor with MM being almost always fatal. Median 
survival from diagnosis has been reported to range from 8 to 14 months (Chahinian et 
al. 1982, Antman et al. 1988, Ribak and Selikoff 1992). The current treatment is 
inadequate, with surgery, radiotherapy and chemotherapy showing little improvement 
in long-term patient survival. The incidence of MM has been increasing rapidly since 
its first description in the early 1960s. Mathematical modelling suggests that MM 
related deaths in Britain will continue to rise for the next 20 years, from the current 
annual total of 1500 to more than 3000 cases per year. This represents as much as 1% 
of all mortality for men bom in the 1940s, one of the worst affected cohorts (Peto et 
al. 1995). A recent report from the British Thoracic Society (2001) showed a 75% 
increase in MM deaths between 1988 and 1998, and over the next 35 years MM will 
be responsible for approximately a quarter of a million deaths in Western Europe 
alone (Peto et al. 1999).
There is a long latent period between the initial exposure to asbestos and death, with a 
study by Yates and colleagues (1997) suggesting a mean of 41 years. It is rare for1 
cases to appear less than 15 years after exposure (Doll and Peto, 1985). The extensive 
development time of MM accounts for the rising incidence, even 30 to 40 years after 
the enforcement of strict laws regulating the importation and use of asbestos.
MM is predominantly a male disease; from 1987 to 1991 the recorded death rate from 
MM in Britain was over 7 times higher in men than women (44 per million for males 
and 6 per million for females). The discrepancy between the sexes may be due to the 
higher risk of occupational exposure to asbestos in male dominated employment.
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Rates of incidence are higher in professions which involve greater contact with 
asbestos, such as construction, shipbuilding and carpentry (Peto et al., 1995). 
Asbestos use in Western Europe remained high until 1980 and large quantities are still 
used in some European countries today, as well as many developing countries, posing 
a very real threat to those exposed. Elucidation of the cellular mechanisms involved 
in MM progression will give greater insight into MM biology and may lead to the 
development of novel strategies to treat this terminal disease.
1.2 Pathogenesis of malignant mesothelioma
The exact cause of transformation from normal mesothelium to MM has not been 
determined. However, MM is strongly associated with a previous inhalation of 
asbestos fibres. Asbestos has been shown to have a number of properties and effects 
on cells that would be consistent with malignant transformation and tumourigenesis, 
which are detailed below.
1.2.1 The mesothelium
The mesothelium comprises a monolayer of flattened cells covering serosal cavities 
and organs, and provides a smooth frictionless surface facilitating movement within 
the body. Mesothelium covering the internal organs is referred to as the visceral 
mesothelium, whereas the parietal mesothelium lines the body wall. 
Embryologically, the mesothelium develops from mesodermal tissue by the gradual 
differentiation from round or cuboidal cells to elongated flattened cells lining the 
coelomic cavities (Hesseldahl and Larsen, 1969, Moore, 1982). Mesothelial cells 
have an epithelial like cobblestone morphology that changes to a more cuboidal 
appearance upon stimulation (Whitaker et al., 1991). Many studies provide evidence 
linking ECM components to enhanced tumour progression (examined in section 1.7). 
Mesothelial cells synthesise ECM-related proteins, including elastin, fibronectin, 
biglycan, decorin and collagen types I, m  and IV (reviewed by Mutsaers 2002). 
When cultured on bovine corneal endothelial cell ECM (a substrate closely 
mimicking human mesothelial subcellular basement membrane) mesothelial cells 
grow more densely and at a faster rate (Niedbala et al., 1986).
1 .2 .2  Asbestos minerals
Inhalation of asbestos fibres, the collective term for a group of naturally occurring
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fibrous minerals, is strongly linked to the malignant transformation of the 
mesothelium. There are two groups of asbestos minerals, serpentine and amphibole, 
both of which are capable of causing pulmonary disease. Chrysotile asbestos exists as 
bundles of ‘curly’ fibres that break down over time after the leaching of magnesium 
and silica (Jaurand et al., 1984). Amphibole asbestos is more durable in the lung and 
has straight rod-like fibres. Amphibole fibres have an iron content of approximately 
27%, greater than the 1 -  6 % found in chrysotile fibres mainly as a surface 
contaminant (Hardy and Aust, 1995).
Asbestos
Serpentine Amphibole
Chrysotile Actinolite Amosite Anthophyllite Crocidolite Tremolite 
‘white’ ‘brown’ ‘blue’
Figure 1.1 Classes of asbestos fibres
Serpentine asbestos accounts for over 95% of the world asbestos consumption 
(Landrigan, 1998), but is often found in association with amphibole ores. Chrysotile, 
derived from serpentine minerals, is also referred to as ‘white asbestos’. Amphibole 
minerals contain 5 species of asbestos (figure 1.1): actinolite, amosite (‘brown 
asbestos’), anthophyllite, crocidolite (‘blue asbestos’) and tremolite. Amphibole 
fibres are more toxic than chrysotile (Kamp and Weitzman, 1999) with crocidolite 
being the most pathogenic fibre in the induction of MM in humans (Mossman et al., 
1990).
The size and dimensions of fibres have been implicated in the pathogenicity of 
asbestos. Several animal studies have shown that long thin fibres (>5 pm) are more
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H: However, these studies involved the direct exposure of fibres to the lung pleura, 
which is not truly representative of inhaled fibre exposure.
fibrogenic and capable of inducing MM than short fibres (Lemaire, 1985, Platek et 
al., 1985, Davis et al., 1986). Additionally, longer fibres are more potent inducers of 
cytotoxicity (Goodglick and Kane, 1990), cell proliferation (Adamson and Bowden, 
1987, Woodworth et al., 1983), inflammation (Donaldson et al., 1989) and oxidant 
production (Mossman et al, 1989).
Interestingly, any fibre, regardless of chemical composition, with dimensions of <0.15 
|Lim in width and >8 pm in length is capable of inducing MM (Stanton et al, 1972, 
1977, 1981, Davis et ah, 1978, Suzuki, 1984). There are over a 100 natural fibrous 
minerals of these proportions as well as many man-made fibres (Leineweber, 1980). 
However, inhaled fibre concentration and durability in biological tissue affect the 
carcinogenicity of the fibres and therefore the only non-asbestos fibre to pose an 
oncogenic threat to humans is the mineral erionite (Rohl et al., 1982; Baris et al, 
1991, 1996). Several regions of Turkey have naturally high deposits of erionite, 
which is mined and used as a building material. In these villages MM is responsible 
for more than 50% of the total deaths (Emri et al, 2002).
Numerous animal models support the role of asbestos in tumour induction and 
demonstrate that administration of asbestos leads to the development of MM 
(Whitaker et al., 1984, Craighead et al., 1987, Walker et al., 1992, Davis et al., 1992). 
The exact mechanisms by which asbestos initiates cancer are unknown. Studies in the 
literature suggest that chromosomal aberrations, cell signalling pathway stimulation 
and the increased or uncontrolled production of growth factors and their receptors 
and inflammation may all be important.
1.2.3 Asbestos induces chromosomal abnormalities
Inhaled asbestos fibres accumulate heterogeneously in the lung, concentrating in 
“black spots” on the parietal pleura (Boutin et al., 1996) demonstrating that asbestos 
preferentially accumulates near the mesothelial layer with potential carcinogenic 
effects. Asbestos fibres can induce chromosomal damage in a wide variety of 
mammalian cells. Hesterberg and Barrett (1985) demonstrated in vitro using Syrian 
hamster embryo cells that asbestos fibres interfere with chromosomal segregation 
through physical interaction with the mitotic apparatus, thought to result in
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aneuploidy and other chromosomal aberrations. Chrysotile and crocidolite have been 
shown to induce chromosomal damage in rat mesothelial cells, including aneuploidy 
(Craighead et al, 1987), and translocations and deletions (Libbus and Craighead, 
1988). Also, human mesothelial cells exposed to asbestos have an increased number 
of numerical and structural chromosomal abnormalities (Olofsson and Mark, 1989).
Multiple chromosomal abnormalities are often observed in human MM, perhaps 
leading to the loss or inactivation of tumour suppressor genes or the activation of 
oncogenes. Frequent losses occur in many chromosomes such as 1 (Lee et al, 1996, 
Rozet et al, 1998), 6 (Bell et al, 1997, Ribotta et al., 1998), 13 and 14 (Bjorkqvist et 
al, 1999, De Rienzo et al, 2000), however no common abnormality has been 
observed in either animal or human MM. A study by Lu et a l (1994) showed that 
over 60% of samples from a series of human MM had an allelic loss at chromosome 
3p21, a deletion of which is associated with myeloid leukaemia (Weiser, 2002). 
Additionally, the DNA mismatch repair gene hMLHl is also localised to 3p21 and is 
mutated in hereditary colon cancer (Papadopoulos et al, 1994), suggesting a tumour 
suppressor role for this region of chromosome 3.
1.2.4 Asbestos generates reactive species
Rich in iron, asbestos fibres catalyse redox reactions that generate the production of 
reactive oxygen species (ROS), such as superoxide (O2’) and the hydroxyl radical 
(HO*), as well as reactive nitrogen species (RNS; Kamp et al, 1992, Mossman and 
Churg, 1998, Hardy and Aust, 1995). ROS and RNS can potentially damage proteins, 
cell membrane lipids, DNA and RNA leading to cellular dysfunction, cytotoxicity and 
malignant transformation (Kamp and Weitzman, 1999).
1.2.5 Asbestos stimulates cell signalling pathways
The mitogen-activated protein kinase (MAPK) signalling pathway involves a series of 
phosphorylation events, initiated by the extracellular signalling-related kinases 
(ERK), c-jun NH2 kinase (JNK), the stress-activated protein kinases (SAPK) or p38 
(Karin, 1995). The MAPK pathway can induce the expression of activator protein-1 
(AP-1) transcription factors, such as c-fos and c-jun, which interact with regulatory 
DNA sequences (Angel and Karin, 1991). Expression of both c-fos and c-jun is
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required for the transition of the cell cycle from Gi to the S phase leading to cell 
proliferation.
Crocidolite asbestos activates ERK in rat pleural mesothelial (RPM) cells, chelation 
of the surface iron abrogating this effect (Jimenez et al., 1997). This suggests that 
iron-catalysed redox reactions are important in asbestos-regulated cell signalling. 
Asbestos fibres induce phosphorylation of the ERK and MAPK pathways in human 
mesothelial cells and also directly autophosphorylate the epidermal growth factor 
receptor (EGER) leading to the triggering of the ERK cascade (Zanella et al., 1996). 
Faux et al. (2000) have demonstrated that RPM cells have an increased expression of 
EGFR upon phagocytosing long fibres of crocidolite and erionite. Intense staining for 
EGFR is seen after 24 hr, which later colocalises with proliferating cell nuclear 
antigen (PCNA) at 48 hr, suggesting that carcinogenic fibres induce EGFR which 
initiates cell signalling leading to cell proliferation.
Additionally, RPM cells exposed to asbestos exhibit a dose-dependent increase in c- 
fos and c-jun mRNA levels and a higher AP-1 DNA binding activity with increased 
cell proliferation (Heintz et al., 1993, Timblin et al., 1998). Sandhu et al. (2000) 
showed that upon asbestos treatment RPM cells upregulate the proto-oncogenes c- 
myc, fra-1 and EGFR. These studies suggest that the ability of asbestos to induce key 
regulators of the cell cycle may be important in the malignant transformation of the 
mesothelium.
1.2.6 Increased levels o f growth factors and receptors are present in mesothelioma
Compared with normal mesothelium, MM produces higher levels of many growth 
factors and cytokines, which may contribute to malignant growth. Additionally, the 
uptake of asbestos fibres by macrophages and mesothelial cells results in the release 
of a variety of cytokines and growth factors which can induce inflammation and 
further stimulate the release of cytokines (Branchaud et al., 1993, Kane 1992).
Transforming growth factor alpha (TGF-a) is a potent mitogen and inducer of 
inflammation. TGF-a is a member of the EGF superfamily and is also capable of 
binding to the EGFR to initiate intracellular cell signalling (Harris et al., 2002).
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Elevated levels of TGF-a are present in the serum of asbestosis patients with cancer, 
in some cases several years before the diagnosis of disease (Partanen et a l, 1995). 
Asbestos transformed rat mesothelial cells express functional EGFR and TGF-a, and 
neutralising antibodies to TGF-a inhibit the growth of these cells suggesting an 
autocrine growth loop (Walker et al, 1995), an effect also observed in human MM in 
vitro (Morocz et al., 1994).
Platelet-derived growth factor (PDGF) is a dimeric growth factor consisting of A and 
B chains, as well as the recently identified C and D chains (Li et al, 2000, Bergsten et 
al, 2001). Originally isolated from platelets, PDGF is a potent mitogen and 
chemotactic molecule, and is produced by several cell types including endothelial 
cells, fibroblasts, macrophages and osteoblasts (Matoskova et al., 1989). There are 
five identified isoforms of PDGF; PDGF-A A, -AB, -BB, -CC and -DD. Human MM 
cell lines produce PDGF A and B chains at higher levels than normal mesothelial cells 
(Gerwin et al, 1987, Versnel et al, 1988, Van der Meeren et al, 1993). Human MM 
cell lines express PDGF-P receptors (binding PDGF-AB, -BB and -DD) whereas 
normal mesothelium express predominantly PDGF-a receptors (Versnel et al, 1991), 
which have an affinity for all PDGF chains apart from D. A significant proportion of 
human MM were shown to express the PDGF-p receptor whereas non-neoplastic 
mesothelium did not (Ramael et al, 1992). This has also been demonstrated in rat 
MM (Walker et al, 1992). PDGF-BB is a chemoattractant for human MM cells 
(Klominek et al, 1998) and also stimulates MM to produce glycosaminoglycans 
(Tzanakakis et al, 1995). Transfection of human MM cells with a hammerhead 
ribozyme that cleaves PDGF B chain mRNA resulted in a decreased expression of 
PGDF B chain and decreased cell growth in vitro and in vivo (Dorai et al, 1994) 
suggesting a role for PDGF B chain in MM growth.
Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis 
and vascular permeability. Also, VEGF induces endothelial cell proliferation and 
causes vasodilation through the stimulation of nitric oxide synthase (Yang et al,
1996). VEGF is secreted by most cell types, such as platelets (Pinedo et a l, 1998) 
and fibroblasts (Gentilleti and Fava, 2003), but usually not by endothelial cells 
themselves. VEGF is at significantly higher levels in the conditioned medium of MM
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cell lines compared with normal mesothelial cells (Strizzi et al., 2001). Exogenous 
VEGF increased MM cell proliferation, and neutralising antibodies to VEGF or its 
receptors significantly reduced proliferation. VEGF is elevated in malignant pleural 
effusions (Zebrowski et al., 1999), and has been associated with angiogenesis in 
human MM (Ohta et al., 1999).
Hepatocyte growth factor / scatter factor (HGF/SF) is produced by mesenchymal and 
stromal cells, and acts in a paracrine fashion on malignant and non-malignant 
epithelial derived cells promoting proliferation, motility and invasion (Nishimura et 
al., 1999, Kuba et al., 2000, Gmyrek et al., 2001). Conditioned media from 
fibrosarcomatous or mixed phenotype MM cell lines contained HGF/SF which was 
absent in epithelial MM cell lines (Harvey et al., 1998). Immunoreactivity for 
HGF/SF has also been observed in tissue sections of human MM samples (Thirkettle 
et al., 2000), with an association between the expression of HGF/SF and it’s receptor 
(c-met) and increased microvessel density (Tolnay et al., 1998). Klominek et al. 
(1998) observed that human MM cell lines express c-met and that HGF/SF stimulates 
cell migration and proliferation.
The insulin like growth factor (IGF) family, produced primarily by the liver, consists 
of IGF-I, -II and proinsulin (Yu et al., 2003). Insulin acts on the liver, muscle and 
adipose tissue, whereas the IGFs enter the circulation and are important in functions 
throughout the body (LeRoith, 1997). Both IGFs are essential for embryonic growth, 
post-natally IGF-I is important in normal cell proliferation, differentiation and 
postnatal growth, although the physiological role of IGF-II is undetermined (LeRoith,
1997). There is an elevation of IGF-II associated with fibrous tumours of the pleura 
(Mori et al, 1999, Kerber, 2000). Also, IGF-I increased the production of ECM 
proteoglycans (shown to be associated with tumourigenesis in section 1.7) by human 
MM cell lines (Tzanakakis et al., 1996, Syrokou et al., 1999). In a hamster model of 
MM, temperature-inducible antisense to the IGF-I receptor reduced cell proliferation 
and the overexpression of the IGF-I receptor resulted in an increased number of 
tumours in vivo (Pass et al, 1996, 1998).
Interleukin 6  (IL-6 ) is a pleiotropic cytokine that is involved in the regulation of 
immune responses and haematopoiesis (Tilg et al., 1997). Many different cell types
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produce IL- 6  in response to infection, trauma or immunological challenge. 
Depending on the experimental system, IL- 6  has been shown to have both pro- and 
anti-inflammatory effects, although increasing evidence suggests a predominant 
immunosuppressive role for EL- 6  (Tilg et al., 1997). IL- 6  is elevated in pleural 
effusions taken from human MM patients (Monti et al., 1994) and is measurable in 
the conditioned media of primary MM cell lines in culture (Schmitter et al., 1992, 
Motoyama et al., 1993). A murine model of MM demonstrated increased levels of 
EL- 6  before macroscopically detectable tumour growth (Bielefeldt-Ohmann et al., 
1995). Also, antibodies to IL- 6  reduced the disease symptoms (cachexia, abdominal 
distension and diarrhoea) but not tumour growth. Interferon a  treatment reduced EL- 6  
at both the mRNA and protein level and increased the number of tumour infiltrating 
lymphocytes and macrophages, suggesting that IL- 6  is an immunosuppressor in MM 
leading to enhanced tumour growth.
Transforming growth factor-beta (TGF-P) is a multitalented cytokine, which has 
crucial developmental and homeostatic functions in an array of tissue types (section 
1.3). There is evidence that TGF-P levels are raised in MM. Kuwahara et al. (2001) 
have reported that rat MM cells produce 30 -  70 times more TGF-P than normal rat 
mesothelial cells. Also, Madea and co-workers (1994) investigated the levels of TGF- 
p in pleural effusions taken from MM and primary lung cancer patients, and found that 
TGF-p levels in MM were 3 - 6  times higher than in primary lung cancer. Fitzpatrick 
et al. (1994) have shown that MM cells produce both TGF-Pi and -P2 and that their 
inhibition with inducible antisense RNA reduced the anchorage-independent growth of 
MM cells in vitro and the tumourigenicity of MM cells in vivo. Additionally, Marzo 
et al. (1997) demonstrated that antisense oligonucleotides specific to TGF-P2 inhibit 
the in vitro and in vivo growth of MM. Collectively, these studies provide very strong 
evidence suggesting a key role for TGF-P in MM tumourigenesis.
In summary, the pathogenesis of MM is unknown. However, asbestos has been shown 
to induce chromosomal mutations and to stimulate cell signalling pathways. 
Additionally, aberrations in signalling pathways, growth factors and their receptors are 
observed in MM. One such growth factor, TGF-P, is found at extremely elevated 
levels in MM. Furthermore, TGF-P is the most potent stimulator of collagen
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A role for Simian Virus 40 in the development of MM has also been suggested, however 
this is controversial (literature reviewed by Carbone et a l 2003).
production characterised to date. These observations suggest that the elevated level of 
TGF-P associated with MM may be contributing to the extremely fibrous nature of 
this tumour with characteristically dense ECM. The role of TGF-P in MM, and other 
tumour settings, is reviewed in the following section.
1.3 Transforming growth factor-beta and tumourigenesis
The TGF-p superfamily consists of a large number of structurally related 
polypeptides. Members of this superfamily have a wide and varied role in the 
development, homeostasis and repair of virtually all tissues in organisms (Massague, 
1998). The TGF-P superfamily contains several subfamilies, including the bone 
morphogenic proteins (BMPs), growth and differentiation factors (GDFs), activins 
and the TGF-Ps.
The most widely studied member of the superfamily is TGF-P, of which there are 5 
known isoforms (TGF-P1-5). Three mammalian TGF-P isoforms exist, each encoded 
by separate distinct genes, and are expressed in a tissue specific fashion (Pasche, 
2001). There is high homology amongst the isoforms and they are tightly conserved 
between species indicating a critical biological function. TGF-P is a multifunctional 
cytokine regulating many key processes such as cell proliferation, differentiation, 
adhesion, motility, mobility, apoptosis, immune response, angiogenesis and ECM 
deposition (Hsu et al., 2002). Overproduction of TGF-P is known to lead to disease 
states where the accumulation of ECM is exaggerated. Due to the regulatory role of 
TGF-P and the recent elucidation of the TGF-p signalling pathway (section 1.3.1) 
there has been a great deal of interest in the role of TGF-P in tymour progression 
Elevated levels of TGF-p protein production have been found in association with 
many different tumour types, such as brain tumours (Chen et al., 1997), lung 
carcinomas (Kong et al., 1996), gastrointestinal malignancies (Saito et al., 1999, 
Ebert et al., 2000) as well as MM (Kuwahara et al., 2001, Madea et al., 1994). 
However, the role of TGF-p in promoting MM tumour growth has not been fully 
elucidated.
TGF-P is secreted from the cell in a latent dimeric complex consisting of the C- 
terminal mature TGF-P and an attached N-terminal pro-domain, LAP (latency
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associated peptide), bound together by disulphide bonds (Gentry et al, 1988). This 
complex is referred to as the small latent complex (SLC, figure 1.2). The interaction 
between TGF-p and LAP results in the inactivation of the biological activity of TGF- 
p; pi-LAP can inactivate all of the mammalian TGF-p isoforms with no isoform 
specific differences (Miller et al, 1992).
The SLC can also bind to latent TGF-p binding protein (LTBP); LTBP forms a 
covalent bond with the LAP portion of the SLC (Saharinen et al, 1999). When latent 
TGF-p associates with LTBP the whole complex is known as the large latent complex 
(LLC, figure 1.2). The LTBP portion of the LLC has been demonstrated to facilitate 
the binding of latent TGF- pi to the ECM (Taipale et al, 1994), and LTBP contains 
three domains shown to be capable of binding to human dermal or lung fibroblast 
matrices (Unsold et al, 2001). It has been found that most cell cultures secrete TGF- 
P as part of the LLC (Koli et al., 2001).
LAP
dimer
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Figure 1.2 Schematic representation of the large latent TGF-P complex. The
small latent complex (SLC) contains the C-terminal mature TGF-p and it’s N- 
terminal pro-domain, LAP (latency associated peptide). This complex associates with 
latent TGF-P binding protein (LTBP) via disulphide bonds to form the large latent 
complex (LLC). Modified from Annes et al. (2003).
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LTBP is a family of four separate genes which give rise to four main isoforms of 
LTBP (1 -  4), although splice variants do exist (Unsold et al., 2001). LTBP-1 is 
found with fibronectin and fibrillin-rich matrices (Taipale et al, 1996, Isogai et al., 
2003) and LTBP-2 is associated with microfibrillar structures and fibronectin-rich 
fibres (Koli et al., 2001). LTBP-3 is the smallest LTBP and can only be secreted 
from cells in association with TGF-Pi (Chen et al., 2002, Penttinen et al., 2002), and 
may be important in the secretion and targeting of TGF-Pi. The recently 
characterised LTBP-4 has also been shown to be ECM-bound and to be susceptible to 
proteolytic release by plasmin (Saharinen et al., 2002).
Matrix bound TGF-P is released from the LLC by multiple proteinases from the same 
family of serine proteases, including plasmin, cathepsin D, mast cell chymase and 
leukocyte elastase (Lyons et al., 1990, Taipale et al., 1992, 1995). It is believed that 
cleavage of LAP from the SLC to yield bioactive TGF-P also occurs at the same time 
(Koli et al., 2001). LAP can also be cleaved from the SLC by the a vP6 integrin. It 
has been demonstrated that (XvP6 integrin induces the activation of SLC associated 
TGF-P and that avP6 null mice exhibited exaggerated inflammation and are protected 
from bleomycin induced fibrosis, consistent with a decrease in active TGF-P (Munger 
eta l, 1999).
1.3.1 TGF-P mediated intracellular signalling
The predominant TGF-P signalling cascade, the Smad pathway, is outlined in figure 
1.3. TGF-P binds to the TGF-P cell surface receptor II (TpRII), part of a family of 
transmembrane glycoprotein receptors with large extracellular domains and a 
cytoplasmic serine/threonine kinase domain. The kinase activity of TPRII and 
subsequent association with TpRI are essential for TGF-P signalling (Wrana et al, 
1992). Once bound, TGF-p recruits TPRI into the complex to be transphosphorylated 
by TPRH allowing the phosphorylation of cytoplasmic substrates to proceed (Wrana 
et al, 1994). A third group of TGF-P receptors are also expressed on the cell surface, 
TPRID, although they are not directly involved in TGF-p signalling. TpRIH has two 
related members, endoglin and betaglycan, which are also transmembrane 
glycoproteins with large extracellular domains, but have a small intracellular portion
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Figure 1.3 TGF-p Smad mediated intracellular signal transduction. Activated 
Smad complexes translocate to the nucleus and associate with transcription factors, 
co-stimulators and repressors to drive transcription. TGF-p induces Smad7 
production, which inhibits R-Smad phosphorylation and prevents TGF-p signalling. 
Smad proteins are marked for degradation via proteosomes by ubiquitination.
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that has no kinase domain and no identifiable signalling function (Lopez-Casillas et 
al, 1993). TPRHI is considered to be an accessory receptor regulating the interaction 
of TGF-P with the functional signalling receptors (Wang et al, 1991). However, 
TpRin null mice develop lethal heart and liver defects in utero (S ten vers et al., 2003). 
Furthermore, cells cultured from the embryonic TPRIH knockout mice exhibit 
reduced sensitivity to TGF-P2-induced growth inhibition and reporter gene activation, 
effects not observed with the other TGF-p isoforms. These results suggest an 
important role for TPRIQ in mediating TGF-P2 function.
The Smad family of signalling molecules mediates BMP / TGF-p intracellular 
signalling from the activated receptor complex. The mammalian family of Smads 
consists of 8  structurally related proteins, Smadl to Smad8 . Based on function, the 
Smads can be divided into three groups (Hill, 1999), receptor-regulated Smads (R- 
Smads), the common mediator Smad (co-Smad) and inhibitory Smads (anti-Smads). 
BMP signalling is mediated by R-Smads 1, 5 and 8  and anti-Smad6  whereas TGF-p 
signalling is mediated by R-Smads 2 and 3 and anti-Smad7 (Piek and Roberts, 2001). 
Both pathways use Smad4 as the co-Smad.
During TGF-P signalling, the intracellular portion of the TpRII/I activated complex 
associates with R-Smads, which become phosphorylated themselves (Wrana et al, 
1994). The chaperone protein SARA (Smad Anchor for Receptor Activation) 
localises co-Smads to the cell membrane and recruits them to the activated TpRII/I 
complex (Wu et al, 2000). After dissociation from the receptor the activated R-Smad 
associates with the co-Smad, Smad4, and this complex translocates to the nucleus and 
initiates transcription (Nakao et al, 1997a). Anti-Smads can form a stable association 
with the activated TpRI thereby blocking the association and subsequent activation of 
R-Smads (Nakao et al, 1997b). Smad7 mRNA remains localised with the nuclear 
membrane, but is translocated to the cytoplasm upon TGF-P 1 stimulation (Itoh et al,
1998). Smad7 mRNA is highly induced by TGF-pi, stimulated by Smad3/4 binding 
to the Smad7 gene promoter and initiating transcription (Nagarajan et al, 1999). This 
demonstrates that Smad7 is part of a negative feedback loop regulating TGF-P 
responses.
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Upon nuclear transportation, the phosphorylated Smad complex binds to the ‘Smad 
box’ within a gene promoter, a GTCT rich motif that drives transcription (Johnson et 
al., 1999). The Smad complex can interact with an array of transcription factors and 
transcriptional co-stimulators or co-repressors, the balance of which allows tight 
control of TGF-(3-induced transcription. The transcription factor CREB binding 
protein (CBP) / p300 assists Smad-induced transcription. Studies have demonstrated 
that inhibition of CBP function decreased the level of TGF-(3-induced transcription 
(Feng et al., 1998). Smads can also bind directly to transcription factors from the Jun 
family of AP-1 transcription factors (Liberati et al., 1999). The oncoprotein Evi-1 
interacts with Smad3 and inhibits Smad3 and Smad3/4 transcriptional activation 
(Kurokawa et al, 1998). The proto-oncoprotein Ski prevents association of Smad2/3 
complex with CBP / p300 thereby preventing TGF-p transcriptional activation 
(Akiyoshi et al, 1999). The proto-oncoprotein SnoN also reduces TGF-P 
transcriptional activity. Overexpression of SnoN in human foetal kidney cells has 
been shown to repress Smad3 transcriptional activity (Sun et al., 1999). 
Phosphorylated R-Smads are ubiquitinated in multiple sites in response to TGF-p, and 
the nuclear accumulation of ubiquitinated Smads results in their degradation by 
proteasomes (Lo and Massague, 1999).
The Smad pathway is recognised as the predominant TGF-P mediated intracellular 
signalling cascade, but TGF-p can also signal via the MAPK and ERK pathways 
(reviewed by Mulder, 2000). There is likely to be cross talk between the different 
signalling pathways allowing further cellular control of TGF-P signal transduction. 
Smad signalling and MAPK/JNK signalling converges at API-binding promoter sites 
with a co-operation between the two signalling pathways to mediate TGF-P-induced 
transcription (Zhang et al, 1998). TGF-P induces an association of c-Jun and c-Fos 
(JNK pathway intermediates) with Smad3 (Engel et al., 1999). Both Smad and JNK 
pathways may be required for the full signalling response as stimulation of the JNK 
pathway alone resulted in a lower transcriptional activity when compared to activation 
of both pathways together (Engel et al., 1999).
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1.3.2 TGF-Pfunction
TGF-(3 has a multifunctional physiological role initially playing a vital role in 
specifying developmental fate. TGF-P isoforms are expressed differentially during 
development and the differing phenotypes of the TGF-Pi, -P2 and -P3 null mice 
provide evidence for distinct TGF-P isoform roles in vivo (Shi et al., 1999). 
Approximately three weeks after birth, TGF-P 1 null mice develop a progressive 
wasting disease leading to death, and examination reveals a massive autoimmune 
inflammation affecting multiple organs such as the heart, lungs, and salivary glands 
(Shull et al., 1992). TGF-Pi null SCID mice exhibited no inflammation and survived 
well into adulthood (Diebold et al., 1995). This suggests the importance of TGF-P 1 in 
suppressing inflammation. Also, when treated with carcinogens, TGF-P 1 
heterozygous mice have an increased development of lung and liver cancers, 
implicating TGF-Pi as a tumour suppressor (Tang et al, 1998).
Two-thirds of TGF-P2 null mice die prenatally and the remaining third are bom with 
impaired oxygen perfusion and die shortly after birth with cardiovascular, skeletal and 
craniofacial defects (Sanford et al, 1997). There is little phenotypic overlap with the 
other TGF-P isoform null mice suggesting numerous non-compensated functions for 
TGF-P2 . Targeted disruption of murine TGF-P3 results in death within 24 hr of birth 
due to abnormal pulmonary development, and the pups exhibit a cleft palate 
(Kaartinen et al., 1995). Disruption of the murine TPRII gene causes early embryonic 
lethality and hyperplasia of T-cells resulting in the expansion of lymph nodes and 
spleen (Oshima et al, 1996, Lucas et al., 2000).
TGF-Pi is the most well characterised isoform. Experimentally, isoform specific 
effects of TGF-P have not been conclusively established, although the differing 
phenotypes of the TGF-P knockout animals suggests that there may be non­
overlapping functions of the different TGF-P isoforms. Shah et al. (1995) have 
shown that the neutralisation of endogenous TGF-P 1 and -P2 reduced scarring in a rat 
model of wound healing, an effect also achieved by the application of exogenous 
TGF-P3. This suggests that TGF-Pi and -p2 have a different role to TGF-P3 in wound 
healing.
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Cell transformation
In culture TGF-P can initiate the transformation of epithelial cells into fibroblastoid 
cells, a process termed epithelial to mesenchymal transformation (EMT) (Miettinen et 
al., 1994). EMT is essential to the malignant transformation of early stage tumour 
cells into fully malignant and invasive carcinomas, the acquisition of fibroblastoid 
features enhancing stromal and vascular invasion (Oft et al., 1996). Cui et al. (1996) 
demonstrated in a TGF-P i over-expressing murine model of skin carcinogenesis that 
TGF-Pi initially was a tumour suppressor inhibiting malignant transformation. 
However, in those animals that did develop skin tumours the malignant conversion 
rate was greatly increased, with a much higher incidence of the more malignant 
spindle cell carcinomas. Further evidence for the importance of TGF-P in EMT has 
been demonstrated by Portella et al. (1998). Keratinocytes cultured with TGF-Pi 
were transformed to a malignant metastatic keratinocyte cell line. When cloned and 
injected subcutaneously into nude mice the cell lines spontaneously converted to a 
fibroblastoid phenotype. However, those clones that had been stably transfected with 
a dominant negative TPRII were unable to undergo this mesenchymal switch in vivo, 
demonstrating the importance of an intact TGF-P signalling pathway in EMT. 
Additionally, the induction of Raf, a serine/threonine protein kinase which activates 
the ERK/MAPK pathways, increased TGF-p production in Madin-Darby Canine 
Kidney (MDCK) epithelial cells (Lehmann et al., 2000). The increase in TGF-p 
production resulted in EMT of the MDCK cells, whilst also inhibiting TGF-P-induced 
apoptosis. The invasive behaviour of the MDCK cells through collagen type I gels 
was also enhanced. Although untested in MM, these studies demonstrate that TGF-P 
may advance tumour progression by the stimulation of EMT, whilst suppressing 
apoptosis and increasing cell migration.
Cell proliferation
TGF-P has varying effects on cell proliferation, depending on both the cell type and 
the concentration of the growth factor. All three mammalian TGF-P isoforms inhibit 
the proliferation of epithelial and endothelial cells (Cheifetz et al., 1990). TGF-Pi is a 
potent inhibitor of epithelial cell proliferation, reducing the expression of cyclin 
dependent kinase (cdk) genes, such as c-myc and KC, which drive the cell cycle past 
checkpoints (Howe et al., 1991, Coffey et al., 1988). TGF-P also exerts growth
36
inhibitory effects by inducing the expression of cell cycle progression suppressor 
proteins such as cdk inhibitor p27Kipl (Polyak et al., 1994).
TGF-p has been demonstrated to have concentration dependant effects on several cell 
lines. For example, TGF-P stimulated fibroblast (Kimura et al., 1989) and smooth 
muscle cell (Battegay et al, 1990) proliferation at low concentrations, but inhibited 
proliferation at higher concentrations. Additionally, the culture of human 
subconjunctival fibroblasts with an optimal concentration of TGF-P (10' 6 mM) 
increased proliferation and migration, but concentrations above or below this peak 
decreased proliferation and migration (Cordeiro et al., 2000). These observations 
demonstrate that TGF-P has biphasic effects on cell proliferation.
TGF-pi induces the production of prostaglandin E2 (PGE2) in human fibroblasts, 
which inhibits cell proliferation and collagen production (Keerthisingam et al, 2001). 
TGF-p-induced anti-proliferative effects have also been observed in a human breast 
cancer cell line (Fenig et al., 2001). In this study, endogenous TGF-Pi stimulated the 
production of bFGF, which reduced the proliferation of the cancer cell line.
The stimulatory effect of TGF-p on murine cell proliferation in culture has been 
attributed to induction of autocrine PDGF. This in turn causes upregulation of c-fos 
and c-myc, both of which are important for the Gi to S phase transition of the cell 
cycle (Leof et al, 1986). TGF-p 1-induced proliferation of human foreskin fibroblasts 
in culture was blocked with PDGF antibodies (Soma and Grotendorst, 1989). 
Furthermore, the subcutaneous injection of TGF-Pi into rat skin resulted in an 
upregulation of PDGF expression in vivo, further supporting the role of PDGF in 
TGF-p-induced proliferation. Additionally, in human fibroblasts TGF-Pi has been 
demonstrated to induce the production of CTGF which is a potent fibroblast mitogen 
(Howell et al., 2001).
Interestingly, studies on rat and murine MM have shown that neither endogenous nor 
exogenous TGF-P altered MM cell proliferation compared to the controls (Fitzpatrick 
et al., 1994, Kuwahara et al., 2001). This suggests that the pro-tumourigenic effects
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of TGF-P in MM act independently of proliferation, perhaps by suppressing the 
immune response, or enhancing angiogenesis and ECM production.
Immune suppression
Evasion from the host immune system allows the rapid unchecked proliferation of 
malignant growths that would otherwise be targeted by inflammatory cells. The most 
dramatic example of the importance of TGF-P in immune suppression is evidenced in 
the TGF-pi null mice which die shortly after birth from autoimmune disease (Shull et 
al., 1992). TGF-p is a potent inhibitor of cytotoxic T-lymphocyte (CTL) generation 
from mixed lymphocyte cultures and inhibits their proliferation (Ranges et al, 1987). 
The overexpression of TGF-P i in an UV-induced fibrosarcoma murine tumour cell 
line by cDNA stable transfection resulted in enhanced tumourigenicity due to evasion 
of host T-cell mediated tumour cytotoxicity (Torre-Amione et al., 1990). The 
expression of antisense oligonucleotides against TGF-pi and TGF-P2 in a murine MM 
cell line reduced in vivo tumourigenicity and also increased the number of tumour 
infiltrating CTLs (Fitzpatrick et al, 1994). Evidence suggests that TGF-P may have 
biphasic effects on CTLs, at low concentrations stimulating proliferation (Kondo et 
al., 1993) whilst at higher concentrations inhibiting proliferation (Beck et al., 2001). 
These observations suggest that the high levels of TGF-P observed in MM are 
immunosuppressive, promoting tumour growth. However, this section demonstrates 
that TGF-P has many protumourigenic properties, and other TGF-P related effects 
aside from immune suppression might be promoting MM tumour growth.
Apoptosis
TGF-P is a potent inducer of cell death, the initiation of apoptosis in cells of the 
immune system contributing to its immunosuppressive properties. Although no 
evidence exists for TGF-P-induced apoptosis in MM, this has been observed in other 
tumours. TGF-P induces growth arrest and apoptosis in human lymphocytes 
(Chaouchi et al, 1995, Lomo et al, 1995). The induction of apoptosis in a B-cell 
lymphoma cell line has been demonstrated to be Smad pathway dependent. 
Retroviral transfection with dominant negative Smad2 or Smad3 blocked TGF-p 
mediated apoptosis and also retroviral overexpression of the inhibitory Smad7 
protected against apoptosis in a dose-dependent fashion (Patil et al., 2000). This has
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also been demonstrated in hepatocytes, myeloid and epithelial cells (Yamamura et al., 
2000). The balance of pro- and anti-apoptotic factors determines cellular fate 
(Schuster and Krieglstein, 2002). Saltzman et al (2002) demonstrated in a B-cell 
lymphoma cell line that TGF-P decreased the expression of the anti-apoptotic protein 
BCL-Xl, a member of the BCL-2 family, whilst stimulating the apoptotic caspase 
pathway.
Several tumour cell lines respond to TGF-p-induced apoptosis. The expression of a 
truncated TPRII in a breast carcinoma cell line resulted in resistance to TNF-a- 
induced apoptosis, with molecular analysis revealing an alteration in the expression of 
BCL-2 protein expression (Tobin et al, 2001). The transfection of a murine glioma 
cell line with TGF-Pi enhanced the level of TNF-a mediated apoptosis in vitro and 
improved survival rates in an in vivo murine glioma model (Ashley et al., 1998). 
Treatment of glioma and trigeminal neurinoma cells with TGF-Pi in vitro resulted in 
an inhibition of cell proliferation followed by cell rounding and detachment leading to 
apoptosis (Marushige and Marushige, 1994).
Although a clearly defined pro-apoptotic role for TGF-P is evident in the literature, 
Lei et al (2002) observed in a breast cancer cell line that inhibition of TGF-P by 
expression of soluble TpRIII resulted in an increase in apoptosis, suggesting that in 
this case TGF-P inhibits apoptosis. The role of TGF-P suppressed apoptosis in MM is 
unknown, although MM produces elevated levels of TGF-p in comparison to normal 
mesothelial cells and other primary tumours (Fitzpatrick et al., 1994, Maeda et al., 
1994). It is possible that the high levels of TGF-P produced by MM may inhibit 
apoptosis occurring in the tumour cells and thereby enhance tumour growth.
Angiogenesis
Angiogenesis is essential for malignant growth beyond 1 - 2  mm in diameter 
(Edwards et al., 2001). Tumour-induced neovascularisation ensures an adequate 
supply of nutrients to the growing tumour and also increases the rate of metastasis, 
where cells detached from the primary tumour are able to reach the blood system and 
travel to distant sites. TGF-P stimulates angiogenesis by a combination of direct and 
indirect effects. For example, the angiogenic factor VEGF is induced by TGF-P
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(Pertovaara et al., 1994). Also, the increase in ECM production by TGF-p may be 
important in vascularisation, as TGF-P treated endothelial cells grown in collagen gels 
were stimulated to form tube-like vessel structures (Madri et al., 1988). TGF-P can 
also recruit inflammatory cells, connective tissue cells and epithelial cells that express 
VEGF in response to TGF-P (Roberts and Spom, 1989). VEGF can directly stimulate 
the migration and invasion of endothelial cells in culture through a collagen matrix 
(Vernon and Sage, 1998). Neutralising antibodies to TGF-P reduced the number of 
vessels observed histologically within human prostate cancer solid tumours in a 
subcutaneous murine flank model (Tuxhom et al, 2002). Elevated levels of TGF-P 
have been shown to be significantly correlated to increased angiogenesis and worse 
patient prognosis in human colorectal carcinomas (Xiong et al, 2002) and to 
increased microvessel density and depth of tumour invasion in human gastric 
carcinomas (Choi et al, 1997). The importance of TGF-P mediated angiogenesis to 
MM growth is unknown.
ECM elaboration
The ECM is a prerequisite for malignant tumour growth (Dvorak, 1986). There is a 
wealth of data in the literature suggesting the importance of ECM components in 
malignant progression (reviewed in section 1.7). TGF-P has a major role in the 
regulation of ECM formation, degradation and remodelling (Kingsley, 1994). Also, 
TGF-P strongly stimulates the expression of many different matrix proteins, such as 
fibronectin, vitronectin, tenascin, elastin, proteoglycans and collagen (Saharinen et 
al., 1999). All isoforms of TGF-P are potent stimulators of collagen production in 
vitro (Coker et al. 1997). Exogenous TGF-P has been shown to increase the mRNA 
stability of ECM components collagen, fibronectin and thrombospondin in confluent 
cultures of murine 3T3 cells, which results in a higher yield of protein product 
(Penttinen et al., 1988).
Smads 3 and 4 have been demonstrated to be crucial for the TGF-P mediated 
transcription of human collagen genes (Vindevoghel et al, 1998, Chen et al, 2000a). 
In the case of the a2(I) collagen gene a Smad3 DNA binding site within the gene 
promoter was identified, which when disrupted led to a decrease in a2(I) collagen 
transcription (Chen et al., 2000a). Also, Vindevoghel et al. (1998) have demonstrated
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that TGF-P induced transcription of the human type VII collagen gene (COL7A1) 
promoter is dependent upon Smad4 in breast carcinoma cells. Additionally, Chen et 
al. (1999, 2000a) have shown that the interaction of Smad3 with the human a2(I) 
procollagen gene promoter is required for the full TGF-P transcriptional response in 
fibroblasts.
A study by Nakao et al. (1999) provides further evidence demonstrating TGF-P- 
induced collagen production. It was shown that adenovims mediated expression of a 
Smad7 transgene (preventing TGF-P signalling) significantly suppressed bleomycin- 
induced fibrotic changes in mice, with a reduction in type I procollagen mRNA 
production, hydroxyproline content and Smad2 phosphorylation. Interestingly, 
Smad7 expression did not affect the numbers of macrophages, lymphocytes or 
neutrophils in the BALF.
TGF-P also increases the turnover of the ECM by repressing the synthesis of TIMPs 
(potentially increasing MMP-induced degradation) and increasing the activity of lysyl 
oxidase, an enzyme vital for the stability of collagen which catalyses cross-link 
formation (Feres-Filho et al., 1995). TGF-p decreases the proteolytic activity of cells 
by increasing the expression and secretion of several proteases and protease regulators 
such as matrix metalloproteinases, plasmin, plasmin activators and plasmin activator 
inhibitor (Massague, 1998).
TGF-P itself can be associated with the ECM in a latent form through LTBP (Taipale 
et al., 1994) and can be released by matrix degrading proteinases (Lyons et al., 1990, 
Sato et al., 1990). Interestingly, there appears to be a feedback mechanism whereby 
the formation of ECM decreases TGF-Pi gene expression (Streuli et al., 1993), 
thereby limiting further ECM deposition. However, MM is phenotypically extremely 
fibrous with a matrix rich in collagen, and also produces high levels of TGF-p, 
suggesting that this feedback loop is not present. The combination of elevated TGF-P 
and ECM present in MM provides a large reservoir of TGF-P within the tumour 
vicinity that may exert pro-tumourigenic effects. Possible mechanisms by which 
TGF-P could promote tumour growth are detailed below.
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1.3.3 Mechanisms for the promotion o f tumourigenesis by TGF-p 
As described above, TGF-P is a potent inhibitor of cell proliferation and can also 
induce apoptosis. However, in some carcinomas a switch occurs during the malignant 
process and the tumour suppressor functions of TGF-P are blocked. The growth 
inhibitory and apoptotic effects are lost whilst other TGF-P responses that are 
beneficial to tumour growth, such as the promotion of angiogenesis and ECM 
production, remain intact (Akhurst, 2002). The role of TGF-pi on early and late 
malignant growth was investigated in a model of skin carcinoma using TGF-Pi 
overexpressing transgenic mice (Cui et al, 1996). During the early stages of 
malignancy TGF-Pi acted as a tumour suppressor inhibiting malignant conversion. 
However, overexpression of TGF-p i in established tumours resulted in a more 
invasive phenotype. This study demonstrated a bimodal action of TGF-Pi in 
melanoma tumour spread, as during early tumour growth TGF-P i was growth 
inhibitory but stimulatory at later stages.
How does this switch from growth inhibition to tumour promotion in response to 
TGF-P occur? High expression levels of TPRII are important for inhibition of cell 
proliferation, whereas the production of tumour promoting ECM components are 
retained at low TpRII levels, suggesting that a higher intensity of TGF-P signalling is 
required for proliferation modulation responses (Chen et al., 1993, Cui et al, 1995). 
Also, Smad2 and Smad3 knockout mice have different phenotypes suggesting that 
they exert different roles in TGF-P signal transduction (Waldrip et al., 1998, Datto et 
al., 1999). Thus, the balance of activated TPRII/I and Smad 2/3 may be important in 
determining downstream signalling targets (Piek and Roberts, 2001). Therefore, 
mutations or alterations in the expression of TGF-p signalling pathway components 
may result in a change in TGF-P response, such as loss of the tumour suppressing 
inhibition of cell growth whilst retaining responses contributing to malignant growth.
TGF-P and related signalling pathway components are altered in a host of 
malignancies. Elevated production of TGF-P resulting in an increased tumour growth 
rate in vivo has been demonstrated in breast carcinoma (Tobin et al., 2002), prostate 
cancer (Steiner and Barrack, 1992) and sarcoma (Chang et al, 1993). Also, as
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previously mentioned, MM produces highly elevated levels of TGF-P in comparison 
to normal mesothelial cells and other tumours (Kuwahara et al., 2001, Madea et al., 
1994), although the role of TGF-P in MM growth is not fully understood.
Resistance to the tumour suppressor functions of TGF-P in malignant growth occurs 
through a variety of mechanisms. Mutations in the TGF-P receptors would alter 
downstream signalling. Mutations in the TPRII gene occur in colon cancers (Grady et 
al, 1999), gastric tumours (Yang et al., 1999), lung adenocarcinoma (Kim et al., 
1999, 2000) and lowered levels of the receptor are observed in small cell lung 
carcinomas (de Jonge et al., 1997). However, no studies have been conducted to 
determine the presence of any mutation in the TGF-P signalling pathway in MM.
Altered expression of TpRI or TPRH can also lead to TGF-P resistance in human 
tumours. A down-regulation of TPRI and II was found in a study on human 
colorectal carcinomas (Matsushita et al., 1999). A decrease in TPRII expression was 
demonstrated in prostate cancer (Williams et al., 1996). Complete loss of TPRI and 
TPRD were observed in a series of human T-cell lymphomas, along with a marked 
decrease in TPRD mRNA production (Kadin et al., 1994).
Inactivating mutations or alterations in TGF-P signalling pathway intermediates leads 
to a TGF-P resistant state. Mutations in Smad4 are found in approximately 50% of 
pancreatic cancers (Chiao et al, 1999) and also occur in gastric (Powell et al., 1997) 
and colorectal carcinomas (Miyaki et al., 1999). Yanagisawa et al. (2000) have 
described Smad2 and Smad4 mutations in human lung cancers. Hu et al. (2000) have 
demonstrated a decreased expression of Smad4 in ovarian cancer which may lead to a 
decrease in the intensity of TGF-P signalling. These mutations in the signalling 
pathway of TGF-p may suppress the anti-proliferative effects, whilst signalling 
through the MAPK and ERK pathways may promote pro-tumourigenic properties. 
For example, an inhibitor of TGF-Pi-induced MAPK and ERK signalling prevented 
human ovarian cancer cell invasion into matrigel, suggesting that TGF-P-induced 
signalling via these pathways promotes tumour invasion (Kobayashi et al., 2003).
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A study of TGF-p mediated inhibition of proliferation in human glioma cell lines 
demonstrated that Smad3 stimulated a cyclin dependent kinase inhibitor to stop the 
cell cycle, although this inhibitor was mutated in the majority of the carcinoma cell 
lines (Rich et al., 1999). However, most of the cell lines retained other pro- 
tumourigenic responses to TGF-P, such as ECM production and the secretion of 
angiogenic cytokines, all of which would contribute to malignant growth. Kleeff et 
al, (1999) have shown that Smad7 mRNA levels are increased in human pancreatic 
cancer cells in comparison with normal pancreatic tissue. As Smad7 is an antagonist 
of TGFP signalling, overexpression would prevent TGF-P signalling and inhibit anti­
proliferative effects.
1.3.4 Inhibition o f TGF-p as an anti-tumour strategy
As demonstrated above, there is a wealth of literature documenting the escape of 
tumour cells from the inhibitory effects of TGF-P on proliferation and apoptosis. In 
these cases the production of TGF-p by tumour cells and stromal cells contributes to 
late stage tumour progression and therefore inhibition of the elevated levels of TGF-P 
in MM or related downstream signalling elements could be beneficial in the treatment 
of this disease.
TGF-p activity can be inhibited by using recombinant soluble betaglycan (TPRIH) as 
a neutralising agent (Vilchis-Landeros et al., 2001). Recombinant soluble betaglycan 
reduced tumour growth and metastasis in a model of human breast cancer 
(Bandyopadhyay et al, 2002) with an associated decrease in angiogenesis. A soluble 
chimeric protein containing a portion of the TPRII when administered 
intraperitoneally increased mammary tumour apoptosis and reduced tumour cell 
intravasation and lung metastases in a transgenic murine model of breast carcinoma 
(Muraoka et al., 2002). Soluble TPRII was also demonstrated to inhibit TGF-P 
signalling in human pancreatic cancer cell lines and reduced tumour growth and 
vascularisation in a subcutaneous murine model (Rowland-Goldsmith et al, 2001).
Decorin is a small leucine-rich glycoprotein capable of binding to and neutralising 
TGF-P (Hildebrand et al, 1994). Overexpression of decorin in vivo reduced TGF-P 
induced lung fibrosis (Kolb et al., 2001). Decorin expressed ectopically in glioma
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cells reduced TGF-P bioactivity and the expression of TGF-Pi and TGF-P2 mRNA 
and protein synthesis as well as strongly inhibiting tumour formation in vivo (Stander 
et al., 1998).
Inducible antisense oligonucleotides to TGF-P 1 and TGF-P2 have been shown to 
reduce the mRNA expression of these isoforms when transfected into murine MM cell 
lines (Fitzpatrick et al,. 1994). A murine MM cell line transfected with TGF-P2 
inducible antisense oligonucleotides exhibited reduced proliferation in vitro and an 
inhibition of tumour growth was observed when these cells were introduced into a 
murine model of MM (Marzo et al, 1997). Also, in a Fisher 344 rat spontaneous MM 
cell line, antisense oligonucleotide-mediated inhibition of TGF-Pi was shown to 
decrease the basal level of TGF-P 1 production and both the anchorage dependent and 
independent in vitro rate of proliferation (Kuwahara et al., 2001). TGF-P is a potent 
inducer of collagen production, and collagen has been demonstrated to promote 
tumourigenesis (section 1.7). Therefore, TGF-P-induced collagen production may be 
important to MM growth. However, the effect of neutralising TGF-P on MM ECM 
production was not examined in any of the above studies.
Monoclonal antibodies have been hailed as “magic bullets” in the treatment of disease 
due to their ability to be delivered systemically and still target and neutralise specific 
molecules without harming healthy neighbouring cells (Gura, 2002). A large area of 
monoclonal antibody research is focussed on cancer treatment. The use of TGF-P 
monoclonal antibodies has primarily centred on reducing the pro-fibrotic effect of the 
TGF-P isoforms, and would thus be suited for examining the effect of TGF-P-induced 
collagen production in MM growth. For example, TGF-pi and -P2 antibodies 
administered to a rat model of cutaneous scaring reduced collagen deposition (Shah et 
al., 1995). The Cambridge Antibody Technology TGF-P2 antibody (CAT-152) has 
been extensively characterised (Thompson et al., 1999). This antibody inhibits TGF- 
P2 function by associating with TGF-P2 , which prevents TPRD binding. CAT-152 
reduced scarring in a rabbit model of glaucoma surgery and the same antibody 
reduced the ECM remodelling associated with TGF-P2 in human cataract formation 
(Cordeiro et al., 1999, Wormstone et al., 2002). Also, antibodies to TGF-P2 , and all 
TGF-P isoforms, have also been successfully used to reduce the matrix expansion and
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fibrosis in diabetic rat and mouse in vivo models (Hill et al, 2001, Ziyadeh et al., 
2000).
In summary, TGF-(3 is a multifunctional cytokine with multiple tumour enhancing 
properties, and is found at elevated levels in MM. Inhibition of TGF-p in MM using 
inducible antisense reduced tumour growth through increased immune surveillance. 
The role of TGF-p-induced angiogenesis, apoptosis and ECM production in MM 
growth is unknown. Also, TGF-P potently stimulates collagen production, and 
collagen promotes tumour growth (see section 1.7). The use of TGF-P antibodies 
would provide insight into the importance of TGF-P-induced ECM production to MM 
growth. The principle components of the ECM, and their pro-tumourigenic properties 
are described in the following sections.
1.4 Extracellular matrix components
Animal cells secrete ECM components, which form a complex network of proteins 
and carbohydrates filling the space between cells ‘gluing’ tissue together. The ECM 
determines the mechanical properties of tissue, provides a scaffold for the attachment 
of cells and acts as a reservoir for many growth factors and cytokines controlling cell 
growth, migration and differentiation (Boudreau and Bissell, 1998). The ECM also 
provides a structure on which cells proliferate and migrate. The proteins of the ECM 
consist of several families of molecules, the bulk of which are collagens, interacting 
and binding with non-collagenous matrix, proteoglycans and glycosaminoglycans 
(Johansson, 1996).
1.4.1 Collagens
The collagens are a family of related proteins and are the major class of insoluble 
fibrous protein in the ECM and in the vertebrate body as a whole. All collagens 
contain a triple-helical domain composed of three polypeptide domains (a-chains) 
with a homologous amino acid sequence (Prockop et al. 1979). To date 41 distinct 
collagen a-chains have been identified, and these interact to form 27 known collagen 
isotypes (Pace et al., 2003, Boot-Handford et al., 2003).
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The a-chains have a distinctive amino acid composition rich in L-proline and its 
derivative hydroxy-L-proline (collagen is 21% proline/hydroxyproline). These occur 
regularly in a repeating triplet of Gly-X-Y where approximately every third X is 
proline and every third Y is hydroxyproline (Miller, 1985). The pyrrolidine ring 
structure in proline enables each a-chain to coil into a left-handed helix consisting of 
3 amino acids per turn. This geometry allows three a-chains to twist together forming 
a stable right-handed super-helical structure (Prockop et al, 1979). Glycine, the 
smallest amino acid, and the peptide bonds of the collagen molecule, are in the centre 
of the triple helix making the helical region extremely resistant to proteolysis (Traub 
andPiez, 1971).
There are three main types of collagen. Firstly, fibril forming collagens such as 
collagen types I and HI, confer tensile strength to tissue. Gram for gram collagen type 
I, the most abundant collagen, is stronger than steel (Darnell et al, 1995). Fibrillar 
collagen monomers aggregate into ordered fibrils through covalent intermolecular 
bonds (Hulmes et al, 1973) and demonstrate a characteristic ‘D-spacing’ pattern as 
observed under an electron microscope. This patterning is due to the staggering of 
neighbouring collagen molecules by approximately 300 nm (Prockop et al, 1979).
Secondly are the non-fibril forming collagens, of which the most abundant is the 
basement membrane associated collagen type IV (Madri and Furthmayr, 1980). 
These collagens provide the major structural scaffold of all basement membranes and 
form an open meshed two-dimensional network. The triple helix sequence of 
collagen type IV is interrupted by non-triple helical sequences, which increase the 
flexibility of the molecule (Timpl, 1989).
Lastly are the fibril-associated collagens with interrupted triple helices (FACIT) such 
as collagen types IX, XII & XIV. These collagens do not form fibrils themselves but 
are instead associated with various fibrillar collagens and are thought to act as 
molecular bridges between different ECM components (Sugre et al, 1989, Shaw and 
Olsen, 1991).
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Collagen has been shown to influence cell migration, proliferation and angiogenesis, 
all of which are processes that would stimulate tumour growth. For example, in a 
skin wound the provisional wound matrix is rich in collagens type I, in and IV. For 
re-epithelialization of the wound to occur the migration of keratinocytes is required. 
Human keratinocytes have been shown to have a dramatic rate of migration to 
collagen types I and IV (Woodley et al., 1988). Additionally, collagen type IV can 
sequester pro-angiogenic factors such as VEGF and bFGF, which can be subsequently 
released by MMP-2 and -9 to initiate tumour angiogenesis (Bergers et al, 2000). 
Also, fragments of collagen type I are chemotactic for endothelial cells (Palmieri et 
al., 2000). Collagen has also been demonstrated to have many pro-tumourigenic 
properties, which are reviewed in section 1.7.
1.4.2 Collagen biosynthesis
Figure 1.4 summarises the key steps in collagen biosynthesis. Procollagen DNA is 
transcribed to pre-mRNA in the cell nucleus and modified by the capping of the 5’ 
end with a methylated G and the polyadenylation of the 3’ end (Bateman et al., 1996). 
The intronic sequences are spliced out to form a functional mature mRNA that is 
translated to protein on the membrane-bound polysomes in the rough endoplasmic 
reticulum (RER). The preprocollagen a-chain contains an N-terminal hydrophobic 
signal peptide which is believed to facilitate movement across the RER. During 
translation, or shortly after polypeptide synthesis, this peptide is proteolytically 
cleaved (Chambers and Laurent, 1997). The resultant procollagen a-chain is 
extensively processed through a series of co- and post-translational modifications, 
including the hydroxylation of proline and lysine residues in the Y position of the 
Gly-X-Y triplet. Hydroxylation catalysed by prolyl 4-hydroxylase and lysyl 
hydroxylase result in 4-hydroxyproline and hydroxylysine respectively, and require 
the essential co-factors ferrous iron and ascorbic acid (Kivirikko et al., 1989). 
Collagen a-chains must each contain at least 90 residues of 4-hydroxyproline to form 
a stable triple helix at 37°C. Without ascorbate there is insufficient hydroxylation and 
the a-chains are unable to form normal fibrils at body temperature (Rosenbloom et 
al., 1973; Berg and Prockop, 1973). The physiological importance of proline and 
lysine hydroxylation is evident in scurvy, where ascorbate deficiency leads to unstable
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collagen triple helices resulting in weakened bone and dentin, impaired wound 
healing and blood capillary breakdown with associated haemorrhaging.
The hydroxylation of proline residues in the X position occurs by prolyl 3- 
hydroxylase, but this is dependent on the neighbouring Y position being occupied by 
4-hydroxyproline (Tryggvason et al., 1976, Risteli et al, 1977). Glycosylation 
ofcertain hydroxylysine residues also occurs. The specific function is unknown but 
the attached carbohydrate is thought to adjust the biological properties of the collagen 
(Kivirikko and Myllyla, 1979, Bateman et al, 1996). Finally, mannose-rich 
oligosaccharides are transferred onto the c-propeptides of fibrillar collagens and some 
domains in non-fibrillar collagens (Kaplan et al, 1987, Hirschberg and Snider, 1987).
Once the post-translational modifications are completed within the ER, procollagen 
assembly occurs. The c-propeptide domains of three a-chains fold individually and 
trimerise through association of the c-propeptide domains in. a zipper-like fashion to 
form a fully folded procollagen molecule (Prockop, 1990). Newly synthesised 
procollagens in the ER are associated with molecular chaperones, suggesting their 
importance in the procollagen folding pathway (Lamande and Bateman, 1999). 
Binding protein (BiP), GRP94 and protein disulphide isomerase (PDI; also a subunit 
of prolyl 4-hydroxylase) catalyse the folding of the c-propeptide domain through 
intrachain disulphide bond formation, and HSP47 assists the formation of the triple 
helix (Lamande and Bateman, 1999).
Procollagen molecules are transported from the RER to the Golgi apparatus where 
they are packaged into secretory vesicles. During secretion the N- and C-propeptides 
are enzymatically cleaved by procollagen N- and C-proteinase respectively 
(Tuderman and Prockop, 1982, Tanzawa et al, 1985). Removal of the C-propeptide 
results in an approximate 1 0 ,0 0 0 -fold decrease in the solubility of procollagen and is 
essential for fibril formation (Parsons et al, 1999).
Fibrillar collagens spontaneously assemble into fibrils (Wood, 1960), initially held 
together by weak electrostatic interactions. Cross-link formation is crucial for the 
physical and mechanical properties of the fibrils and provides collagen fibrils with
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their characteristic high tensile strength (Bateman et al, 1996). Lysyl oxidase 
facilitates cross-linking by catalysing the formation of aldehydes between lysine or 
hydroxylysine residues on neighbouring fibrils (Eyre et al, 1984).
Non-fibrillar collagens contain similar residues to the fibrillar collagens so lysyl 
oxidase catalysed covalent cross-linking may also occur (Henkel and Glanville, 
1982). Collagen type IV is covalently cross-linked, resulting in the formation of an 
open meshed network structure as observed in basement membranes (Yurchenco and 
Furthmayr, 1984).
1.4.3 Non-collagenous matrix proteins
The ECM is also composed of non-collagenous components, several of which have 
also been demonstrated to be pro-tumourigenic (section 1.7). Fibronectins are a 
family of related proteins derived from alternatively spliced pre-mRNA from a single 
gene (Tamkun et al, 1984, Komblihtt et al, 1985). Fibronectins have a demonstrated 
importance in cell migration and differentiation, wound healing, blood coagulation 
and tumour formation and metastasis (Hynes, 1990).
Tenascins are large and complex extracellular matrix proteins consisting of three 
members, C, R and X (Bristow et al, 1993). Tenascins have a limited distribution in 
the body, with each form expressed at different locations. Tenascin C is an important 
ECM protein in embryogenesis, wound healing and in tumours, tenascin R is found 
exclusively in the central nervous system and tenascin X has been observed in muscle 
and around blood vessels (Johansson, 1996).
Vitronectin, along with fibronectin, is the major cell adhesion protein in blood plasma 
and serum (Johansson, 1996). Vitronectin has been associated with the surface of 
neural crest cells (Delannet et al, 1994) and in the matrix of vessel walls (Guettier et 
al, 1989).
Elastin and fibrillins provide elasticity to tissues that are subject to repetitive 
distension, although their distribution is not confined to these tissues alone (Cleary 
and Gibson, 1997). Elastin fibres are composed of a disorganised core of elastin,
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surrounded by a lattice of microfibrils (Rosenbloom et al., 1993). Fibrillins are 
virtually identical in structure to elastins (Arteaga-Solis et al., 2000).
The proteoglycans (PGs) are a family of highly glycosylated multi-domain core 
proteins. PGs have distinct protein backbones with covalently attached carbohydrate 
rich glycosaminoglycans (GAGs). Due to the negative charge and varying pore sizes 
of PGs and the attached GAG chains these molecules are able to act as molecular 
sieves controlling the movement and storage of signalling molecules according to size 
and charge (Ruoslahti and Yamaguchi, 1991).
Decorin and biglycan belong to a group of small leucine rich PGs and are capable of 
binding and holding TGF-P in a neutralised state (Hildebrand et al., 1994, Yamaguchi 
et al., 1990, Kolb et al., 2001). They are commonly found in most connective tissues 
and share a similar structure; decorin with one binding site for GAG attachment and 
biglycan containing two (Fosang and Hardingham, 1996). Decorin and biglycan have 
been implicated in connective tissue reorganisation and organ differentiation during 
mouse embryogenesis (Wilda et al, 2000). Decorin has also been shown to bind 
fibrillar collagens (Scott and Orford, 1981).
The GAG hyaluronan is abundant in the early stages of ECM production by most 
mammalian cells and is found in early embryogenesis (Fraser and Laurent, 1997). 
Mesothelial cells in culture synthesis hyaluronan, which is upregulated following 
injury of the mesothelial layer (Yung et al., 2000). The elastic properties of hydrated 
hyaluronan allow the maintenance of shape in soft connective tissues that have 
applied stresses. Hyaluronan functions as a space-filler in tissues and also has a 
protein and cell binding role (Delpech and Delpech, 1984, Aruffo et al., 1990). 
Additionally, hyaluronan may also protect cells from viral infections, the cytotoxic 
effects of lymphocytes and may be important in cell differentiation (Heldin and 
Pertoft, 1993). Hyaluronan may also prevent tumour cell dissemination and growth of 
ovarian tumour cells in the peritoneal cavity (Jones et a l, 1995). Furthermore, MM 
pleural effusions containing elevated levels of hyaluronan correlated with longer 
patient survival (Thylen et al., 2001), suggesting that hyaluronan has a suppressive 
role in MM growth.
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1.5 Integrins
Tumour growth is dependent upon the proliferation and migration of cells through the 
surrounding stromal tissue. Cell movement occurs by the application of a force 
against a surface, and adhesion to a solid surface is the first step in cell migration.
The integrins are a major family of heterodimeric transmembrane receptors consisting 
of a  and P subunits. Integrins connect the cell to the external ECM, anchor the 
cytoskeleton to the plasma membrane on the inside of the cell and serve as receptors 
for signal transduction events leading to cell proliferation, survival / apoptosis, shape, 
motility and gene expression (Hynes, 2002).
A recent review of the literature reported 18 a  and 8  P mammalian subunits that are 
known to assemble into 24 distinct integrins, each having a specific function and 
varying ligands (Hynes, 2002). Activation of integrins must occur for binding and 
adhesion to the ECM. Integrins have various states of affinity for their ligands with 
bi-directional signal transduction. The level of affinity can be regulated by 
extracellular factors, ‘outside-in’ signalling, or by intracellular processes, ‘inside-out’ 
signalling (Schwartz and Ingber, 1994, Holly et al., 2000). These signalling pathways 
provide a sophisticated attachment-detachment mechanism controlling the extent of 
cell adhesion to the ECM.
Normal mesothelial cells produce ai_6 , Pi and p3 integrin subunits (Boylan et al.,
1995, Leavesley et al., 1999, Liaw et al., 2001). However, malignant cells express a
different integrin profile, MM produces ai.6 , Oy, Pi, P3 and P4 (Boylan et al., 1995,
Barth et al., 1997, Klominek et al., 1997, Koukoulis et al., 1997, Giuffrida et al.,
1999). Also, variation in integrin expression is observed between the different MM
cell phenotypes. Epithelial-like MM cell lines express more intense staining for the
0 6 , a v and Pi integrin subunits than fibroblast-like MM cell lines (Koukoulis et al.,
1997, Giuffrida et al., 1999). The variation in integrin expression may be responsible
for the differences observed in disease progression between MM morphologies.
~ " " ~~ _  | (Parker and Neville, 2003)
Palecek et al. (1997) established that the rate of cell migration is dependent upon the 
level of cell adhesion to the ECM, controlled by the variables of ECM density, 
integrin expression and activation. The rate of migration against the extent of
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adhesion could be plotted as an approximate bell-shaped curve (figure 1.5). A low 
level of adhesion results in a slow rate of migration as there is not enough traction for 
the cells to move significantly (figure 1.5 A). Increasing the adhesion up to an 
optimal level results in the highest rate of cell migration (figure 1.5 B). Further cell 
attachment leads to impaired mobility (figure 1.5 C), probably due to the inability to 
detach. Depending on the starting position on this curve, altering integrin expression / 
activation or changing the ECM density may have different effects on migration. 
Migration would be enhanced by increasing the level of adhesion when less than 
optimal, but when optimal, further adhesion would decrease the rate of migration.
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Figure 1.5 The rate of cell migration is dependent upon the level of cell adhesion to 
the surrounding ECM (adapted from Holly et al., 2000).
In the literature there are no obvious trends in the quantitative and qualitative changes 
of integrin expression / activation amongst different tumour types. For example, 
bladder carcinomas exhibit increased expression of oti integrin (Liebert et al., 1994), 
whereas decreased levels of Oi are found in human melanoma and breast carcinomas 
(Schadendorf et al., 1993, Gui et al., 1994). The above model of the level of adhesion 
affecting cell migration may explain how different integrin profiles could lead to a 
similar malignant phenotype.
The 0604 integrin (laminin binding) is heavily implicated in epithelial tumours 
(Mercurio and Rabinovitz, 2001). Increased expression of Ot604 is observed in skin
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carcinoma (Tennenbaum et al., 1993), bladder cancer (Grossman et al., 2000) and 
new expression is seen in thyroid tumours (Serini et al., 1996). Overexpression of 
0 6 0 4  increases the formation of papilloma and squamous cell carinoma (Watt, 2002).
The (3i subunit is predominately associated with collagen and laminin adherence. Pi 
integrin expression is higher and it’s surface distribution altered in human breast 
cancer cells compared to non-malignant cells (Weaver et al, 1997). When attached to 
ECM components (fibronectin, laminin, collagen type IV) the pi integrin stimulates 
survival signals preventing the chemotherapy-induced apoptosis of small cell lung 
cancer cells (Sethi et al, 1999). Human hepatocellular carcinoma has an increased 
expression of Pi integrin compared to non-cancerous liver tissue (Ozaki et al, 1998), 
the Pi integrin protecting tumour cells from chemotherapy-induced apoptosis by a 
MAPK dependent pathway (Zhang et al, 2002).
The altered expression of integrins in the different tumour types above is likely to 
contribute to the malignant properties of cell motility, proliferation and metastasis. 
This evidence suggests that the dysregulation of cell-ECM interactions are important 
in malignant transformation.
1.6 Matrix metalloproteinases
As well as penetrating and invading the surrounding ECM in order to grow, malignant 
tumours must also have a mechanism to detach from the ECM to metastasise to 
distant sites. There are several families of proteins, including serine proteases, 
cathepsins and matrix metalloproteinases (MMPs), which are capable of cleaving 
various components of the ECM allowing cell invasion and detachment. MMPs are a 
group of over 20 enzymes capable of degrading the ECM, and are the only enzymes 
that can denature and digest fibrillar collagens (Rintoul and Sethi, 2001). MM has 
been demonstrated to produce MMP-1, MMP-2, MMP-3, MMP-9 as well as the 
natural antagonists of MMPs, TIMPs 1, 2 and 3 by RT-PCR. Several of the MM cell 
lines also expressed MMP-7 and MMP-10 (Liu et al, 2001).
It is widely believed that elevated levels of MMPs are associated with more invasive 
and metastatic tumours. Human fibrosarcoma cells stably transfected with MMP-13
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have an enhanced invasive capacity through collagen type I gels and matrigel (Ala- 
Aho et al., 2002), an effect blocked by addition of a synthetic MMP inhibitor or 
TIMP-3. Expression of MMPs has been demonstrated in human lung carcinomas by 
in situ hybridisation (Zucker et al., 1992, Kossakowska et al, 1996), Northern 
blotting (Sato et al., 1992) and ELISA (Iizasa et al., 1999). In an animal model of 
experimental melanoma, MMP inhibitors were shown to reduce both tumour growth 
and secondary lung metastases in a dose-dependent manner (Naglich et al., 2001). 
The use of MMP inhibitors in the treatment of renal and lung carcinoma patients is 
currently being investigated in ongoing clinical trials (Falardeau et al., 2 0 0 1 , 
Wojtowicz-Praga etal., 1998).
The view that MMPs only role is to degrade ECM has been altered in recent years 
with the discovery that MMPs are dynamic molecules with many cellular functions 
(McCawley and Matrisian, 2001). The ECM acts as reservoir, sequestering growth 
factors and cytokines (Boudreau and Bissell, 1998), and the proteolysis of ECM by 
MMPs can release fragments with biological activities (Werb, 1997). MMPs-2, -3 or 
-7 can cleave decorin and release TGF-pi (Imai et al, 1997). MMPs have also been 
demonstrated to cleave and activate growth factors. Yu and Stamenkovic (2000) have 
shown that MMPs-2 and -9 are capable of activating pro-TGF-Pi to localise TGF-Pi 
to the cell surface. Vascular endothelial growth factor (VEGF) release mediated by 
MMP-9 has been shown to be vital for angiogenesis in a mouse model of pancreatic 
islet tumours (Bergers et al, 2000). MMP-3 and -7 have also been shown to cleave 
E-cadherin generating a fragment that can stimulate Madin-Derby canine kidney cells 
to migrate and invade collagen type I gels (Noe et al., 2000).
The literature cited above suggests that many of the MMPs produced by MM may be 
important in cell migration, invasion into the surrounding ECM and in the release of 
cytokines that stimulate angiogenesis and ECM synthesis, all of which may promote 
tumour growth.
1.7 The role of the extracellular matrix in tumourigenesis
To grow beyond a minimal size of 1 to 2 mm, all solid tumours require ECM 
(Folkman, 1985), with interactions between tumour cells and the ECM crucial to
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cancer progression. The ECM may account for over 90% of total tumour mass in 
fibrous tumours, although other cancers such as medullary carcinomas have minimal 
stroma (Dvorak, 1986). Inflammatory cell infiltration rarely accounts for more than a 
few percent of tumour mass.
Although tumour specific differences exist, common features are apparent between all 
invasive and metastatic tumours, including adhesion to the ECM through cell ECM- 
interaction, invasion and migration through the tumour stroma (Varani, 1987). The 
ECM has a demonstrated role for invasion. For example, carcinoma cells implanted 
into granulation tissue have a more invasive phenotype (Dingemans et al., 1993, 
Gabbert, 1985). ECM proteins can also act as a reservoir to release growth factors 
increasing tumourigenesis (Wemert, 1997). The role of several common ECM 
proteins in the tumour growth of different malignancies is summarised in table 1.1. It 
has been proposed that prevention of the generation of tumour stroma may be useful 
in cancer treatment, depriving tumours of support, survival and growth factors 
(Dvorak, 1986). MM has a dense ECM, and therefore this approach may be 
applicable to MM treatment.
1.7.1 ECM components associated with malignant mesothelioma
Although a characteristically fibrous tumour rich in ECM, the role of ECM proteins in 
MM have not been fully elucidated. MM cell lines migrate to fibronectin, laminin 
and collagen type IV in vitro, an effect that can be inhibited by incubation with 
blocking integrin Pi antibodies (Klominek et al., 1997). Increased levels of 
hyaluronan are observed in MM which contributes to invasive growth in soft agar (Li 
and Heldin, 2001). Also, fibrinogen deposition is a feature associated with MM 
(Wojtukiewicz et al., 1989). Furthermore, EGF, IGF and PDGF stimulate MM cells 
to produce proteoglycans (Sykrokou et al., 1999), the expression of which influences 
cell morphology and aggregation (Dobra et al., 2000). Interestingly, mesothelioma 
cell cultures also have a greater capacity to produce collagen than benign mesothelial 
cells (Castor et al., 1969, Behbehani et al., 1982, Whitaker et al., 1984, Craighead et 
al., 1987), suggesting a role for collagen in MM. However, the function of collagen 
in MM is unknown and further studies are required to determine the effect of 
inhibiting collagen production on MM cell proliferation and tumour growth.
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Three different MM cell morphologies have been demonstrated in vitro and in vivo; 
epithelial-like with a cobblestone appearance, fibrosarcomatous (fibroblast-like, 
elongated spindle shaped) and biphasic (mixed epithelial and fibroblast-like 
morphology). Fibroblast-like cell morphology is associated with a worse prognosis 
(Fusco et al, 1993). Fibroblast like MM cell lines produce more matrix PGs such as 
decorin and biglycan than epithelial-like MM cell lines (Dobra et al., 2000), 
suggesting a role for these PGs in more aggressive tumour growth.
ECM
Component
Evidence for pro-tumourigenic properties
Collagen Association of collagen type I and III with breast tumours 
(Kauppila et al., 1998)
Collagen type I and El expression increased in tobacco smoke-induced hamster 
lung cancers (Laitakari and Stenback, 2001)
Human colorectal malignancies contain increased collagen type I and V
(Fischer et al., 2001)
Collagen type IV protected small cell lung cancer cells (SCLC) from 
chemotherapy-induced apoptosis (Sethi et al., 1999)
Collagen type IV increased astrocytoma cell migration (Berens et a l ,  1994)
Desmoplasia around breast carcinoma contained increased collagen V
(Barsky et al, 1982)
Desmoplasia associated with increased occurrence and metastases of skin cancers
(Breuninger et a l ,  1997)
Increased collagen & prolyl hydroxylase in breast tumours 
(Al-Adnani etal., 1975)
Inhibition of collagen production with a proline analogue reduced breast 
carcinoma growth in vitro and in vivo (Lewko etal., 1981)
Table 1.1 ECM components associated with tumourigenesis
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Fibronectin Enhanced breast cancer cell proliferation (Simpson-Haidaris & Rybarczyk, 2001)
Increased the mitogenic and migratory effects of VEGF, PDGF and bFGF on 
breast carcinoma cells (Elliot et al., 1992, Miralem et al., 2001)
Increased glioma cell migration (Enam etal., 1998)
Required for mammary tumours to form colonies 
(Sauliner et al., 1996,1997)
Hyaluronan Increased invasion of human glioma cells (Radotra and McCormick, 1997) 
Increased migration of melanoma cells (Yoshinari etal., 1999) 
Increased levels associated with breast carcinoma (Madan et al., 1999)
Laminin Increased proliferation and migration of corticotroph tumour cells 
(Kuchenbauer et al., 2001)
Increased migration of astrocytoma and glioma cells 
(Berens et al., 1994, Mahesparan et al., 1997)
Prevented chemotherapy-induced apoptosis of SCLC (Sethi et al., 1999)
Osteopontin
*
Upregulated in murine skin carcinoma and enhanced cell adhesion, migration, 
invasion and in vivo  growth (Craig etal., 1990, Philip etal., 2001)
Mixture of 
basement 
membrane 
proteins
Increased colon cancer cell proliferation and migration (Ohtaka e ta l ,  1996)
Increased growth of malignant breast epithelial cells (Petersen et al., 1992)
Increased breast carcinoma incidence and growth in v ivo  (Noel et a l,  1994)
Increased human lung cancer cell proliferation and malignant phenotype
(Pavelic e ta l ,  1992)
Increased human hepatocarcinoma and ovarian cancer cell migration and 
proliferation (Vlodavsky et al., 1980, Crickard et a l ,  1983)
Table 1.1 continued. ECM components associated with tumourigenesis
* Osteopontin is a glycosylated phosphoprotein which has been shown to bind
collagen type I and fibronectin
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The experimental evidence described in this section demonstrates that the ECM has 
growth promoting effects on tumours, increasing migration, proliferation, invasive 
capacity, aggregation and colony formation in vitro and the incidence and ability to 
metastasise in vivo. This suggests that modulation of ECM production, of which 
collagen is a major component, may be useful in the control of MM tumour growth. 
The next section describes several strategies for inhibiting collagen production as a 
means of attenuating MM tumour growth.
1.8 Inhibition of collagen biosynthesis
Overexpression of MMPs, the natural enzymes capable of degrading collagen, would 
reduce the amount of collagen present in the ECM. However, MMPs are involved in 
the activation of growth factors and can stimulate the invasion and migration of cells 
(section 1.6). In addition, MMPs act at the protein level, degrading ECM after it has 
been produced and therefore giving an opportunity for cell-matrix interactions to 
occur. The use of an antagonist with minimal non-specific effects would be more 
desirable.
As collagen synthesis is a complex multi-step process (see figure 1.4), its production 
could be inhibited at several points. These include procollagen gene transcription, 
translation of mRNA to protein, hydroxylation or glycosylation of procollagen a- 
chains, intracellular transport, cleavage of the procollagen terminal peptides or chain 
polymerisation and fibril cross-linking.
Procollagen gene transcription can be inhibited by glucocorticoids (Cutroneo et al., 
1981, Dik et al., 2003), and glucocorticoids have been shown to reduce the collagen 
accumulation associated with instillation of bleomycin into rat lungs (Sterling et al., 
1982). Antisense oligonucleotides which hybridise to double stranded DNA can also 
inhibit gene transcription, and those that target mRNA prevent translation (see review 
by Helene and Toulme, 1990).
Proline hydroxylation can be prevented by bivalent cations, such as Zn2+, which are 
believed to bind essential co-factors (Anttinen et al., 1984). Chemical inhibitors of 
prolyl hydroxylase have been developed (Hales and Beattie, 1993, Baader et al 1994,
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Matsumura et al., 1997), although it has been noted that the high affinity of prolyl 
hydroxylase for its substrate is an obstacle in reducing the activity of the enzyme 
(Fuller, 1981).
P-aminopropionitrile (BAPN) binds irreversibly to and inactivates lysyl oxidase 
(Tang et al, 1983). Several studies have appeared in the literature demonstrating the 
ability of BAPN to reduce collagen deposition in models of fibrotic disease 
(Zuckerman et al., 1980, Kagan, 1994, Ledwozyw, 1995).
Proline analogues have been used to disrupt the translation of procollagen mRNA to 
protein. Uitto and Prockop (1975) demonstrated that proline analogues were 
incorporated into nascent procollagen a-chains preventing the normal triple-helical 
conformation leading to an increased rate of degradation. The analogues used 
decreased the rate of total protein synthesis but the effects were small compared to the 
marked reduction in extracellular procollagen production.
Figure 1.6 The dipolar ion form (neutral pH) of proline and thiaproline. The
Y carbon (C-4) of proline is substituted to a S in thiaproline, preventing chain 
elongation of the growing polypeptide chain.
The proline analogue thiaproline differs from proline by the substitution of the y 
carbon (C-4) to a sulphur atom (see figure 1.6 above). Once incorporated into a 
growing polypeptide chain, thiaproline prevents further elongation leading to 
truncated peptides which are degraded (Uitto and Prockop, 1974, Busiello et al, 
1979). Additionally, as the y carbon on proline is hydroxylated by prolyl
s
Proline Thiaproline
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hydroxylase, incorporation of thiaproline into procollagen a-chains would decrease 
the amount of hydroxyproline and may therefore destabilise the triple helical 
structure. Thiaproline has been used as an inhibitor of collagen production and has 
been shown to inhibit collagen accumulation in both the glomerular basement 
membrane and heart ventricles of diabetic db/db mice (Lubec et al., 1994 and 1997) 
with no apparent toxicity at the doses used. In these studies thiaproline was given 
orally to the mice as part of their diet. The combination of the ease of in vivo 
administration, specificity and demonstrated efficiency in reducing collagen 
accumulation make thiaproline suitable for investigating the role of collagen in MM 
tumour growth.
1.9 Summary and aims of study
The literature reviewed in this introduction has highlighted several key points. MM is 
an extremely aggressive tumour, with an unknown pathogenesis, inadequate therapy 
and very poor patient prognosis. A better understanding of MM biology may lead to 
improved treatment. Evidence in the literature supports a strong role for the ECM in 
malignant cell proliferation, migration, invasion and in vivo tumour growth. Although 
a characteristically fibrous tumour shown to express collagen, hyaluronan, and 
fibronectin amongst others, the role of the ECM in MM proliferation and 
tumourigenesis is unknown. Previous studies in other tumours suggest that collagen, 
the predominant ECM component, will promote MM growth, and therefore strategies 
aimed at inhibiting collagen production would be of use. In other carcinomas, 
inhibition of collagen production or the blocking of cell-collagen interactions has 
been shown to decrease tumour growth. The proline analogue thiaproline is specific, 
non-toxic and decreases the accumulation of collagen in vivo.
Furthermore, in many cancers TGF-P is produced at elevated levels and there is 
aberrant expression of TGF-P receptors or there is dysregulation in TGF-P 
intracellular pathways leading to persistent signalling. These alterations have been 
demonstrated to contribute to the tumourigenicity of malignant cells. TGF-P has 
many pro-tumourigenic effects, such as enhancing cell proliferation, migration, 
invasion, immune suppression, angiogenesis and ECM production. Additionally,
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TGF-P is a highly potent inducer of collagen production, and inhibition of TGF-p 
with neutralising antibodies has been demonstrated to attenuate fibrosis in vivo. MM 
also produces elevated levels of TGF-P compared to normal mesothelial cells and 
other primary lung carcinomas. Therefore, it was hypothesised that TGF-P-induced 
collagen production may be stimulating MM tumour growth, as both collagen and 
TGF-P have pro-tumourigenic properties. The use of TGF-P antibodies would be 
appropriate for studying the effect of TGF-p-induced collagen production on MM 
tumour growth.
The above observations led to the formulation of the global thesis hypothesis:
The ECM is vital to the progression o f malignant mesothelioma with 
TGF-/3-induced collagen production stimulating cell proliferation
and tumour growth
Although previous studies have assessed the role of the ECM and TGF-P separately in 
various tumour settings, there have been no reports investigating the importance of 
collagen and it’s production by TGF-P in the growth of MM. The specific aims of 
this thesis are to:
(i) Measure the levels of collagen and TGF-p produced by normal and malignant 
mesothelial cells lines in vitro.
This aim will be achieved by measuring hydroxyproline as an assessment of collagen 
production in MM cell cultures using High Performance Liquid Chromatography 
(HPLC). The amount of TGF-P produced by MM cell cultures into conditioned 
media will be measured using the mink lung epithelial cell TGF-P bioassay, 
consisting of the TGF-p response element PAI-1 fused to a luciferase reporter gene.
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(ii) Determine the importance of collagen production for MM cell proliferation in 
vitro, and for tumour growth in an established subcutaneous animal model by 
using thiaproline to inhibit collagen production.
Cells will be cultured on differing collagen substrates and proliferation assessed to 
determine any effect on cell proliferation. The proline analogue thiaproline will be 
used to inhibit collagen production in vitro and the effect on cell proliferation 
observed. Thiaproline administered in vivo will be used to assess the effect of 
inhibiting collagen production on tumour growth. Tumour tissue will be analysed by 
HPLC to determine the collagen content.
(iii) Evaluate the effect of TGF-p neutralising antibodies on MM cell proliferation, 
collagen production and tumour growth in vivo.
A panel of TGF-P neutralising antibodies will be assessed for their specificity and 
potency to neutralise TGF-Pi, -P2 and -p3 . The effect of specifically inhibiting TGF-P 
isoforms with these antibodies on MM cell proliferation, collagen production and 
tumour growth in vivo will be assessed. Tumours will be analysed for collagen 
content by HPLC to determine whether TGF-P-induced collagen production plays a 
role in MM tumour growth.
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Chapter Two 
Materials and Methods
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2.1 Maintenance of cell lines in tissue culture
Human Malignant Mesothelioma (MM) cell lines (JU77, LO6 8 , N036 and ONE58; 
characterised by Manning et al., 1991) and murine MM cell lines (AB1, AB22 and 
AC29; | derived by Davis et al., 1992) were provided as a generous gift by Prof. 
B.W.S. Robinson (University Department of Medicine, Queen Elizabeth II Medical 
Centre, Perth, Western Australia). The normal human mesothelial cells (NM20) used 
were obtained and subsequently characterised from effusions of patients with heart 
failure (Heldin et al., 1992, Langerak et al, 1996).
Cells were maintained in 75 cm tissue culture flasks (Helena Biosciences, Tyne & 
Wear, UK) in 10 ml of standard growth medium consisting of Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen, Paisley, UK) supplemented with 10% (v/v) heat 
inactivated foetal bovine serum (FBS; Imperial Laboratories, Andover, UK), L- 
glutamine (4 mM; Invitrogen), penicillin (200 units/ml), and streptomycin (200 
units/ml). Flasks were incubated at 37°C in a humidified atmosphere of air containing
10% co2.
The malignant cell lines used exhibited loss of contact inhibition and when dense 
would pile up and continue growing over the cell monolayer. Cultures were judged to 
be confluent when cells were touching and fully surrounded by neighbouring cells but 
still existing as a monolayer. Upon visual confluence cells were passaged into new 
culture flasks. The growth medium was aspirated and the cell layer washed twice with 
10 ml of phosphate buffered saline (PBS; Oxoid, Basingstoke, UK) to remove any 
residual medium. Cells were incubated with a 1 ml solution of trypsin (0.05%, w/v) / 
ethylenediaminetetraacetic acid (EDTA, 0.02%, w/v; Invitrogen) at 37°C until they 
detached from the flask surface. The cells were observed under an Olympus TCK-2 
inverted phase contrast light microscope (Olympus Optical Co., Tokyo, Japan) to 
ensure adequate detachment. The trypsin was neutralised with 9 ml of standard 
medium and the cell suspension split at an appropriate ratio depending on the cell line 
and transferred to new flasks containing 10 ml of standard medium.
Cell number was determined using an improved Neubauer haemocytometer (BDH- 
Merck, Lutterworth, UK). For experimental procedures, the required number of cells
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were transferred to a sterile 50 ml polypropylene centrifuge tube and centrifuged (300 
x g, 5 min, 4°C) using a bench centrifuge (MSE Mistral 3000, Loughborough, UK), 
the supernatant discarded and the cell pellet resuspended at the appropriate 
concentration in DMEM containing 1% (v/v) FES, prior to plating. All experiments 
were conducted in 1% serum. Serum free conditions resulted in loss of cell adhesion 
to tissue culture plastic and cell death.
2.1.1 Freeze storing o f cells
Cells were detached from flasks and pelleted as described previously. The cell pellet 
was resuspended in DMEM containing 20% (v/v) FBS. An equal volume of solution 
containing 20% (v/v) dimethyl sulphoxide (DMSO; Sigma Aldrich, Poole, UK) / 20% 
(v/v) FBS in DMEM was added dropwise to the cell suspension. The cells were 
transferred to cryovials (Nalge Nunc, Naperville, USA) and allowed to slowly freeze 
overnight at -70°C before being transferred into liquid nitrogen.
2.1.2 Thawing o f cells
Cells were recovered from liquid nitrogen storage by heating in a 37°C waterbath. 
The cells were then transferred to a flask containing standard growth medium and 
incubated at 37°C. The growth medium was aspirated and replaced the following day 
to remove the DMSO solution.
2.1.3 Isolation o f murine normal mesothelial cells
Normal mesothelial cells were isolated from the anterior peritoneal wall of 8 week-old 
female CBA mice (Harlan, Oxon, UK) for comparison with syngeneic malignant cells. 
Animals were sacrificed by cervical dislocation. The skin on the abdomen was 
separated from the underlying abdominal wall and the abdominal wall excised and 
placed into a 50 ml centrifuge tube containing 25 ml of trypsin (0.25%, w/v) / EDTA 
(0.02%, w/v). Tissue from three mice was placed in each tube of trypsin / EDTA. 
The tubes were shaken for 30 min at 37°C in a shaking incubator, the intact tissue 
removed and discarded and the remaining cell suspension centrifuged (300 x g, 5 min, 
4°C) in a bench centrifuge. The supernatant was discarded and the pellet resuspended 
in 10 ml of mesothelial cell growth medium consisting of DMEM supplemented with 
15% (v/v) FBS, 4 mM L-glutamine, 5 ng/ml epidermal growth factor (Roche
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Diagnostics, Lewes, UK), 0.4 pg/ml hydrocortisone (Sigma Aldrich), 200 units/ml 
penicillin and 200 units/ml streptomycin. Cells were plated into 75cm tissue culture 
flasks and split 1:1 when confluent. Cells were characterised as mesothelial cells 
based on their morphology in culture. At confluence, mesothelial cells adopt a 
cobblestone appearance. Mouse mesothelial cells could not be characterised by 
standard cytokeratin expression immunohistochemically as mouse cytokeratin 
antibodies are not available. Cultures were used up to passage 3.
2.2 Cell proliferation assays
2.2.1 Assessment o f DNA synthesis by measurement o f H-thymidine incorporation
To investigate the effect of test mediators including; porcine transforming growth 
factor-Pi (TGF-P0, TGF-P2, TGF-(33 (R&D Systems Europe, Abingdon, UK), 
thiaproline (Sigma Aldrich) and TGF-P neutralising antibodies (R&D Systems Europe 
and Cambridge Antibody Technology, Cambs, UK) on cell proliferation, a tritiated 
thymidine (3H-TdR, Amersham, Buckinghamshire, UK) assay was used to measure 
DNA synthesis. Cells were plated into 96 well tissue culture plates in DMEM 
containing 1% (v/v) FBS (4000 cells / 100 jul / well). Only the central 10 x 6 wells of 
the plate were used to avoid edge artefact effects. The outer wells were filled with 100 
pi of DMEM. After 24 hr the medium was removed and replaced with fresh DMEM 
containing 1% (v/v) FBS supplemented with the test mediator (100 pi / well) and 3H- 
TdR (74 KBq/ml). After 24 hr in culture the cells were lysed by the addition of 10 pi 
of 10 M NaOH to each well and the plate frozen at -40°C prior to further analysis.
The lysed cells were thawed and the DNA harvested and washed on glass filter mats 
(ICN Biomedicals, Aurora, Ohio, USA) with a Micro96 cell harvester (Skatron, Lier, 
Norway). The filter for each well was shaken into 4 ml of Ecoscint A scintillation 
fluid (National Diagnostics, Atlanta, USA) contained in Pico 2000 polyethylene vials 
(Packard Instruments). The samples were read on a Minaxip liquid scintillation 
counter (Packard Instruments). Incorporated 3H-TdR was measured in disintegrations 
per minute (d.p.m.) with the background count (scintillation fluid alone) subtracted 
from all values.
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2.2.2 Substrate dependent proliferation
Coated tissue culture plates were used to study the influence of collagen on cell 
proliferation. Rat tail collagen type I (First Link, Birmingham, UK) and murine 
collagen type IV (Sigma Aldrich) were diluted in PBS to a range of concentrations 
between 0 - 1 0  pg/ml, and 50 pi of these solutions were applied to a 96 well plate. 
The plate was left open in a tissue culture hood overnight to dry. The following day 
the wells were washed with 100 pi PBS. To block non-specific binding of cells to any 
uncoated plastic on the bottom of the wells, 50 pi of 3% bovine serum albumin (BSA; 
w/v) in PBS was added to each well for 1 hr. The BSA solution was aspirated and 
cells plated at 4000 cells / lOOpl / well. The rate of proliferation was assessed by the 
measurement of DNA synthesis, as detailed above (section 2.2.1).
2.3 Cytotoxicity assays
The proline analogue thiaproline was used in this study as an inhibitor of collagen 
synthesis. To ensure that thiaproline was being used at non-toxic concentrations, cell 
integrity and viability after thiaproline exposure was assessed using two standard 
biochemical markers of toxicity:
(i) cellular uptake of the supravital dye neutral red,
(ii) release of cytoplasmic lactate dehydrogenase (LDH).
2.3.1 Neutral red cytotoxicity assay
Neutral red is a cationic dye that readily diffuses across the plasma membrane of 
viable cells. The dye concentrates in the lysosomal matrix through electrostatic 
bonding to anionic sites. Disruption to the cell surface and the sensitive lysosomal 
membrane leads to decreased uptake and binding of the dye. This allows 
discrimination between viable and damaged cells.
Cells were plated in 96 well tissue culture plates in DMEM containing 1% (v/v) FBS 
(4000 cells / 100 pi / well) and incubated for 24 hr when experimenting on 
subconfluent cells, or allowed to grow to visual confluence (3 days). The culture 
medium was aspirated and groups of 6 wells supplemented with thiaproline (0 -  50 
mM) in DMEM containing 1% (v/v) FBS.
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After 24 hr the culture medium was removed and the cell layer washed with 100 pi of 
PBS. Cells were incubated with a 100 pi solution of neutral red (0.005% w/v in 
DMEM containing 1% (v/v) FBS) at 37°C for 3 hr. The first row received DMEM 
supplemented with 1% (v/v) FBS without neutral red to serve as a blank for the 
spectrophotometric analysis.
Following incubation, the neutral red solution was removed by gentle blotting over 
absorbent paper and the cells were washed with 2 x 100 jLtl of PBS to remove any 
excess dye. The cells were lightly fixed with 100 p,l per well of an aqueous solution of 
formaldehyde (4% v/v) and calcium chloride (1% w/v). This was limited to 2 min to 
avoid damage to the lysosomes. The fixative was removed by blotting and the bound 
neutral red eluted from the cells by adding 200 pi of a solution of glacial acetic acid 
(1% v/v) and ethanol (50% v/v) to each well. To aid the elution of the dye into the 
acetic acid-ethanol solution, the 96 well plate was placed on an orbital shaker 
(Luckham, Sussex, England) at room temperature (RT) for 30 min. The absorbance 
per well was measured at 540 nm on a microplate photometer (Titertek Multiskan MC, 
ICN Flow, Buckinghamshire, UK) using the wells that did not receive neutral red 
treatment as blanks.
2.3.2 Measurement o f lactate dehydrogenase release
Cellular release of lactate dehydrogenase (LDH) was measured using a CytoTox 96® 
Non-Radioactive Cytotoxicity Assay (Promega, Madison, USA) to determine the 
cytotoxic effects of thiaproline in vitro. LDH is a stable cytosolic enzyme (catalysing 
the interconversion of lactate and pyruvate) released upon cell lysis. Released LDH in 
culture supernatants was measured with a 30 min coupled enzymatic assay, which 
leads to the conversion of a tetrazolium salt into a red formazan product. The intensity 
of the colour is proportional to the number of lysed cells and is therefore an index of 
cytotoxicity.
Cells were seeded at 4,000 cells per well in 100 pi of DMEM containing 1% (v/v) 
FBS in a 96 well plate. The cells were grown to confluence and the medium replaced 
with thiaproline (0 -  40 mM) in DMEM containing 1% (v/v) FBS at 37°C for 24 hr.
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The supernatant from each well (containing LDH release caused by the experimental 
treatment) was transferred to another 96 well plate, and 100 /xl of lysis buffer (9% v/v 
Triton® X-100) was added to each well containing the intact cell layer and incubated at 
37°C for 60 min. The plate was then centrifuged (250 x g, 4 min). Aliquots from all 
wells (50 pi) were transferred to a fresh 96 well plate and 50 /xl of reconstituted 
substrate mix (lyophilised diaphorase, lactate and NAD+ reconstituted with 1% BSA in 
PBS) was added to each well of the plate. The plate was wrapped in foil to protect it 
from light and incubated at RT for 30 min. A 50 /xl volume of stop solution (1M 
acetic acid) was added to each well and the absorbance was read at 490 nm on a 
microplate photometer.
Cell death was expressed as a percentage of experimentally-induced cell LDH release 
over the maximum possible cell LDH release using the formula:
% Cytotoxicity = Supernatant LDH content (OD490) 100
Maximum (supernatant + lysed cell layer) LDH release (OD490) 1
2.4 Measurement of procollagen production by High Performance Liquid 
Chromatography
Procollagen production by cultured cells was assessed by measuring hydroxyproline 
(hyp) in the ethanol-insoluble protein fraction of the cell monolayer and media 
compartments using a high performance liquid chromatography (HPLC) method 
developed in this laboratory (Campa et al, 1990; McAnulty et a l , 1991).
Hyp represents approximately 12% of the primary amino acid sequence of procollagen 
(Laurent et al., 1981) and is essential for the formation of the collagen triple helix. 
However, the amino acid is not at a significant level in other proteins with the 
exception of elastin (between 0.9 -  1.9% depending on species; Paz et al. 1982), 
complement protein Clq (4% hyp; Reid, 1979), acetylcholinesterase (5% hyp; Mays 
and Rosenberry, 1981) and surfactant apolipoprotein A (5.9% hyp; Hawgood, 1989). 
Mesothelioma cells in culture have not been shown to produce these proteins, and 
assuming that they do not, measuring the hyp content from cell cultures is taken to
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represent procollagen production. However, some of the hyp measured may be from 
non-collagenous protein.
All water used for the preparation of HPLC buffers was purified and deionised using a 
Millipore Water Purification System (Millipore R010 followed by Milli-Q Plus; 
Millipore, Watford, UK). HPLC components and solvents used for the preparation of 
HPLC buffers and solutions were of HPLC grade and obtained from BDH-Merck.
2.4.1 Cell culture conditions
Cells from confluent cultures were trypsinised and counted (section 2.1), resuspended 
in DMEM containing 10% (v/v) FBS and seeded into 12 well tissue culture plates 
(5xl04 cells / ml / well). For all collagen synthesis experiments, duplicate plates were 
prepared; one for hyp measurement and the other to obtain cell number. Both plates 
were treated identically.
When confluent, the culture medium in each well was removed and replaced with 1 ml 
of pre-incubation medium (DMEM containing 1% (v/v) FBS supplemented with 50 
pg/ml ascorbic acid and 0.2 mM proline). After 24 hr the pre-incubation medium was 
removed and replaced with incubation medium consisting of test solutions in 1 ml of 
DMEM containing 1% (v/v) FBS supplemented with 50 pg/ml ascorbic acid and 0.2 
mM proline. One plate containing cells exposed to fresh pre-incubation medium was 
used to obtain cell counts at the beginning of the experiment (to, 4 wells; section 
2.4.2), and the remaining wells were stored at -40°C to determine the level of hyp at 
the start of the incubation period in the cell layer and medium.
After 24 hr of treatment with the incubation medium the plates designated for hyp 
analysis were stored at -40°C whilst cell counts were performed on the duplicate set of 
plates.
2.4.2 Assessment o f cell number
The culture medium was removed from the plates for cell counts and each well was 
washed with 1 ml PBS to remove any remaining serum. Cells were incubated with 1 
ml of trypsin (0.05%, w/v) / EDTA (0.02%, w/v) at 37°C for 4 min and cell
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detachment confirmed by phase-contrast light microscopy. The cells were 
resuspended in the trypsin / EDTA solution and counted as described previously 
(section 2.1).
2.4.3 Cell harvesting
The plates were thawed and the cell layer in each well scraped into the medium using 
a cell scraper (Orange Scientific, Oxfordshire, UK). The contents of each culture well 
were aspirated and transferred to glass tubes. Each well was washed with a further 1 
ml of PBS to remove any remaining protein, which was then transferred to the 
corresponding tube. Proteins were precipitated by the addition of absolute ethanol to a 
final concentration of 67% (v/v) at 4°C overnight.
2.4.4 Separation o f ethanol-insoluble and ethanol-soluble protein fractions 
Precipitated protein (ethanol-insoluble) was separated from free amino acids and small 
peptides (ethanol-soluble) by filtration onto a Durapore membrane filter (filter type 
0.45 pm HV, Millipore) using a vacuum filtration unit (Millipore). The proteins 
adhered to the filter were washed with 2 x 1.5 ml of 67% (v/v) ethanol. The filters 
were transferred to hydrolysis tubes and hydrolysed in 3 ml of 6 M HC1 at 110°C for 
16 hr. Hydrolysates were decolourised with approximately 30 mg of activated 
charcoal (BDH-Merck) and filtered through a membrane filter (filter type 0.65 pm 
DA, Millipore).
2.4.5 Derivatisation o f samples
An aliquot (150 pi) of the decolourised hydrolysate was placed into a 1.5 ml 
microfuge tube and the sample dried under vacuum and heat on a Speed-Vac sample 
concentrator (Savant, Lutterworth, UK). The hyp content of the concentrated 
hydrolysate was isolated and measured by reverse-phase-HPLC following 
derivatisation with 7-chloro-4-nitrobenzo-2-oxa-l,3-diazole (NBD-C1) as described 
previously by Campa et al. (1990). NBD-C1 reacts with amino and imino 
(hydroxyproline and proline) acids to produce light absorbing reaction products. 
Imino acid reaction products exhibit strong light absorption between wavelengths of 
450 -  550 nm, whereas amino acid products have limited absorbance in this range. 
Also, the reaction with imino acids occurs an order of magnitude faster than the
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reaction with amino acids (Perrett, 1985). Therefore, the reaction with NBD-C1 and 
the measurement of absorbance between 450 -  550 nm gives a quantitative 
measurement of the amount of imino acid in the sample when compared to a standard 
containing a known concentration of hyp. Incubation times past 20 min were found to 
have no significant effect on the extent of derivatisation (Lindblad and Diegelmann, 
1984).
Each dried hydrolysate sample was re-dissolved in 100 pi HPLC-grade deionised 
water, buffered with 100 pi of 0.4 M potassium tetraborate (pH 9.5) and reacted with 
100 pi of 36 mM NBD-C1 in methanol. The samples were vortexed and incubated at 
37°C for 20 min in the dark (NBD-C1 derivatised samples are light sensitive). To stop 
the reaction, the pH of each sample was lowered by the addition of 50 pi of 1.5 M 
HC1. To make the samples compatible with the initial HPLC running buffer, 150 pi of 
concentrated buffer A (167 mM sodium acetate in 26% acetonitrile v/v, pH 6.4) was 
added to each sample. Following vortexing and filtering (0.2 pm pore size syringe 
filter unit, Millipore, Watford, UK) samples were loaded onto a cooled autosampler 
(4°C, System Gold 507e, Beckman Coulter, High Wycombe, UK) from which a 100 
pi aliquot was injected onto the HPLC column and eluted with an acetonitrile gradient.
2.4.6 Instrumentation and chromatographic conditions
Derivatised samples were separated on a Beckman System Gold HPLC apparatus 
(Beckman Coulter) with a reverse-phase cartridge column (LiChroCART 
LiChrospher, 250 mm length x 4 mm diameter, 5 pm particle size, 100RP-18) 
protected by a directly coupled precolumn (LiChrosorb, 4 x 4  mm, 5 pm particle size, 
100RP-18). The column was continuously maintained at 40°C in a heated oven. 
Running buffers A (8% v/v acetonitrile and 50 mM sodium acetate, pH 6.4) and B 
(75% v/v acetonitrile) were freshly prepared and filtered (0.22 pm pore size type GV 
filter, Millipore) prior to use. The column was equilibrated in running buffer A for 40 
minutes before being injected with the first sample. The first three samples measured 
on the column were hyp standard solutions (containing 50 pmol hyp) which were 
subsequently used for calibration.
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NBD-C1 derivatives were eluted through the column in an acetonitrile gradient, 
generated by a shift in the relative proportions of the running buffers over time. The 
column running conditions are summarised in table 2.1. Post-column detection was 
achieved by monitoring absorbance at 495 nm using a flow-through variable 
wavelength monitor. The signal was processed for later quantification using an on­
line chromatographic computing integrator (System Gold, Beckman Coulter). A 
defined peak corresponding to hyp eluted from the column approximately 5 min after 
sample injection. Total running and column regeneration time was 25 min per sample.
Column
Mobile phase buffers
Column flow rate 
Column temperature 
Wavelength for detection 
Elution gradient
LiChrospher, 100 RP-18, 250 x 4mm, 5pm 
A -  aqueous acetonitrile (8%, v/v)
50 mM sodium acetate, pH 6.4 
B -  aqueous acetonitrile (75%, v/v)
1.00 ml/min 
40°C 
495 nm
Time (min) % Buffer B
0 0
5 5
6 80
12 80
12.5 0
25 0
Table 2.1 Chromatographic conditions and buffers for the separation of 
hydroxyproline by reverse-phase HPLC (modified from Campa et al., 1990)
75
2.4.7 Quantification o f hydroxyproline
Hyp content in each sample was determined by comparing the area of the hyp peak on 
the chromatogram generated to those obtained from the standard solutions, derivatised 
and separated under identical conditions. All values were corrected for the amount of 
hyp in the ethanol-insoluble protein fraction of the to sample, representing hyp content 
in the cell layer and medium at the onset of the incubation period. The to corrected 
hyp value represented the procollagen produced by the cells over the 24 hr incubation 
period. The data was corrected for cell number and expressed as nmol hyp / 106 cells / 
24 hr. The calculations used for quantifying hyp are shown below:
nmol hyp = acid hydrolysis volume (3000 jliI) X 500 pi reaction mix X HPLC value 
volume aliquot dried (150 p i)  100 p i  loaded on column 1000
To correct for cell number: nmol hyp X 106 = nmol hyp / 106 cells /  24 hr
cell number
2.5 Assessment of non-collagen protein synthesis
The measurement of non-collagen protein synthesis was based on the uptake of 
tritiated phenylalanine into the ethanol-insoluble protein fraction. As the proportion of 
phenylalanine in procollagen is very low (0.8 -  1.2% depending on species; Miller and 
Gay, 1982) incorporated radiolabelled phenylalanine into protein can be used as an 
assessment of non-collagenous protein.
Cell culture conditions were similar to those described for the measurement of 
hydroxyproline (section 2.4.1), except for the addition of 74 KBq/well of L-[4-3H- 
phenylalanine] (3H-phe, Amersham) to the incubation medium. Aliquots (25 pi) of 
decolourised ethanol-insoluble protein hydrolysate (prepared as described in sections
2.4.2 -  2.4.4) were shaken into 4 ml of Ecoscint A scintillation fluid (National 
Diagnostics) contained in Pico 2000 polyethylene vials (Packard Instruments). 
Samples were read on a Minaxi(3 liquid scintillation counter (Packard Instruments). 
The H-phe content per well was measured in disintegrations per minute (d.p.m.) with 
the background count (scintillation fluid alone) subtracted from all values.
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2.6 Transforming Growth Factor-p activity bioassay
Measurement of active and latent TGF-pi, -P2 and -p3 production in MM conditioned 
media and the characterisation of TGF-p neutralising antibodies were performed using 
a transfected mink lung epithelial cell (MLEC) bioassay, kindly provided by Dr D. 
Rifkin, New York Medical Centre, USA. The cell line was maintained in culture in 
standard growth medium supplemented with 200 pg/ml gentamycin (Sigma Aldrich). 
The MLEC cells were stably transfected with a TGF-P sensitive p800neoLUC vector 
(Abe et al, 1994). The vector contained a truncated 800 base pair fragment (-799 to 
+71) of the 5’ end of the human plasminogen activator inhibitor-1 (PAI-I) gene fused 
to the firefly luciferase reporter gene (figure 2.1).
Figure 2.1 Map of p800neoLUC vector stably transfected into MLEC cell line, 
amp - ampicillin resistance gene, neo - neomycin resistance gene with flanking 
SV40 incorporation sequences (SV40)
Upon treatment with TGF-P, transfected MLEC cells were stimulated to produce 
intracellular luciferase via the PAI-1 promoter, the promoter being equally sensitive to 
all three mammalian isoforms of TGF-P. Following incubation, the cells were lysed 
and firefly luciferase activity measured via a bioluminescent reaction with beetle 
luciferase substrate (Promega). This transfected MLEC assay is extremely sensitive 
and covers a wide range of TGF-P concentrations (0.005 -  0.75 ng / ml), whilst being 
specific to TGF-P. Other modulators that may be present in biological fluids, such as 
EGF, FGF, IL -la  and PDGF do not activate the truncated PAI-1 construct (Abe et al, 
1994).
SV40
P800neoLUC
Firefly luciferase
PAI-1 promoter
SV40
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Confluent MLEC were trypsinised and counted (section 2.1) and resuspended in 
standard growth medium at 1.6 x 105 cells / ml. Cells were plated in 96 well tissue 
culture plates (100 pi / well) and incubated in 10% CO2 for 3 hr at 37°C. Following 
cell attachment the medium was aspirated and 100 pi of TGF-p standards 
(recombinant TGF-Pi, -p2 , or -p3 depending on the isoform being examined, in 
DMEM, 0 -  1 ng / ml range) and test samples were applied in triplicate to the cell 
layer. The plate was incubated in 10% CO2 overnight (16 hr) at 37°C.
Following overnight incubation, the medium was aspirated and each well gently 
washed with 50 pi PBS. The cell layers were then lysed with 100 pi of 1 x cell lysis 
buffer (Roche Diagnostics) and incubated at RT for 20 min on an orbital shaker. 
Luciferase activity was assayed using the Luciferase Assay System (Promega). A 30 
pi aliquot of the contents of each tissue culture plate well was transferred to an opaque 
96 well Optiplate (Packard). Reconstituted beetle luciferase substrate (150 pi, 
Promega) was added to each test sample using a Tropix microplate luminometer 
(Perkin Elmer, Massachusetts, USA), which also measured the relative luminosity 
(relative light units, R.L.U.) of each sample over a 5 sec interval via Tropix WinGlow 
software (Perkin Elmer). A standard curve was plotted from the known concentrations 
of TGF-p (figure 2.2A) allowing conversion of R.L.U. to TGF-P conc. (ng/ml) and the 
quantity of active TGF-p present in the test samples calculated.
2.6.1 Assessment o f active and total TGF-P in MM conditioned medium samples 
Normal and malignant mesothelial cell cultures were grown to confluence in 75 cm 
flasks, the monolayer washed with 10 ml PBS and then quiesced with serum free 
DMEM for 24 hr. The cell monolayer was washed with 10 ml PBS and replaced with 
10 ml of serum free DMEM for 24 hr and then the medium removed and stored at - 
70°C. The remaining cell layer was trypsinised and cell number determined (section 
2.1).
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Figure 2.2 Dose-dependent induction of PAI-1-mediated luciferase 
expression (R.L.U.) by TGF-Pi. MLEC cells stably transfected with a PAI-
1 / luciferase construct were incubated with increasing concentrations of 
TGF-Pi for 16 hr and luciferase production measured via a bioluminescent 
reaction. A demonstrates a typical sigmoidal-shaped standard curve, B 
represents the linear portion of the standard curve from which TGF-P 
concentrations in test samples were calculated. The data are representative 
of three repeat experiments. Standard curves using TGF-p2 and -p3 had a 
similar appearance.
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TGF-P activity in the test samples was assayed with the MLEC bioassay (section 2.6). 
Initial experiments were performed to ensure that the test sample R.L.U. values were 
within the linear range of the standard curve (figure 2.2B). Samples that gave higher 
R.L.U. values than the linear portion of the standard curve were appropriately diluted 
with serum free DMEM. Latent TGF-P (TGF-P:LAP) was activated by heating the 
samples at 80°C for 10 min in a waterbath (Gleizes et al, 1997). A time course was 
performed to ensure that total activation was occurring at 1 0  min using two separate 
conditioned medium samples (figure 2.3). Activated samples were diluted accordingly 
with serum free DMEM and assayed. TGF-P production was represented as ng TGF-P 
/ 106  ce lls /24 hr.
2.6.2 Characterisation o f TGF-p neutralising antibodies
The ability of specific TGF-P antibodies to neutralise TGF-Pi, -p2 and -P3 was 
assessed using the MLEC assay (section 2.6). Test and control antibodies (table 2.2) 
were incubated with 0.1 ng / ml of TGF-Pi, -P2 and -P3 for 30 min at 37°C, a separate 
standard curve constructed for each TGF-P isoform. The antibody/TGF-P solution 
was then assayed with the MLEC assay to determine the efficacy and specificity of the 
antibody. Antibodies were used at the concentrations recommended by the 
manufacturers.
2.6.3 Quantitation o f TGF-P isoforms produced in normal and malignant 
mesothelial cell conditioned medium
To determine the amount of different active and latent TGF-p isoforms produced by 
normal and malignant cells, unheated and heated conditioned medium (section 2 .6 .1 ) 
were incubated with R&D Systems TGF-P neutralising antibodies and TGF-p activity 
measured. Conditioned medium was diluted with DMEM to a concentration of 0.1 ng 
/ ml TGF-p and incubated with R&D Systems anti-TGF-Pi, anti-TGF-P2 , and 
Cambridge Antibody Technology pan-specific TGF-P antibodies with the appropriate 
control antibodies for 30 min at 37°C. TGF-P activity was measured using the MLEC 
assay (section 2.6) and the amount of TGF-pi, -p2 and -P3 calculated by comparing the 
different antibody treatment groups to each other and the antibody-free samples. TGF- 
P isoform production was represented as ng TGF-P / 106 cells / 24 hr.
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Figure 2.3 Heating time course of AB1 and AC29 conditioned medium.
Conditioned medium harvested from AB1 (A) and AC29 (B) cell monolayers were 
collected and heated at 80°C to activate latent TGF-|3. TGF-p activity was 
assessed via luciferase production using the MLEC bioassay. This data suggested 
the optimal activation of latent TGF-P occurred between 5 and 10 min at 80°C, 
after which the amount of retrievable TGF-p decreased. The data are 
representative of three repeat experiments.
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Chicken anti-human TGF-Pi Chicken globulin
(R&D Systems) (Jackson ImmunoResearch, Pennsylvania,
100 ng / ml USA) 100 ng / ml
Goat anti-human TGF-p2 Normal goat IgG
(R&D Systems) (R&D Systems)
100 ng / ml 100 ng / ml
Goat anti-worm TGF-p3 Normal goat IgG
(R&D Systems) (R&D Systems)
100 jig / ml 100 ng / ml
anti-TGF-p i;-P2, -P3 murine IgGl irrelevant murine IgGl
(R&D Systems) (R&D Systems)
100 ng / ml 100 ng / ml
anti-TGF-Pi human IgG4 irrelevant human IgG4
(Cambridge Antibody Technology) (Cambridge Antibody Technology)
100 ng / ml 100 ng / ml
Acidified anti-TGF-Pi human IgG4 Acidified irrelevant human IgG4
(Cambridge Antibody Technology) (Cambridge Antibody Technology)
150 ng / ml 150 ng / ml
anti-TGF~p2 human IgG4 irrelevant human IgG4
(Cambridge Antibody Technology) (Cambridge Antibody Technology)
100 ng / ml 100 ng / ml
anti-TGF-P i,-P2, -p3 murine IgGl irrelevant murine IgGl
(Cambridge Antibody Technology) (Cambridge Antibody Technology)
100 ng / ml 100 ng / ml
Table 2.2 Concentration of R&D Systems and Cambridge Antibody Technology 
control and TGF-p antibodies used for in vitro characterisation
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2.7 Animal models of mesothelioma
Tumour growth studies in vivo were performed in female 8  week-old BALB/c and 
CBA mice (Harlan). The MM cell lines AB1 and AB22 were derived in BALB/c mice 
and AC29 cells in a CBA mouse. Introducing these cell lines back into the same strain 
of mouse does not initiate a host response. Female mice were used as this sex has a 
more constant body weight from 8  weeks of age upwards compared to the males, 
allowing the maintenance of an even dosing of thiaproline and TGF-P antibodies. 
Two murine models of mesothelioma were compared to determine the most consistent 
and reproducible method of tumour growth.
2.7.1 Intraperitoneal model o f mesothelioma
Two groups of mice were injected intraperitoneally with 106 syngeneic MM cells in 
100 pi of serum free DMEM and a further control group received no tumour cells 
(Davis et al., 1992). After 18 days of thiaproline treatment (section 2.7.3), animals 
were sacrificed by cervical dislocation, a midline laparotomy performed and the 
abdomen contents examined. The nodular nature of the tumour scattered around the 
mesentery made dissection and separation from the host impractical. Thus, abdominal 
weight was chosen as a measure of tumour growth and the entire abdominal contents 
removed, weighed on a microbalance (Mettler, London, UK) and snap frozen in liquid 
nitrogen.
2.7.2 Subcutaneous model o f mesothelioma
Mice were anaesthetised in a gas box with 4% halothane (Ohmeda, BOC gases, 
London, UK), 1.5 1/min oxygen and 1.5 1/min nitrogen (BOC gases) until unconscious. 
The hind flanks were shaved and both sides injected subcutaneously above the thigh 
with 106 syngeneic MM cells in 100 pi of serum free DMEM (figure 2.4). In pilot 
studies the two largest dimensions of the tumour were measured externally with 
microcallipers, and used to calculate tumour area. At 10 and 18 days (thiaproline 
treatment, section 2.7.3) and 15 and 19 days (TGF-P neutralising antibody studies, 
section 2.7.4) after injection of tumour cells, animals were sacrificed by cervical 
dislocation and the subcutaneous tumours surgically removed. The tumour from one 
flank was weighed on a microbalance and immersed in 4% paraformaldehyde (Sigma 
Aldrich). These tumours were paraffin embedded for histology (section 2.9). The
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tumour from the other flank was weighed on a microbalance and snap frozen in liquid 
nitrogen. These tumours were transferred to a -70°C freezer for subsequent collagen 
analysis (section 2.7.5).
Figure 2.4 Subcutaneous injection of syngeneic cells into hind flanks of 8  week-
old female mouse
2.7.3 Thiaproline in vivo studies
From day 1, one group of injected animals received thiaproline dissolved in their 
drinking water at an approximate dose of 100 mg/kg/day. The control injected group 
received normal drinking water. The thiaproline-treated water was prepared fresh 
daily and water intake measured by graduations on the water bottles. The mice were 
fed mouse chow ad libitum and were monitored daily for signs of ill health. The mice 
were weighed at regular intervals (approximately every three days) throughout the 
experiment.
To measure circulating levels of thiaproline in blood plasma, a midline laparotomy 
was performed and the abdominal contents moved to one side. Blood was harvested 
from the inferior vena cava via a heparinised 25 gauge needle and 1 ml syringe 
(heparin from CP Pharmaceuticals, Wrexham, UK) and stored at 4°C in a heparinised
Injection site on hin
Shaved lower back
23 gauge needle and Hamilton syringe 
containing 106 cells in 100 pi medium
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eppendorf tube (Eppendorf, Hamburg, Germany) to be later analysed for thiaproline 
levels (section 2 .8 ).
2.7.4 TGF-P neutralising antibody in vivo studies
Monoclonal TGF-p antibodies were generously supplied for in vivo studies by 
Cambridge Antibody Technology: CAT-192 (anti-TGF-Pi human IgG4), CAT-152 
(anti-TGF-P2 human IgG4), CAT-001 (irrelevant human IgG4), 1D11 (anti-TGF-pi, - 
P2 , -p3 murine IgGl) and 13C4 (irrelevant murine IgGl).
Groups of 5-10 animals were separated into treatment groups; anti-TGF-P antibody 
treated (5 mg/kg in 100 pi PBS), control antibody treated (5 mg/kg in 100 pi PBS) and 
PBS control treated (100 pi). Prior to injection of tumour cells (24 hr), animals were 
injected intraperitoneally with the treatment antibody / control and subsequently at 3 
day intervals until the end of the experiment using a 2 1  gauge needle and 1 ml syringe. 
Animals had free access to food and water.
2.7.5 Measurement o f tumour collagen content by High Performance Liquid 
Chromatography
Frozen tumours were transferred to a ceramic mortar on ice and kept cool by the 
addition of liquid nitrogen. The tumour was crushed to a fine powder using a ceramic 
pestle. The powdered tumour tissue was hydrolysed in :2 ml of 6  M HC1 at 110°C for 
16 hr. Hydrolysates were decolourised with approximately 30 mg of activated 
charcoal (BDH-Merck) and filtered through a 0.65 pai p)ore DA filter (Millipore, UK). 
A 10 pi aliquot of decolourised sample was diluted 1:1(00 times in deionised H2O. A 
2 0 0  pi aliquot of this diluted sample was dried to remove the acid, derivatised, and the 
hyp content quantified as described in sections 2.4.5 -  22.4.7. The data was corrected 
for the aliquot weight and was expressed as nmol hyp / tuimour.
2.8 High Performance Liquid Chromatography snallysis of thiaproline in blood 
plasma
In order to determine the circulating blood plasma lewels of thiaproline in treated 
versus non-treated mice, HPLC analysis was emjioyeed following the method of 
Lankelma^a/. (1981).
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2.8.1 Sample preparation
Heparinised mouse blood (section 2.7.3) was transferred to a 15 ml polypropylene 
tube and centrifuged at 2000 x g for 5 min to give a plasma supernatant. The 
supernatant was transferred to a fresh 15 ml polypropylene tube and deproteinised 
with 2 M perchloric acid (BDH-Merck) in a 4:1 ratio respectively. The solution was 
centrifuged at 2000 x g for 5 min to pellet the precipitated protein. In order to refine 
the detection method, human blood plasma was prepared by the same method above 
from a 50 ml human blood sample. A 50 pi aliquot of supernatant was injected onto 
the column and the rest stored at -70°C.
2.8.2 Instrumentation and chromatographic conditions
Deproteinised samples were separated on a Beckman System Gold HPLC apparatus 
(Beckman Coulter) with a microparticulate strong cation exchange column (Partisil 
SCX, Whatman, New Jersey, USA). The column dimensions were 250 mm length x
4.6 mm internal diameter and 10 pm particle size. The column was kept at ambient 
temperature. Running buffer consisting of 90% v/v 0.01 M phosphoric acid, pH 2.2 
and 10% v/v acetonitrile was freshly prepared and filtered (0.22 pm pore size type GV 
filter, Millipore) prior to use. The column was equilibrated in running buffer for 40 
min before applying the first sample. The first six samples injected onto the column 
were standard solutions, consisting of duplicates of thiaproline spiked human blood 
plasma at concentrations of 0.01 mM, 0.1 mM and 1 mM, which were used for 
calibration. Plasma samples were eluted through the column in a continuous flow of 
running buffer ( 1  ml / min).
Post-column detection was achieved by monitoring absorbance at 205 nm using a 
flow-through variable wavelength monitor. The signal was processed for later 
quantification using an on-line chromatographic computing integrator (System Gold, 
Beckman Coulter). A peak corresponding to thiaproline eluted from the column 
approximately 8  min after sample injection. Total running and column regeneration 
time amounted to 25 min'per sample.
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2.8.3 Quantification o f thiaproline
Thiaproline content in each sample was determined by comparing the area of the 
thiaproline peak on the chromatogram to those generated from the standard solutions, 
separated under identical conditions. The data was expressed as circulating thiaproline 
(mM) in blood plasma.
2.9 Histology
2.9.1 Tumour tissue processing
Surgically removed tumours (section 2.7.2) were fixed in 4% paraformaldehyde 
buffered in PBS, pH 7.4, at 4°C overnight. The tissue was washed twice in PBS for 30 
min and placed in 15% sucrose in PBS at 4°C overnight. The tissue was then washed 
in PBS for 30 min, 50% ethanol for 30 min and in 70% ethanol at 4°C overnight 
before being further processed and wax embedded (table 2.3) using a Leica TP 1050 
vacuum tissue processor (Leica, Nussloch, Germany).
2.9.2 Tissue section preparation
Wax blocks were placed on ice prior to cutting. Tissue sections (5 pm) were prepared 
using a retraction microtome (Shandon, Runcorn, UK) and placed on poly-L-lysine- 
coated slides (BDH-Merck). The sections were air dried overnight before staining. 
Tissue sections were dewaxed in xylene and rehydrated in decreasing concentrations 
of industrial methylated spirit (IMS; table 2.4) using an automated stainer (Sakura 
DRS-601 Diversified Stainer, Bayer, Newbury, UK) prior to staining. Following 
staining, sections were dehydrated through an increasing concentration of IMS (table 
2.5) using an automated stainer and mounted using an automatic coverslipping 
machine (Sakura Coveraid, Bayer).
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70% industrial 
methylated spirit (IMS)
2:00 37
90% IMS 1:30 Ambient
90% IMS 1:30 Ambient
Absolute ethanol 1:00 Ambient
Absolute ethanol 1:15 Ambient
Absolute ethanol 1:15 Ambient
Absolute ethanol 1:15 Ambient
Xylene 1:00 Ambient
Xylene 1:00 Ambient
Xylene 1:00 Ambient
Paraffin Wax 1:00 60
Paraffin Wax 1:00 60
Paraffin Wax 1:00 60
Table 2.3 Processing schedule of Leica TP1050 Vacuum Tissue Processor to wax
embed tumour samples
Xylene 3
Xylene 3
100% IMS 2
90% IMS 2
70% IMS 2
50% IMS 2
Deionised Water 1
Table 2.4 Dewaxing and rehydrating schedule for paraffin sections
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Deionised Water 1
50% IMS 1
70% IMS 1
90% IMS 1
100% IMS 1
100% IMS 2
Xylene 1
Xylene 1
Xylene 2
Table 2.5 Dehydrating schedule for stained sections
2.9.3 Modified Martius Scarlet Blue stain
Modified Martius Scarlet Blue is a trichrome stain allowing the differentiation of 
compartments within a tissue section through their varying permeabilities to different 
dyes. Dewaxed and rehydrated tumour sections were stained using an automated slide 
stainer. Sections were treated in Lugol’s iodine (BDH-Merck) for 5 min to enhance 
subsequent staining. Sections were decolourised in sodium thiosulphate (BDH- 
Merck) for 3 min and then washed in tap water for 1 min. The nuclei were stained 
using the celestine blue / haematoxylin sequence. The slides were immersed in 
celestine blue (Lamb, London, UK) for 10 min and washed in tap water for 1 min 
followed by deionised water for 30 sec. Slides were then stained in haematoxylin 
(BDH-Merck) for 5 min and sections differentiated in tap water for 30 sec, acid 
alcohol (1% HC1 in 70% ethanol) for 20 sec, and two washes of tap water for 30 sec 
and 2 min. Erythrocytes in the section were stained in aqueous Orange G (Lamb) for 
8 min, the section then differentiated in deionised water for 5 sec. Fibrin within the 
sections was stained in red mix (0.5% ponceax de xylidine and 0.5% acid fuchsin in 
1% glacial acetic acid, BDH-Merck) for 7 min, and the sections differentiated in 
deionised water for 20 sec, phosphotungstic acid (1% in deionised water, BDH- 
Merck) for 30 sec followed by deionised water for 20 sec. Collagen present in the
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sections was stained with Chicago sky blue (1% in glacial acetic acid, Sigma Aldrich) 
for 5 min and then differentiated in 1% acetic acid. The sections were washed, 
dehydrated, cleared and coverslipped (section 2.9.2). Nuclei stained dark blue/black, 
erythrocytes orange/yellow, fibrin scarlet and collagen bright blue.
2.9.4 Reticulin stain
Dewaxed and rehydrated tumour sections were oxidised in acidified potassium 
permanganate (BDH- Merck) for 3 min and then washed in tap water. The sections 
were bleached in 1 % oxalic acid for 2  min and then washed in tap water followed by 
deionised water. The slides were sensitised in 2.5% ferric ammonium sulphate (BDH- 
Merck) for 10 min then rinsed well in deionised water. The sections were 
impregnated with silver solution (ammonia added dropwise to 5 ml 10.2% aqueous 
silver nitrate (BDH- Merck) until precipitate that first formed just dissolved. Sodium 
hydroxide solution (3.1%, 5 ml) was added and ammonia added dropwise until the 
precipitate dissolved and the volume made up to 50 ml with deionised water) for 30 
sec. The sections were washed in deionised water and reduced in 10% aqueous 
formalin (BDH- Merck). The slides were washed in tap water, toned in 0.1% gold 
chloride for 1 min, then washed again in tap water and fixed in 5% sodium 
thiosulphate before being washed and counter stained in 0 .2 % neutral red solution 
(BDH-Merck). The slides were washed, dehydrated, cleared and coverslipped (section 
2.9.2). Reticulin was evident as black fibres within the sections.
2.9.5 Haematoxylin and eosin stain
Dewaxed and rehydrated tumour sections were stained using an automated slide 
stainer. Slides were stained in Gill’s haematoxylin (Shandon) for 5 min and then 
washed in tap water for 20 sec. Sections were differentiated in 1 % acid alcohol (1% 
HC1 in 70% ethanol) for 8  sec and then washed in tap water for 2.5 min. The slides 
were then stained in 1% eosin (Shandon) for 6  min. The sections were washed, 
dehydrated, cleared and coverslipped (section 2.9.2). Nuclei stained dark blue/black, 
cytoplasm varying shades of pink, erythrocytes orange/red, and fibrin deep pink.
2.9.6 Immunohistochemistry
Immunohistochemical techniques allow the identification and localisation of cellular 
and tissue components through the binding of specific antibodies raised against them.
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The site of antigen-antibody interaction is visualised either by direct antibody labelling 
(such as a fluorescent tag) or through the use of a secondary labelling method. 
Dewaxed and rehydrated tumour sections were permeabilised on ice for 5 min with 
PBS, pH 7.0, containing 20 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethane 
sulfonic acid), 300 mM sucrose, 50 mM sodium chloride, 3 mM magnesium chloride 
and 0.5% Triton X-100 (Sigma Aldrich) to unmask the epitopic sites. The slides were 
washed in three changes of PBS for 15 min on a stirrer. Endogenous peroxidase 
activity was blocked by treatment with 3% hydrogen peroxide (Sigma Aldrich) in a 
humidified chamber for 30 min. The slides were washed in three changes of PBS for 
15 min followed by incubation with serum of the host secondary antibody (1:25 
dilution) in a humidified chamber for 2 0  min to reduce non-specific antibody binding. 
The serum was drained off and initially, to determine the optimal concentration of 
primary antibody to use (table 2 .6 ), the tissue was incubated with dilutions of the 
primary antibody (0.1 -  20 pg / ml in PBS) in a humidified chamber overnight at 4°C. 
Once a suitable dilution had been determined for each antibody this was subsequently 
used, with an isotype control antibody at the same concentration (table 2 .6 ).
The slides were washed in three changes of PBS for 15 min and sections incubated 
with the appropriate secondary antibody (1:200 dilution in PBS, table 2.6) for 1 hr in a 
humidified chamber at RT. The sections were washed in PBS three times and 
incubated with a 1 : 2 0 0  dilution of horseradish-peroxidase-conjugated streptavidin 
(Dako, Glostrup, Denmark) in PBS for 30 min. The slides were washed for 15 min in 
three changes of PBS and the peroxidase activity visualised using 
3,3’diaminobenzidine (DAB) substrate for 10 min following the manufacturer’s 
protocol (DAB substrate kit for peroxidase, Vector Laboratories, CA, USA). The 
sections were washed in deionised water, counterstained with 1 % eosin, washed, 
dehydrated and coverslipped (section 2.9.2). Areas of positive reactivity demonstrated 
brown staining.
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Rabbit anti-mouse Collagen 
Type I 
(Chemicon, CA, USA) 
2.5 pg / ml
Rabbit IgG 
(Dako)
Goat anti-rabbit 
biotin-conjugated 
(Dako)
Goat
(Dako)
Rabbit anti-human Collagen 
type III 
(Chemicon)
1 0  pg / ml
Rabbit IgG 
(Dako)
Goat anti-rabbit 
biotin-conjugated 
(Dako)
Goat
(Dako)
Rabbit anti-human Collagen 
type IV (Chemicon)
7.5 pg / ml
Rabbit IgG 
(Dako)
Goat anti-rabbit 
biotin-conjugated 
(Dako)
Goat
(Dako)
Chicken anti-human TGF-Pi 
(R&D Systems)
2  ng / ml
Chicken IgG 
(Jackson 
ImmunoResearch)
Goat anti-chicken 
biotin-conjugated 
(Dako)
Goat
(Dako)
Table 2.6 Primary / control antibodies, blocking serum and secondary antibodies 
used for TGF-pi and collagen type I, type III and type IV immunohistochemistry
2.9.7 Microscopy
Sections were examined using an Olympus BX40 microscope (Olympus Optical Co.) 
and imaged using a JVC KY-F55B colour video camera (Victor Co., Tokyo, Japan) in 
conjunction with Zeiss KS300 imaging software (Carl Zeiss, Welwyn Garden City, 
UK).
2.10 Statistical analysis
All cell data were expressed as mean ± standard error of the mean (SEM) for 6 
replicates. For single group comparisons statistical analysis was performed using an 
unpaired Student’s t-test. Multiple group comparisons were performed using ANOVA 
followed by an ad hoc unpaired Student’s t-test. Due to unequal variances between 
the different tumour groups, statistical analysis comparing the control group to the 
treated groups was performed using a Mann-Whitney U test. The data was shown as a 
spread of tumour weight around the median. A p value less than 0.05 was considered 
statistically significant.
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Chapter Three
Characterisation of normal and malignant 
mesothelial cell lines
93
3.1 Introduction
There is a growing body of evidence suggesting that the ECM, particularly collagen, 
may be important in tumour growth. It is generally believed that ECM protein- 
producing stromal cells, not the tumour cells, are the major contributors to the matrix 
of fibrous tumours (Kauppila et al, 1998, Dahlman et al., 2000, Yen et al, 2002). 
However, previous experiments in this laboratory have shown that MM cells in culture 
synthesise collagen (a key ECM component) at rates three to four times greater than 
normal mesothelial cells, comparable to that of lung fibroblasts, the predominant 
collagen producing cells in the lung. The role of ECM proteins in MM have not been 
fully elucidated. MM cells also secrete TGF-p, a key regulator of cell growth and 
ECM / collagen production, at elevated levels compared to normal mesothelial cells 
and other tumour types (Fitzpatrick et al., 1994, Maeda et al., 1994). Additionally, 
different MM morphologies have been shown to affect disease progression, fibroblast­
like cell morphology associated with a worse prognosis (Fusco et al., 1993). The 
development of suitable panels of human and murine MM tumour cell lines in 
conjunction with animal models has enabled the biology of MM to be investigated in 
more depth (Manning et al, 1991, Davis et al., 1992). This initial chapter sought to 
characterise a series of murine and human normal and malignant cell lines. 
Specifically, to;
1 . establish the morphology of the cell lines,
2. quantitate the amount of active and latent TGF-P produced,
3. assess the ability of exogenous TGF-P to induce procollagen production,
4. and to determine whether any correlation between cell morphology and
procollagen / TGF-P production was evident.
3.2 Malignant mesothelioma cell line morphology
Murine (figure 3.1) and human (figure 3.2) cell lines were viewed under a light 
microscope at approximately 50% confluence and when the cells were fully confluent. 
All malignant cell lines exhibited loss of contact inhibition, continuing to grow by 
piling on top of the cell monolayer. Murine and human cell lines were heterogeneous 
in morphology, both species exhibiting epithelial and fibroblast-like cell lines. The 
mouse MM cell line AC29 (figure 3.1) was biphasic, containing epithelial and 
fibroblastic type cells. Morphologically, the most similar malignant cell line to normal
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Normal mesothelial cells 
subconfluent
Normal mesothelial cells 
confluent
Epithelial-like Epithelial-like
AB1 subcontinent
Fibroblast-like
AB1 confluent
Fibroblast-like
AB22 subconfluent
Epithelial-like
AB22 confluent
Epithelial-like
AC29 subconfluent
Biphasic
AC29 confluent
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Biphasic
Figure 3.1 Murine normal and malignant mesothelial cell line 
morphology. Images of subconfluent and confluent murine 
mesothelial and MM cell lines demonstrate heterogeneity in cell 
appearance. Magnification 200x.
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NM20 confluentNM20 subconfluent
Normal mesothelial cells ■ 1 ^  \|  Normal mesothelial cells
Fibroblast-like
JU 77 subconfluent
Fibroblast-like
Fibroblast-like
Figure 3.2 Human normal and malignant mesothelial cell line 
morphology. Subconfluent and confluent human mesothelial and 
MM cell cultures appeared heterogeneous in morphology. 
Magnification 200x.
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primary cultured murine mesothelial cells was AB22, which had a characteristic 
epithelial ‘cobblestone’ appearance at confluence (figure 3.1). The most similar to 
NM20 (normal human mesothelial cell) was the malignant line LO6 8  (figure 3.2).
3.3 Malignant mesothelioma cell line endogenous TGF-p production
The amount of active, latent and total (active + latent) TGF-p produced by the cell 
lines into conditioned media was measured using a bioassay sensitive to all three 
mammalian isoforms of TGF-p. All of the cell lines examined expressed detectable 
TGF-P bioactivity (figure 3.3), although heterogeneity was seen between cell lines. 
Comparatively, similar trends were observed in active, latent and total TGF-P 
production between cell lines. AC29 was consistently the highest producer in the 
murine panel of cell lines. Compared to non-malignant CBA cells the malignant cell 
line AC29 produced a significantly higher amount of TGF-P (increases in AC29 of 
approximately 15-fold active, 17-fold latent and 17-fold total TGF-p production 
compared to non-malignant control, pcO.OOl in each case). The murine MM cell line 
AB22 was the lowest producer of TGF-P, although still significantly elevated 
compared to the CBA control cells with increases of approximately 3-fold active, 1.6- 
fold latent and 1.7-fold total TGF-P production, pcO.OOl in each case.
TGF-P production by the human normal mesothelial cell line NM20 was unable to be 
quantitated as during the 24 hr serum free quiescence period cells would round up and 
detach from the monolayer, indicative of cell death. Therefore it was not possible to 
compare TGF-P production in the human panel of MM cell lines with normal cells. In 
the human panel of cells, N036 was the highest producer of TGF-p, L068 was the 
lowest.
The majority of TGF-p produced by the cell lines was latent (approximate percentage 
of total TGF-P production that was latent: CBA normal mesothelial cell control 94%, 
AB1 97%, AB22 87%, AC29 95%, JU77 63%, L068 72% and N036 8 6 %). The 
exception was the human cell line ONE58 that had a latent TGF-p production of 
approximately 5% of the total.
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Murine cell lines Human cell lines
A ctive TGF-p pro duction
0.4
0.3
0.2
0.1
0.35
0.25
0.15
0.05 I
Latent TGF-p production
1.6
1.2
0.8
0.4
Total TGF-p production
Non-malignant AB1 
CBA cells
AB22 AC29
2.5
1.5
0.5
JU77 LO68 NQ36 ONE58
Figure 3.3 Active, latent and total TGF-P production by normal and malignant 
cell lines. Conditioned media harvested from normal and malignant cell monolayers 
were assayed for active and latent TGF-p (section 2.6.1). The results are 
representative of three sets of conditioned media each assayed at least twice. Each bar 
represents the mean ± SEM for six replicate wells. *p<0.001 for AC29 TGF-P 
production compared to CBA non-malignant control mesothelial cells.
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3.4 Malignant mesothelioma cell line collagen production
Figure 3.4 demonstrates the effect of exogenous TGF-pi on cell number and 
hydroxyproline (hyp) production over 24 hr in confluent cultures of the murine MM 
cell line, AC29. Compared with the to value representing cell number at the beginning 
of the experiment, there was an approximate 2 -fold increase in cell number with 0 - 1  
ng/ml TGF-Pi, and an approximate 1.5-fold increase with 10 ng/ml TGF-Pi (figure 
3.4A). All of these values represent a significant increase compared with to (p<0.001). 
However, at 24 hr there were no significant differences between the treatment groups 
compared with the medium control, although TGF-Pi at 1 and 10 ng/ml significantly 
reduced cell number compared with 0.1 ng/ml TGF-Pi (23% p<0.05 and 38% pcO.OOl 
decrease respectively).
Figure 3.4B shows the effect of TGF-Pi on hyp production. The value at to represents 
the amount of hyp in the ECM associated with the cell layer, which is small in 
comparison to the total hyp produced over 24 hr (to approximately 12% of control after 
24 hr). There was a significant increase in hyp compared to the medium control in all 
treatment groups at 24 hr, with the effect appearing to plateau at 1 ng/ml TGF-Pi (both 
1 and 10 ng/ml TGF-Pi increased hyp production by approximately 100% compared 
with the medium control; pcO.OOl).
Procollagen production over the course of the experiment was calculated by 
subtracting the mean to hyp value from all experimental hyp values (figure 3.4B). In 
addition, each group was corrected for changes in cell number at the end of the 
incubation period (figure 3.4A). The data derived from this adjustment was expressed 
as nmol hyp / 106 cells / 24 hr (see figure 3.5). Increasing the concentration of TGF-Pi 
induced a dose dependent increase in procollagen production, with maximal effects 
observed at 1 ng/ml TGF-pi (2.5-fold increase compared with medium control, 
pcO.OOl; 10 ng/ml TGF-pi - 2.8-fold increase compared with medium control, 
pcO.OOl). The effect of increasing concentrations of TGF-pi on procollagen 
production was also assessed in the human JU77 cell line (figure 3.6). TGF-Pi 
induced procollagen production in a dose-dependent manner with maximal stimulation 
observed at 1 0  ng/ml (over a 6 -fold increase compared with medium control, 
pcO.OOl).
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Figure 3.4 The effect of an increasing concentration of TGF-Pj on AC29 cell 
number and hydroxyproline production. Confluent cultures of AC29 cells were 
incubated with 0 - 10  ng/ml TGF-P! in DMEM supplemented with 1% FBS. Cell 
number (A) and hydroxyproline production (B) were assessed 24 hr later. T0 
values represent the cell number and hydroxyproline at the beginning of the 
experiment. Statistically significant differences from medium control group are 
indicated by * representing p<0.001. Each bar represents the mean ± SEM for six 
replicate cultures. This data is representative of three repeat experiments.
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Figure 3.5 Increasing concentrations of TGF-p! increased AC29 cell 
procollagen production dose dependently. Procollagen production in response to 
0-10  ng/ml TGF-p! was assessed in the murine MM cell line AC29 (section 2.4). 
Each bar represents the mean ± SEM for six replicate cultures. Statistically 
significant differences from medium control group are indicated by * and ** 
representing p<0.005 and p<0.001 respectively. The data shown is representative 
of three separate experiments.
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Figure 3.6 Increasing concentrations of TGF-p, increased JU77 cell procollagen 
production dose dependently. JU77 human mesothelioma cells were incubated with 0 
-10 ng/ml TGF-P, for 24 hr and procollagen production measured (section 2.4). Each 
bar represents the mean ± SEM for six replicate cultures. Statistically significant 
differences from medium control group are indicated by * and ** representing p<0.05 
and p<0.01 respectively. This data is representative of three separate experiments.
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Table 3.1 summarises the basal and TGF-Pi induced procollagen production for 
murine (AB1, AB22 and AC29) and human (JU77, L068, N036 and ONE 58) MM 
cell lines, and the human normal mesothelial cell line NM20. Collagen measurements 
for murine CBA normal mesothelial cells were not possible due to difficulties in 
culturing these cells in vitro. However, there was over a doubling in basal procollagen 
production in the lowest human MM collagen procollagen producer L068 compared 
with the human control mesothelial cell line NM20 (L068 0.26+0.08, NM20
0.10±0.01 nmol hyp / 106 cells / 24 hr). The murine cell lines produced significantly 
more basal procollagen than the human cell lines, with the lowest murine procollagen 
producer, AB1 (1.37±0.09 nmol hyp / 106 cells / 24 hr) 2.5 fold higher than the 
greatest human procollagen producer, JU77 (0.57±0.16 nmol hyp / 106 cells / 24 hr, 
p<0.005).
The percent increase in procollagen production upon TGF-Pi stimulation was also 
assessed. All cell lines demonstrated an increase in procollagen production upon 
TGF-Pi treatment, the highest increase observed in JU77 at 10 ng/ml TGF-Pi 
(approximate 540% increase compared with the medium alone control, p<0.001).
3.5 Discussion
3.5.1 Malignant mesothelioma cell line TGF-P production
The majority of cell lines examined produced high levels of TGF-p compared to 
normal CBA mesothelial cells (figure 3.3), with the murine malignant cell lines 
producing significantly higher levels than non-transformed murine mesothelial cells. 
An elevation of TGF-p production in malignant vs. non-malignant cells has also been 
observed by Kuwahara et al. (2001). Spontaneous rat mesothelioma cell lines 
produced 30 -  70 times more TGF-P than normal rat mesothelial cells. Interestingly, 
the lowest murine and human TGF-p producing cell lines, AB22 and LO6 8  
respectively, were also the most similar morphologically to untransformed mesothelial 
cells (figures 3.1 and 3.2). This observation suggests that TGF-P may play a role in 
the process of malignant transformation as tumour cells demonstrating the highest 
levels of TGF-P production are morphologically more distinct from their normal 
counterparts. TGF-P has been demonstrated to induce transformation of fibroblasts to 
myofibroblasts (Desmouliere et al., 1993) and keratinocytes to myofibroblasts (Jester
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Cell Line
Hydroxyproline (nmol hyp / 106 cells / 24 hr) according to TGF-Pi concentration (ng/ml)
0 0.1 1 10
' A B1 1.37 ±0.09 1.61 ±0.12 
(17.79 ± 9.03)
2.23 ±0.40 
(62.73 ± 28.99)
2.79 ±0.29* 
(103.77 ±21.67)
Murine 4 AB22 1.58 ±0.07 3.88 ±0.12*** 
(146.13 ±7.75)
6.29 ±0.10*** 
(298.84 ± 6.58)
8.43 ±0.11 *** 
(434.54 ± 6.84)
 ^ AC29 1.55 ±0.12 2.09 ± 0.06 ** 
(34.72 ±4.10)
3.83 ± 0.23 *** 
(146.47 ± 15.03)
4.34 ± 0.33 *** 
(179.56 ±21.44)
r NM20 ( v J 0.10 ±0.01 — 0.28 ±0.01*** 
(185.71 ±5.89)
JU77 0.57 ±0.16 0.84 ± 0.27 
(46.56 ± 47.01)
1.83 ±0.94* 
(220.32 ±73.19)
3.66 ± 0.24 *** 
(540.48 ± 42.26)
Human ^ LO68 0.26 ± 0.08 0.37 ± 0.03 
(41.16 ±11.31)
0.55 ± 0.02 ** 
(106.14 ±8.09)
0.47 ± 0.03 * 
(77.94 ±13.16)
N036 0.52 ± 0.28 0.74 ± 0.09 
(41.28 ±16.42)
0.87 ±0.14 
(56.51 ±29.27)
0.83 ±0.11 
(58.89 ±21.31)
ONE58
V
0.34 ± 0.04 0.81 ±0.01*** 
(134.59 ±0.82)
1.21 ±0.09 *** 
^ ( 2 4 1 .7 1  ±28.71)
1.67 ±0.11 *** 
(387.37 ±31.21)
Table 3.1 Basal and TGF-|3i-induced procollagen production in murine MM and human normal and malignant mesothelial cell lines.
Confluent cultures of cells were incubated with 0 - 1 0  ng/ml TGF-pi in DMEM shpplemented with 1% FBS. Procollagen production was assessed 
24 hr later. Values were corrected for cell number and procollagen production expressed as nmol hyp / 106 cells / 24 hr. The figures in brackets 
represent the percent change ± SEM compared with media con tro l^— indicates that measurements were unable to be made. Statistically 
significant differences from medium control group are indicate^by *, ** and *** representing p<0.05, p<0.01 and pcO.OOl respectively. Data is 
representative of at least two independent experiments^ ^ 7
et al., 1996), and is perhaps important in the transformation of mesothelial cells to 
mesothelioma.
Heterogeneity was evident in TGF-p production between the cell lines, which was 
consistent with findings in other studies (table 3.2). Fitzpatrick et al. (1994) examined 
TGF-p production in the same cell lines and found much higher levels of TGF-p 
production. However, in both studies AC29 was the highest producer of active and 
latent TGF-P.
Cell line TGF-P production This study Fitzpatrick et al, 1994
Murine non- Active 0 . 0 2 -
malignant Total 0.36 -
AB1 Active 0.13 <0.33
Total 4.57 <0.33
AB22 Active 0.08 <0 . 1
Total 0.62 4
AC29 Active 0.33 6.95
Total 6.46 48.38
JU77 Active 0 . 1 2 2 . 2
Total 0.33 3.2
LO6 8 Active 0 . 0 1 1.34
Total 0.04 4.08
N036 Active 0.29 5.3
Total 2.05 12.73
ONE58 Active 0.17 5.48
Total 0.18 15.8
Table 3.2 A comparison of TGF-P production by malignant mesothelioma cell 
lines from two independent studies. Active and total TGF-p production is expressed 
as ng / 106 cells / 24 hr.
There are several possible reasons why the two different studies do not match exactly. 
Media containing 1% FBS was used in the Fitzpatrick et al. study and conditioned
Murine
Human
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media was collected over a 48 hr period, whereas in this study serum free medium 
over a 24 hr period was used. The presence of growth factors such as EGF and bFGF 
in serum affects the proliferation of non-transfected MLEC which would interfere with 
the measurement of TGF-P (Abe et al, 1994). These differences may have increased 
the amount of measurable TGF-P in the study by Fitzpatrick et al.. Also, different 
TGF-P bioassays were used to quantitate TGF-P activity, the study by Fitzpatrick and 
colleagues using a MLEC growth inhibition assay and this study using the more 
sensitive and specific transfected MLEC bioassay. Although the total values differed 
between the two studies, the proportion of active to total TGF-P produced by each cell 
line were similar in both cases.
The majority of TGF-P secreted by the cell lines was latent (figure 3.3). TGF-P is 
secreted in a latent form in a complex with LTBP (Taipale et al, 1994). In some cases 
LTBP acts as a chemoattractant, it has been shown to stimulate rat arterial smooth 
muscle cells to migrate (Kanzaki et al., 1998). The ECM acts as a reservoir for 
various growth factors and cytokines, and is important in sequestering TGF-P 
(Boudreau and Bissell, 1998). Latent TGF-P is localised to the ECM by LTBP 
(Taipale et al., 1994) creating a store of TGF-p. Proteases such as plasmin, thrombin, 
and elastase release matrix bound TGF-P to form a soluble pool of latent TGF-P 
(Taipale et al., 1992, 1995). In the soluble pool, plasmin and Cathepsin D dissociate 
LAP and TGB-p to yield active TGF-P (Lyons et al., 1988). ECM-bound TGF-Pi can 
also be cleaved and released by MMPs-2, -3 or -7 (Imai et al., 1997), and MMPs-2 
and -9 are capable of activating pro-TGF-Pi to localise TGF-Pi to the cell surface (Yu 
and Stamenkovic, 2000). MM cells have been shown to produce these MMPs (Liu et 
al., 2001), as well as plasminogen activator (Schoenberger et al, 1987) and thrombin 
(Pacchiarini et al., 1991). Thus, there is a large reservoir of latent TGF-P within the 
MM cell lines tested capable of rapidly increasing the local concentration of active 
TGF-P with the potential to stimulate collagen production and promote tumourigenesis 
in vivo.
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3.5.2 TGF-Pi stimulated malignant mesothelioma cells to produce procollagen in 
vitro
Basal and TGF-pi-induced procollagen production was measured in a range of murine 
and human MM cell lines (table 3.1). TGF-pi is the most effective inducer of 
procollagen production characterised to date, and has been demonstrated to potently 
stimulate fibroblast procollagen mRNA production (Varga et al., 1987), fibroblast 
procollagen protein production in vitro (Coker et al., 1997) and the deposition of 
collagen in vivo (Roberts et al., 1986). TGF-pi was used in this study to stimulate 
procollagen production in MM cell lines. All experiments were conducted in 1% 
serum to maintain cell adhesion and viability. Although the presence of serum may 
have acted as a stimulus to raise the basal level of procollagen production, a further 
increase in procollagen production was observed after TGF-Pi incubation. The data
obtained showed that the MM cell lines tested produced basal levels of ^focollagen,\
which was increased in a dose responsive fashion following incubation with ^GF-Pi.
\
\
\
Of the murine cell lines, AB22 had the largest increase in procollagen production with
the addition of exogenous TGF-Pi (table 3.1; at 10 ng /ml TGF-pi approximate 430%
\
increase compared to the basal level) whilst having the lowest endogenous TGF-P \
\
production (figure 3.3). Conversely, the human cell line N036 had the lowest \ 
percentage increase in procollagen production with 10 ng /ml  TGF-Pi (table 3.1) but 
the highest endogenous TGF-p production (figure 3.3). This suggests that there could 
be an autocrine loop of active TGF-P production by MM cells stimulating endogenous 
procollagen production. Cell lines producing higher levels of TGF-p may have 
maximally stimulated endogenous procollagen production and therefore responded 
less to exogenous TGF-P than in those cell lines producing lower quantities of TGF-p. 
The role of exogenous TGF-p isoforms on MM basal procollagen production was 
examined later by the use of TGF-P neutralising antibodies (chapter 6 ).
3.5.3 Correlation between malignant mesothelioma cell morphology, TGF-p 
production and procollagen production , —^
TGF-P is known to induce the transformation of fibroblasts into/myofibroblasts 
(Desmouliere et al., 1993), and is perhaps involved in thel progression of normal
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mesothelium to MM. The murine cell lines AB1 and AC29 have a more fibroblast- 
like phenotype than AB22 cells (figure 3.1), and produced relatively higher levels of 
TGF-P (figure 3.3) compared to the normal mesothelial control cell line. A previous 
study by Davis et al. (1992) demonstrated that AB1 & AC29 were the most 
tumourigenic out of a panel of murine and human MM cell lines at inducing in vivo 
tumours both s.c. and i.p., however no correlation between morphology or growth rate 
was found.
Individual variations in morphology and growth rates are characteristic of human and 
murine MM (Davis et al, 1992). It has been documented that MM cell lines vary in 
morphology and growth (Manning et al, 1991; Davis et al., 1992) and in the
%r
production of various cytokines such as TGF-P (Fitzpatrick et al., 1994; Kuwahra et
al., 2001). This heterogeneity was also observed in the MM cell lines examined in
this study. The procollagen response was similar within species (human and mouse)
but different between species (table 3.1). TGF-P production was consistently greater
in the murine cell lines compared to the human cell lines with the exception of the
human line N036 (figure 3.3). As both groups contained ^celMines^ of varying
morphology, cell type is unlikely to be responsible for the] observed differences.
Interspecies variation in metabolism is likely to account for the differences seen,
smaller organisms (mice) have a faster metabolism than larger animals (humans) and
\
therefore produce proteins such as procollagen and TGF-P at a faster rate. (Vinogradov et al., 2001)
\ ■ v.
3.6 Summary and conclusions
The panel of cell lines examined was heterogeneous in TGF-P and collagen 
production with differing morphologies. All of the cell lines produced measurable 
quantities of procollagen and TGF-P, with a trend towards greater levels in the murine 
MM cell lines. The MM cell lines also produced procollagen and TGF-P at higher 
levels compared with non-malignant control cells. Those cell lines producing higher 
concentrations of endogenous TGF-P were less responsive to TGF-Pi-induced 
procollagen production. There was no obvious relationship between cell morphology,
TGF-P production or procollagen production, although AB22 (most morphologically 
similar to untransformed mesothelial cells) had the lowest TGF-P production,
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suggesting a possible relationship between TGF-P production and malignant 
transformation.
In a panel of cell lines, including the ones characterised in this study, Davis et al. 
(1992) demonstrated that AC29 cells transplanted in vivo had the fastest growth rate; 
forming a subcutaneous 1cm diameter tumour within 25 days in vivo. This chapter 
showed that AC29 was the cell line with the highest TGF-P production and was one 
of the highest producers of procollagen. This suggests a possible correlation between 
TGF-P, procollagen production and tumour growth.
As previously stated, two key characteristics of MM are firstly that it is an extremely 
fibrous tumour containing a dense ECM rich in collagens, and secondly, that elevated 
levels of TGF-p are produced compared to normal mesothelium and other lung 
malignancies. The literature review in chapter one provided evidence for the 
independent importance of both TGF-p (section 1.3) and ECM components such as 
collagen (section 1.7) in promoting tumourigenesis. Also, TGF-P is the most potent 
inducer of collagen production characterised to date and therefore an association 
between TGF-P, collagen production and increased tumourigenesis could be 
hypothesised. Having demonstrated the increased production of procollagen in all of 
the MM tumour cell lines tested in this chapter the first thesis hypothesis was 
formulated:
The ECM is vital to the progression of malignant mesothelioma with 
procollagen production stimulating cell proliferation and tumour growth
Collagen production contributes to an enhanced rate of ECM deposition, which 
contains binding sites for LTBP and therefore leads to the formation of a reservoir of 
latent TGF-P. Collagen and TGF-P may be synergistic in promoting tumourigenesis, 
TGF-P directly stimulates collagen gene transcription whilst collagen forms part of 
the ‘reservoir’ which sequesters latent TGF-P and holds the cytokine within the local 
tumour microenvironment. The observation that cell lines producing a high basal
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level of TGF-|3 had a relatively smaller increase in procollagen production in response 
to exogenous TGF-P suggested that an autocrine loop of TGF-p production 
stimulating collagen production might have been operating in the malignant cells. 
From these results the second thesis hypothesis was generated:
Autocrine TGF-P production by MM promotes malignant cell 
proliferation and tumour growth by enhancing procollagen production
The first hypothesis was tested in chapters 4 and 5, which examined the effect of 
inhibiting collagen production on MM cell proliferation and tumour growth in an 
animal model of MM. The second hypothesis was addressed by examining the effect 
of endogenous and exogenous TGF-P on MM cell proliferation, collagen production 
and in vivo growth, the data obtained shown in chapters 6  and 7.
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Chapter Four
The role of collagen in the proliferation of 
malignant mesothelioma cells in vitro
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4.1 Introduction
In chapter 3 it was established that MM cells produce collagen at a greater rate than
normal mesothelial cells, both basally and in response to TGF-Pi. ECM components 
have been implicated in tumour cell growth in vitro. For example, MM cell lines 
migrate to fibronectin, laminin and collagen type IV (Klominek et al., 1997) and 
exhibit more invasive growth through soft agar when supplemented with hyaluronan 
(Li and Heldin, 2001). Hyaluronan has also been observed to stimulate the migration 
and proliferation of MM cells (Nasreen et al., 2002). Sethi and colleagues (1999) 
observed that ECM proteins promoted the proliferation and prevented the 
chemotherapy-induced apoptosis of small cell lung cancer cells. In addition, the 
inhibition of collagen production with a proline analogue decreased rat breast 
carcinoma cell proliferation (Lewko et al., 1981) revealing the importance of collagen 
in the growth of this tumour. The role of collagen, which is a predominant ECM 
component, in MM growth has not been investigated. This chapter examines the 
importance of collagen in MM proliferation in vitro, and in particular aims to:
1. evaluate the effect of exogenous collagen on MM cell proliferation, ^
2. assess the efficacy of thiaproline as an agent to specifically inhibit collagen^ 
production,
3. and determine the effect of inhibiting endogenous collagen production on MM 
cell proliferation.
cell line AC29 was chosen for the subsequent studies as the cells
one of the highest basal levels of procollagen production, which increased
approximately three fold upon stimulation with 10 ng / ml TGF-pi (figure 3.5). Also, 
studies demonstrated that AC29 cells had the fastest and most reproducible growth in 
vivo (figure 5.2), and as AC29 is a murine cell line the tumour may be easily 
introduced in syngeneic mice for in vivo experiments.
4.2 Effect of collagen matrices on mesothelioma cell proliferation
Following the characterisation of the basal and induced levels of MM cell line 
procollagen, by hyp amino acid production in chapter 3, the effect of growing AC29 
cells on a collagen matrix on cell proliferation was assessed in vitro using 3H-TdR
r
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incorporation studies. Figure 4.1 demonstrates the effect of an increasing 
concentration of fibrillar rat tail collagen type I substrate on AC29 DNA synthesis. 
Thymidine incorporation was dose-dependently increased to a maximum of 11230 ± 
520 d.p.m. / well at 25 ng / well of collagen type I compared to 7090 ± 340 d.p.m. / 
well for medium alone control. This represented an approximate 60% increase 
compared with medium control, pcO.OOl. At higher collagen type I concentrations 
there was a significant increase in thymidine incorporation above the medium control, 
but values were lower compared with the 25 ng / well group (250 ng / well; 
approximate 40% increase compared to medium control, pcO.OOl and also a 
significant decrease compared with 25 ng / well group, pc0.05; 500 ng / well group 
having similar values).
The effect of increasing concentrations of murine basement membrane collagen type 
IV substrate on AC29 cell proliferation was also investigated (figure 4.2). Only 25 ng 
/ well of collagen type IV induced a small but significant increase in thymidine 
incorporation (approximate 20% increase compared with control, pc0.05).
4.3 Determination of the cytotoxic effects of thiaproline in vitro
Having determined that MM cells produce procollagen basally and that exogenous 
collagen can influence AC29 cell proliferation, the effect of inhibiting endogenous 
procollagen production, using the proline analogue thiaproline, was investigated. 
Firstly, the cytotoxic effect of thiaproline on AC29 cells was assessed in order to find 
a range of non-toxic doses for in vitro use. Figure 4.3 demonstrates the effect of an 
increasing concentration of thiaproline on subconfluent AC29 cell viability (as used in 
cell proliferation assays). The mean A5 4 0  at to was 0.15 + 0.01, representing the 
number of cells at the beginning of the assay. With an increasing concentration of 
thiaproline a dose dependent decrease in A540 compared to the medium control was 
observed. Concentrations of thiaproline greater than 10 mM exhibited a lower A540 
than the to value, demonstrating that there were fewer cells than at the beginning of the 
experiment (20 mM; approximately 15% cell death, p<0.05; 30 mM - approximately 
85% cell death, pcO.OOl; 40 mM - approximately 98% cell death, pcO.OOl). 
Concentrations above 40 mM caused total cell death.
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Figure 4.1 Increasing concentrations of collagen type I substrate increased AC29 
DNA synthesis. AC29 DNA synthesis was assessed 24 hr after being cultured on 
collagen type I matrices at a range of concentrations between 0 and 500 ng / well 
(section 2.2.2). Each bar represents the mean ± SEM for six replicate cultures. 
Statistically significant differences from 0 ng collagen / well control group are 
indicated by *, ** and *** representing p<0.05, p<0.005 and p<0.001 respectively. 
This data is representative of 2 experiments.
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Figure 4.2 Collagen type IV substrate had minimal effects on AC29 DNA 
synthesis. AC29 DNA synthesis was assessed 24 hr after being cultured on 0 - 500 
ng / well collagen type IV matrices (section 2.2.2). Each bar represents the mean ± 
SEM for six replicate cultures. This data is representative of 2 experiments.
* p<0.05 compared with 0 ng collagen / well control group.
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Figure 4.3 Assessment of subconfluent AC29 cell viability following thiaproline 
treatment. Cell viability was assessed spectrophotometrically by uptake of neutral 
red and measuring light absorbance at 540 nm 24 hr after treatment with thiaproline 
at a range of concentrations between 0 and 50 mM. Each point represents the mean 
± SEM of six replicate cultures. The broken line represents the mean absorbance 
value at tQ ± SEM. Statistically significant differences from medium control group 
are indicated by * and ** representing p<0.05 and p<0.001 respectively. Data 
representative of three separate experiments.
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The effect of thiaproline on confluent AC29 cell viability (as used in procollagen 
production assays) was also assessed, as shown in figure 4.4. The mean to A540 was 
significantly greater than that of the subconfluent assay (approximately 230% higher, 
pcO.OOl) indicating a greater cell number. Concentrations of thiaproline between 1 -  
30 mM did not significantly reduce A540 compared with the medium control. 
Concentrations greater than 30 mM significantly reduced A540 compared with both the 
medium control (40 mM; approximate 50% reduction, pcO.OOl) and the mean to value 
(similar values as compared with the medium control). This data indicated that 
thiaproline was toxic above 30 mM on confluent cells.
The effect of thiaproline on AC29 cell viability was assessed using an alternative 
cytotoxicity assay measuring LDH release. Figure 4.5A shows that an increasing 
concentration of thiaproline on subconfluent cells caused a dose dependent decrease in 
intact cell layer LDH (representing live cell number) and a concentration dependent 
increase in supernatant LDH (representing lysed cells). When' expressed as a 
percentage of released LDH over total LDH (figure 4.5B), there was a significant 
increase in LDH release to 7.8% at 5 mM (p<0.01) and to 11.5% at 10 mM (p<0.001) 
compared to medium control (6.3%). Although this was suggestive of cytotoxic 
effects at lower concentrations of thiaproline than previously observed, the percentage 
increases obtained in figure 4.5B were minor.
Figure 4.6A demonstrates the cytotoxic effect of thiaproline on confluent AC29 cells. 
Thiaproline induced a dose dependent increase in supernatant LDH release, although 
did not cause a significant decrease in cell layer LDH until over 10 mM. Figure 4.6B 
demonstrates that at 10 mM and above, thiaproline caused a significant increase in the 
percentage of total LDH released (an increase from the medium control value of 
12.8% to 16.1%, pcO.OOl). Based on these data from the two different cytotoxicity 
assays, subsequent experiments were performed using thiaproline at concentrations 
between 0 and 10 mM.
4.4 Effect of thiaproline on AC29 cell procollagen and non-collagen protein 
production
Basal and TGF-P 1-induced procollagen production in response to a range of non-toxic
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Figure 4.4 The effect of increasing concentrations of thiaproline on confluent 
AC29 cell viability. Cell viability was assessed spectrophotometrically 24 hr after 
treatment with thiaproline at a range of concentrations between 0 and 50 mM 
(section 2.3.1). Each point represents the mean ± SEM of six replicate cultures. 
The broken line represents the mean absorbance value at to ± SEM. Statistically 
significant differences from medium control group are indicated by * and ** 
representing p<0.05 andp<0.001 respectively.
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Figure 4.5 Effect of thiaproline on subconfluent AC29 lactate dehydrogenase 
(LDH) release. A demonstrates thiaproline (0 - 50 mM) cytotoxicity towards 
cultured AC29 cells after 24 hr, measured by release of cytoplasmic lactate 
dehydrogenase in the supernatant, in the lysed cell monolayer and as a combined 
total. B represents percentage of total LDH release. Values represent means ± SEM 
of six replicate cultures. * p<0.05, ** p<0.01, *** p<0.001 vs. medium control. 
Data representative of three separate experiments.
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Figure 4.6 Effect o f thiaproline on confluent AC29 LDH release. The cytotoxic 
effects of thiaproline ( 0 - 5 0  mM) on AC29 cells was measured by release of 
supernatant and lysed cell monolayer cytoplasmic lactate dehydrogenase after 24 hr 
in culture (A). B represents percentage of total LDH release. Values represent 
means ± SEM of six replicate cultures. * p<0.05, ** p<0.01, *** p<0.001 vs. 
medium control. Data representative of two independent experiments.
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doses of thiaproline was measured in AC29 cells (figure 4.7). TGF-Pi stimulated 
procollagen production by approximately 150% compared to medium control 
(3.83±0.23 compared with 1.55±0.12 nmol hyp / 106 cells / 24 hr respectively, 
p<0.001). With increasing concentrations of thiaproline both basal and TGF-Pi- 
induced procollagen production were decreased in a dose-dependent manner with a 
maximal effect at 10 mM (compared to media control basal reduction of 
approximately 50%, p<0.001; TGF-Pi-treated reduced by approximately 65%, 
p<0.001). At each concentration of thiaproline there was also a significant increase in 
procollagen production over the basal level with TGF-pi treatment.
To assess the specificity of thiaproline, a comparison of the effects of thiaproline on 
procollagen production and non-collagen protein production in AC29 cells was made 
(figure 4.8). At both 1 and 10 mM, thiaproline decreased non-collagen protein 
production by approximately 15%. However, neither of these reductions were 
significant compared with the medium control. Thiaproline at 1 mM inhibited both 
procollagen and non-collagen protein production to a similar extent (approximately 
20% and 15% respectively). However, at 10 mM thiaproline there was a much greater 
inhibition of procollagen (approximately 50%, p<0.001 compared with medium) than 
non-collagen protein production (approximately 15%). There was a significant 
difference between the inhibition of procollagen and non-collagen protein production 
at 10 mM (p<0.001) suggesting that at this concentration thiaproline has a greater 
specificity towards inhibition of procollagen protein production.
4.5 Effect of thiaproline on cell proliferation in vitro
Having assessed the effect of non-toxic doses of thiaproline on AC29 cell procollagen 
and non-collagen protein synthesis, the effect of thiaproline on cell proliferation was 
examined. The results in figure 4.9 demonstrate that 3H-thymidine incorporation is 
reduced in a dose-dependent manner with an increasing concentration of thiaproline. 
Concentrations of 1, 5 and 10 mM thiaproline resulted in decreases of approximately 
20, 35 and 75% respectively (p<0.005, p<0.001 and p<0.001 respectively, compared 
to medium control).
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Figure 4.7 Increasing concentrations of thiaproline decreased basal and TGF- 
Ppinduced AC29 cell procollagen production in a dose-dependent manner.
Confluent cultures of AC29 cells were incubated with thiaproline at a range of 
concentrations between 0 and 10 mM with and without 1 ng/ml TGF-p!. After 24 hr 
procollagen production was assessed (section 2.4). Each bar represents the mean ± 
SEM for six replicate cultures. * denotes a significant difference of p<0.001 
compared with the relevant media control group (0 mM thiaproline). Data is 
representative of at least four independent experiments.
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Figure 4.8 A comparison of the effect of increasing concentrations of thiaproline 
on AC29 cell procollagen and non-collagen protein production. Confluent AC29 
cells were incubated with thiaproline at 0, 1, and 10 mM. Procollagen and non­
collagen protein production were assessed 24 hr later. The level of protein 
production was expressed as percentage inhibition compared with the media control 
(taken as 0% inhibition). Each bar represents the mean ± SEM for six replicate 
cultures. * denotes a significant difference of p<0.001. Data representative of two 
separate experiments.
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Figure 4.9 Increasing concentrations of thiaproline decreased AC29 DNA 
synthesis in a dose-dependent manner. AC29 DNA synthesis was assessed 
24 hr after culture with 0 - 1 0  mM thiaproline (section 2.2.1). Each bar 
represents the mean ± SEM for six replicate cultures. Statistically significant 
differences from medium control group are indicated by * and ** representing 
p<0.005 and p<0.001 respectively. Data representative of two separate 
experiments.
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4.6 Discussion
4.6.1 Exogenous collagen type I  increased the in vitro rate ofAC29 cell proliferation
The effect of collagen on MM cell proliferation was examined by culturing cells on 
collagen type I and type IV matrices. Figure 4.1 demonstrates that cells grown on 
collagen type I had an increased rate of proliferation at all concentrations examined, 
compared with medium control. Although the MM cells were murine in origin and the 
collagen type I was extracted from rat this is unlikely to affect the experiment as there 
is a high degree of homology between rat and mouse collagen ccl(I) genes. 
Additionally, Miller and Gay (1982) reported that interspecies differences between a 
given type of collagen chain are minimal. Murine collagen type IV caused a relatively 
small increase in cell proliferation compared with the medium control (figure 4.2).
The difference in the proliferative capacity of collagen type I and type IV could be due 
to the differing nature of these two collagens. Type I is a fibrillar interstitial collagen 
commonly found in tumour matrices and may be important in tumour growth. 
Kauppila et al. (1998) have established histologically that there was an increase in 
type I and type III procollagen mRNA in malignant human breast cancer compared to 
benign tumours. They also observed that the expression of both type I and type ID 
procollagens increased with an increasing grade of tumour malignancy, suggesting 
that an increase in fibrillar collagen is associated with worse tumourigenicity.
Ylisimio et al. (2001) have shown that elevated serum levels of the carboxyterminal 
telopeptide of type I collagen (ICTP) and Tissue Inhibitor of Metalloproteinse (TIMP) 
1 are associated with poor prognosis in various lung cancers. This suggests that an 
increased rate of collagen type I production in these cancers may contribute to 
malignancy and lead to a poor prognosis. Further evidence to support a role for 
collagen type I in tumour growth was reported by Simojoki et al. (2001). They 
demonstrated that increased serum levels of the ICTP are associated with a worse 
patient prognosis in ovarian cancer.
Collagen type IV is associated with the basement membrane and therefore may not be 
as important for MM cell proliferation as interstitial collagens. A study by Han et al. 
(1997) demonstrated that a cell binding domain of collagen type IV inhibited the in
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vitro proliferation of human melanoma cells. Applying this observation to MM, it is 
possible that a normal basement membrane prevents cell proliferation, but upon 
malignant transformation an increase in interstitial collagens (seen in malignant breast 
carcinomas by Kauppila et al., 1998) may stimulate cell growth, as demonstrated in 
figure 4.1.
An in vitro study of the effect of various ECM substrates on human MM invasiveness 
through a three-dimensional gel demonstrated that growth on collagen type I substrate 
led to an increased rate of invasiveness when compared with collagen type IV (Ehlers 
et al., 2002). This study suggests that varying substrates have different effects on the 
invasive potential of MM cells, and supports the observations in figure 4.1 and 4.2.
4.6.2 Inhibition o f malignant mesothelioma cell procollagen production reduced the 
rate o f cell proliferation in vitro
To determine the effect of endogenous procollagen production on the proliferation of 
MM cells in vitro, cells were exposed to increasing concentrations of the proline 
analogue thiaproline. Lubec et al. (1994, 1997) demonstrated a reduction in collagen 
accumulation in the heart and the kidney basement membrane of db/db spontaneous 
diabetic mice fed thiaproline. Thiaproline is incorporated into protein in competition 
with proline and prevents chain elongation resulting in truncated peptides which are 
rapidly degraded (Hortin and Boime, 1983). As non-collagen protein contains 
approximately 5% proline and collagen contains 15 -  20% proline there should be a 
preferential inhibition of collagen production.
The use of an amino acid analogue carries the risk of non-specific inhibition, as the 
analogue can be incorporated into any protein containing the amino acid. An 
alternative approach to specifically inhibit collagen production would be the use of an 
inhibitor to a step unique in the processing of collagen (see review by Kagan, 2000). 
Targeting enzymes specific to collagen production (lysyl oxidase and prolyl 4- 
hydroxyalse) have been attempted, but finding compounds capable of effective 
collagen inhibition that are non-toxic has proven difficult. The inhibitor |3- 
aminopropionitrile (BAPN) inactivates lysyl oxidase and prevents collagen 
fibrillogenesis (Tang et al., 1983). However the compound has been reported to be
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toxic, and cross-linkage formation in elastin is also catalysed by lysyl oxidase and 
therefore would be affected by BAPN. Franklin et al. (2001) have described the use 
of a novel series of phenanthrolinones, compounds capable of inhibiting prolyl 4- 
hydroxylase. However, these inhibitors are toxic at effective concentrations in vivo, 
and this is a reoccurring problem with such compounds. In this study, thiaproline was 
chosen as an inhibitor of collagen production, as in other studies appropriate 
concentrations of this analogue have been shown to be effective both in vitro and in 
vivo without toxicity. Thiaproline was initially assessed to determine a suitable range 
of concentrations for in vitro use.
Thiaproline has previously been shown to be non-toxic in vitro at a dose of 120 (xM 
(Gosalvez et al., 1979). Figure 4.3 demonstrates that thiaproline up to a concentration 
of 5 mM did not affect cell viability compared with the medium control. Thiaproline 
at a concentration of 10 mM marginally decreased the number of viable cells 
compared with the medium control, but this number of cells was much greater than the 
to value. The decrease in cell number with 10 mM thiaproline may have been due to 
an inhibition of cell proliferation as opposed to cytotoxic effects. Concentrations of 
thiaproline greater than 10 mM reduced the number of viable cells below the to value, 
indicative of cell death.
Thiaproline had no significant effect on confluent cell cultures compared with the 
medium control up to 30 mM (figure 4.4). Above 30 mM thiaproline caused a 
decrease below the to value suggesting cytotoxicity. These data demonstrate that 
AC29 cells have a better tolerance for thiaproline at confluence compared with 
subconfluence. This may be explained by the fact that at confluence the cells are more 
tightly packed together, surrounded by more ECM and have a lower metabolism than 
subconfluent cells.
These data were verified using an alternative assessment of cytotoxicity measuring 
LDH release. Figure 4.5A demonstrates that increasing concentrations of thiaproline 
on subconfluent AC29 cells increased the number of lysed cells, but decreased the 
total number of cells. Due to the decrease in total cell number, when supernatant LDH 
was expressed as a percentage of the total possible LDH release (figure 4.5B) there
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were significant increases compared with the medium control at concentrations of 
thiaproline above 1 mM, anomalous with the previous observation in figure 4.3.
These data could be interpreted to show that thiaproline is toxic on subconfluent cells 
at concentrations of 1 mM and above. However, morphologically, thiaproline treated 
cells were still adherent and appeared unchanged from the medium control up to 
concentrations of 10 mM. Increasing concentrations of thiaproline also increased 
LDH release when applied to confluent AC29 cell cultures (figure 4.6B), although 
again the morphology of the cells remained unchanged at 10 mM.
Kubo et al. (1999) assessed the cytotoxicity of eosinophil granule major basic protein 
on tumour cell lines using five different methods and found strikingly discrepant 
results amongst the assays. The discordant results between the two cytotoxicity assays 
performed in the current study may have been due to the different characteristics of 
cell viability that each measured. The neutral red assay evaluated lysosomal 
membrane integrity in terms of retention of the neutral red dye whereas the LDH 
release assay assessed the intactness of the cell membrane. These data taken together 
(figures 4.3 -  4.6) demonstrated that thiaproline began to have slight toxic effects at 10 
mM.
Thiaproline is an agent that inhibits protein elongation (Hortin and Boime, 1983) and 
at high concentrations it would be expected to lead to cell damage due to insufficient 
protein production. At a concentration of 10 mM thiaproline showed approximately 
30% toxicity compared with the medium control (figure 4.6B) and inhibited non­
collagen production by approximately 20% (figure 4.8). However, at the same 
concentration of 10 mM, thiaproline inhibited procollagen production by 
approximately 50% (figure 4.8). These data demonstrated that thiaproline although 
having slight toxic effects still exhibited specificity towards procollagen inhibition. 
Therefore, the highest concentration of thiaproline used for in vitro experimentation 
was 10 mM.
Hyp accounts for approximately 12% of the primary amino acid sequence of 
procollagen (Laurent et al., 1981). This amino acid is not at a significant level in other 
proteins with the exception of those indicated in table 4.1. MM cells in culture have
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not been shown to produce these proteins and, as their localisation indicates, they 
, would be unlikely to be present in MM cell cultures. Also, being the predominant 
constituent of the ECM, collagen is likely to contribute to the majority of measurable
Protein Hyp content
(%)
Cell / tissue 
localisation
Major Function
Acetylcholinesterase
5
(Mays and 
Rosenberry, 
1981)
Synaptic / 
neuromuscular 
junctions 
(Schumacher et al., 
1986)
Hydrolyses the 
neurotransmitter 
acetylcholine to terminate 
synaptic signalling
Complement protein 
Clq
4
(Reid, 1979)
Macrophages and 
monocytes 
(Ramadori et al., 1986; 
Martin and Loos, 
1988)
Key molecule in the 
recognition of immune 
complexes
Elastin
0 .9-1 .9  
(Paz et al., 1982)
Blood vessels, skin, 
lung, elastic cartilage 
(reviewed by Kadar et 
al., 2002)
Provides elasticity to 
tissues
Surfactant 
apolipoprotein A
5.9
(Hawgood,
1989)
Lung alveolar surface 
(Hawgood and 
Clements, 1990)
Allows efficient gas 
exchange to occur, aids 
immune functions of lung
Table 4.1 The localisation and function of significant hyp containing proteins
other than collagen
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hyp. Therefore, measuring hyp content from cell cultures is an accurate reflection of 
procollagen production. Incubation of cells with thiaproline resulted in a dose- 
dependent significant decrease in basal and TGF-Pi-induced AC29 procollagen 
production (figure 4.7), demonstrating the ability of thiaproline to inhibit both basal 
and TGF-Pi induced procollagen production.
To establish that the effect of thiaproline was specific to hyp containing proteins, of 
which collagen is the major contributor, cells were incubated with thiaproline and 
procollagen production was compared with non-collagen production (figure 4.8). At a 
1 mM concentration of thiaproline there was a similar inhibition of both procollagen 
and non-collagen protein production. Incubation with 10 mM thiaproline led to a 
significant increase in the level of procollagen inhibition (approximately a two and a 
half fold increase) whereas the level of non-collagen protein inhibition remained 
unchanged compared with that at 1 mM. This data suggests that at a higher 
concentration of thiaproline there was a selective significant increase in the inhibition 
of procollagen production compared with non-collagen protein production, that 
remained unchanged.
Having established that AC29 cells produced procollagen, that cell proliferation was 
stimulated on an exogenous collagen substrate, and that non-toxic doses of thiaproline 
reduced AC29 procollagen production, the effect of thiaproline on AC29 cell 
proliferation was examined. Figure 4.9 demonstrates that thiaproline significantly 
inhibited AC29 cell proliferation in vitro, and as there was selective inhibition towards 
procollagen production at the higher end of the range of concentrations of thiaproline, 
the decrease in proliferation was consistent with inhibition of collagen production.
4.7 Summary and conclusions
Exogenous collagen type I substrate enhanced the proliferation of AC29 cells, as did 
collagen type IV, although to a lesser extent. Thiaproline had minimal toxic effects at 
a concentration of 10 mM on subconfluent AC29 cells and no toxic effects on 
confluent cells. At non-toxic doses thiaproline inhibited AC29 procollagen production 
whilst having a negligible effect on non-collagen protein synthesis. These
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observations confirm the ability of thiaproline to specifically inhibit collagen 
production. Incubation with thiaproline resulted in a dose-dependent decrease in 
AC29 cell proliferation. These data suggest an important role for collagen in AC29 
cell proliferation in vitro, and led to the investigation of the role of collagen in the 
growth of AC29 solid tumours in vivo, described in the following chapter.
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Chapter Five
The role of collagen in malignant 
mesothelioma tumour growth in vivo
132
5.1 Introduction
As demonstrated in chapters 3 and 4, MM cells produce collagen and are stimulated to 
proliferate when grown on collagen substrate. Increasing evidence implicates a role 
for ECM in tumour growth. Lewko et al. (1981) demonstrated that inhibiting collagen 
production with a proline analogue reduced the growth of rat mammary tumours. 
Sethi and colleagues (1999) observed that ECM proteins promoted the proliferation 
and prevented the apoptosis of small cell lung cancer cells. These effects were 
inhibited by the use of antibodies preventing cell-ECM interactions. Whalen and 
Ingber (1989) prevented cell implantation and tumour formation in surgical wounds by 
inhibition of tumour cell attachment to ECM with RGD containing peptides. The 
studies cited above suggest an important role for cell-ECM interactions in tumour 
growth and highlight the potential benefit of inhibiting ECM production in attenuating 
tumour spread. The aim of this following chapter is to test the hypothesis that the 
ECM, in particular collagen, is vital to the growth and progression of MM. 
Specifically, this chapter aims to:
1. find a suitable in vivo model of MM for collagen studies,
2. and to assess the effect of inhibiting collagen production, a major ECM 
component, on MM tumour growth.
5.2 Effect of thiaproline on murine tumour growth models of malignant 
mesothelioma
Chapter 4 demonstrated that non-toxic doses of thiaproline reduced AC29 cell 
procollagen production and cell proliferation in vitro. Thiaproline was further 
examined in this chapter by examining its effects on in vivo MM tumour growth. 
Figure 5.1 demonstrates the effect of thiaproline on AC29 intraperitoneal tumour 
growth. Female CBA mice were inoculated intraperitoneally with 106 syngeneic 
AC29 cells and thiaproline was given orally (as previously described by Lubec et al., 
1994) in drinking water at a dose of approximately 100 mg/kg/day. Controls 
consisted of an AC29-injected group which received untreated water, as did a further 
control group with no MM cell inoculation. Tumours were observed as numerous 
scattered nodules, predominantly attached to the mesentery, and some to the surface 
of the abdominal organs. When culled, the entire abdominal contents were removed.
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Figure 5.1 Intraperitoneal model of MM. Female CBA mice were 
injected intraperitoneally with 106 AC29 cells in lOOpl of DMEM, the 
untreated control receiving DMEM alone. The animals were sacrificed after 
18 days and the entire abdominal contents surgically removed and weighed. 
Each point represents the abdominal content weight for an individual animal.
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At 18 days the untreated control had a mean abdominal organ weight of 3.71 ± 0.10 g, 
the untreated, injected group 3.59 ± 0.15 g and the treated group 3.40 ± 0.10 g. 
Although there was a trend towards decreased weight in the treated group, the large 
spread of abdominal organ weights in each group and high ratio of abdominal content 
weight to tumour weight made this model unsuitable to study the effect of thiaproline 
on MM in vivo growth.
The in vivo growth rates of the murine cell lines were further assessed in a 
subcutaneous murine model. Female BALB/C mice were inoculated subcutaneously 
on both hind flanks with 106 syngeneic AB1 or AB22 cells and CBA mice were 
injected with syngeneic AC29 cells. When the tumours reached an external diameter 
of 1 cm, the animals were culled (several of the tumours reached this size at 18 days, 
the remainder at 25 days). The tumour growth pattern was characterised by a lag 
phase of 5 -  7 days, during which time no tumours were detected, followed by a rapid 
growth to macroscopic tumours. The two longest perpendicular dimensions of the 
excised tumour, measured by microcallipers, were used to calculate tumour area. 
Figure 5.2 demonstrates that AC29 had the fastest rate of growth between 18 to 25 
days. In addition to this experiment, previous studies by Davis et al. (1992) showed 
that out of a panel of murine and human MM cell lines AB1 and AC29 were the most 
tumourigenic at inducing subcutaneous and intraperitoneal in vivo tumours. Also, the 
same study determined that AC29 had the fastest in vivo growth rate. Therefore 
subsequent experiments in this thesis used AC29 cells to induce tumours as an in vivo 
model of MM.
However, the tumours obtained during the pilot experiment (figure 5.2) were very 
nodular (figure 5.3) making calculations of tumour volume based on the measurement 
of length and breadth inaccurate. The possibility of using tumour weight as a 
measurement of growth was examined (figure 5.4). Using weight provided a more 
accurate means of measuring tumour size allowing the measurement of tumours from 
an earlier time-point. Small tumours that were difficult to measure through the skin 
could be surgically removed and weighed on a microbalance. Consequently, all 
subsequent experiments used AC29 cells to induce tumours and tumour weight was 
used as a measure of tumour size.
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Figure 5.2 Pilot study to assess in vivo growth of murine MM cell lines. Female 
CBA mice were inoculated with 106 AB1, AB22 and AC29 cells on both hind 
flanks. The induced tumours were grown to an external diameter of 1 cm (measured 
by microcalipers) and then surgically removed. The excised tumours were 
measured in the two longest dimensions and their area calculated. The data is 
presented as tumour area against time of excision. Each point represents the mean 
of at least two tumours.
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Figure 5.3 Subcutaneous model of MM. Female CBA mice were injected subcutaneously with 106 AC29 cells in lOOpl of 
DMEM. A The animals were sacrificed when tumours were approximately 1 cm in diameter and started to ulcerate through 
the skin (indicated by arrow). B An incision was made and the skin peeled back revealing the underlying tumours. The 
tumours appeared highly vascularised, blood vessels indicated by arrows.
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Figure 5.4 Subcutaneous model of MM using weight as a measurement 
of tumour growth . Female CBA mice were injected intraperitoneally with 
106 AC29 cells in lOOpl of DMEM. Groups of animals were sacrificed at 10 
and 18 days, the tumours surgically removed and weighed. Each point 
represents the mean weight of 10 tumours .
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Subcutaneously inoculated animals were given thiaproline orally in drinking water at 
a dose of approximately 100 mg/kg/day. The control group received untreated water. 
The tumours were excised at 10 and 18 days. Although most tumours were located 
subcutaneously, a few had invaded either the skin or muscle. When excising tumour 
tissue, care was taken to extract only tumour masses. The tumours were generally a 
single large mass, although occasionally several tumour masses were observed. All of 
the tumours exhibited a high degree of vascularity with prominent blood vessels 
supporting the tumours (figure 5.3B).
Figure 5.5 shows the effect of thiaproline on tumour weight at 10 days. The 
thiaproline treated group had a median tumour weight of 10.5 mg (range 5 - 1 2  mg). 
The median tumour weight of the control group was 58 mg (range 30 -  105 mg). This 
represented a reduction in median tumour weight of over 80% with thiaproline 
treatment, p<0.001. The 18 day weights are displayed in figure 5.6. The median 
tumour weight of the treated animals was 106 mg (range 46 -  187 mg), the control 
group also had a median tumour weight of 106 mg (range 27 - 326 mg).
In order to confirm that thiaproline was not affecting animal weight and water 
consumption, these variables were measured at regular intervals throughout the course 
of the experiment in the control and thiaproline treated animals. Figure 5.7A 
demonstrates the weight of thiaproline treated and control animals over 17 days. The 
mean animal weight increased by approximately 10% for the treated group and by 
approximately 12% in the control group over the course of the experiment. These 
values are in accordance with the supplier’s growth curves for the weight of these 
animals. There was no significant difference in animal weight between the two 
groups at any time point. Figure 5.7B shows the effect of thiaproline treatment on 
water consumption in treated and control animals over 17 days. Water consumption 
between treatment groups was similar over time.
To be confident that the tumours were exposed to thiaproline, the circulating levels of 
thiaproline in the blood plasma of control and treated animals were assessed. Figure
5.8 shows a standard curve of thiaproline in water measured by HPLC (example 
chromatogram shown in figure 5.9A), and demonstrates the ability to detect 
thiaproline from a concentration of 0.05 mM. A correlation coefficient of 0.997
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Figure 5.5 Thiaproline reduced subcutaneous mesothelioma 
tumour growth at 10 days. Female CBA mice were inoculated 
subcutaneously with 106 AC29 mesothelioma cells on both hind 
flanks. The control group had free access to drinking water, the 
treated group received water supplemented with thiaproline. The 
induced tumours were excised at 10 days and weighed. Each point 
represents an individual tumour. The median tumour weight is 
indicated by the horizontal bar. * denotes a significant difference 
of p<0.001.
The data are representative of a further two independent 
experiments, expressed as median weight (range) in mg:
Control 20 (9 - 76); thiaproline treated 9 (2 - 41); p<0.01
Control 80 (9 - 365); thiaproline treated 31 (6 - 116); p<0.05
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Figure 5.6 Thiaproline had no effect on subcutaneous 
mesothelioma tumour growth at 18 days. Female CBA mice were 
inoculated subcutaneously with 106 AC29 mesothelioma cells on 
both hind flanks. The control group had free access to drinking 
water, the treated group received water supplemented with 
thiaproline. The induced tumours were excised at 18 days and 
weighed. Each point represents an individual tumour. The median 
tumour weight is indicated by the horizontal bar.
These results are representative of a further independent repeat 
experiment, expressed as median weight (range) in mg:
Control 50 (1 - 365); thiaproline treated 31 (5 - 116)
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Figure 5.7 Thiaproline had no effect on animal weight or water consumption. Female CBA mice were inoculated subcutaneously 
with 106 AC29 mesothelioma cells on both hind flanks. The control group had free access to drinking water, the treated group received 
water supplemented with thiaproline. A The animals were weighed at regular intervals. Each point represents the mean weight of 9 
animals ± SEM. B The water intake of animals was measured at regular intervals. Each point represents the mean water intake per 
mouse derived from 2 cages of 5 animals.
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Figure 5.8 Thiaproline may be quantified by high performance liquid chromatography 
(HPLC). Thiaproline standard solutions (0.05 - 10 mM) were run through a HPLC system and the 
area of a peak eluting at approximately 7.8 minutes corresponding to thiaproline was measured. 
Highlighted section represents an enlarged area of graph demonstrating the ability to detect 
thiaproline from a concentration of 0.05 mM. Similar data was obtained from three independent 
experiments.
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demonstrated a linear relationship between the peak area on the chromatogram and 
the concentration of thiaproline.
Figure 5.9 shows a chromatogram of plasma standards examined for thiaproline. A 
naturally occurring peak in unspiked human blood plasma (5.9B) was eluted at the 
same time as the thiaproline peak (figure 5.9C) which made quantification of low 
thiaproline concentrations impossible. The same problem was encountered when 
analysing blood plasma samples from control (figure 5.10A) and thiaproline treated 
mice (figure 5.10B). The elution conditions were modified several times (the buffer 
composition was altered to a higher percentage of acetonitrile and the running time 
for each sample through the column was increased) but this did not resolve the 
contaminating peak from the thiaproline peak.
5.3 Determination of thiaproline-treated and control tumour collagen content
The collagen content of thiaproline-treated and control tumours was assessed and 
represented as collagen content against tumour weight. The data from the 10 day 
tumours (figure 5.11 A) showed that the thiaproline-treated tumours had a lower mass 
and contained a lower collagen content per tumour compared with control tumours. 
The correlation coefficient between tumour weight and collagen content was 0.97 
demonstrating that an increase in tumour weight was associated with an increase in 
collagen content. Figure 5.1 IB demonstrates that thiaproline-treated tumours 
contained a lower concentration of collagen per mg of tumour weight than the control 
tumours (p<0.001).
5.4 Histology of tumour sections
Thiaproline-treated and control tumours were processed to paraffin wax and sections 
stained for collagen. Figure 5.12 demonstrates Martius scarlet blue staining of control 
and treated tumours at 10 and 18 days. The thick blue fibres apparent in the ECM 
correspond to deposited collagen fibrils and showed a similar distribution of collagen 
in both sets of tumours. Reticulin staining (figure 5.13) showed grey strands in the 
tumour stroma which demonstrated the presence of reticulin (collagen type I and type 
El and elastin) in a similar distribution in all tumour sets.
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Figure 5.9 High performance liquid chromatograms of 
thiaproline standard and control/spiked human blood plasma.
Thiaproline standard solution (A; 0.01 mM), human blood plasma 
(B) and thiaproline-spiked plasma (C; 0.01 mM) were run through a 
HPLC system. TP indicates the elution time for thiaproline.
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Figure 5.10 Chromatograms of mouse blood plasma 
demonstrated a naturally occurring peak masking thiaproline.
Control mouse blood plasma (A) and thiaproline-treated mouse 
plasma (B) were processed on a HPLC system. TP indicates the 
elution time for thiaproline.
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Figure 5.11 Thiaproline reduced AC29 tumour procollagen concentration at 10 days. Female CBA mice were 
inoculated subcutaneously with 106 AC29 mesothelioma cells. The control group had free access to drinking water, 
the treated group received water supplemented with thiaproline. The induced tumours were excised at 10 days and 
weighed. Tumour procollagen content was assessed and plotted against tumour weight (A) and the correlation 
coefficient (r) calculated. The concentration of procollagen per mg of tumour was also calculated (B). Each point 
represents an individual tumour. * denotes a significant difference of p<0 . 0 1  between thiaproline-treated and control 
tumour groups.
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Figure 5.12 Martius scarlet blue staining revealed abundant collagen 
deposition in tumour sections. Female CBA mice were inoculated 
subcutaneously with 106 AC29 mesothelioma cells. The control group had 
free access to drinking water. The treated group received water 
supplemented with thiaproline. The induced tumours were excised at 10 
and 18 days and processed to paraffin sections. Control tumour (A; 10 
day, C; 18 day) and treated tumour (B; 10 day, D; 18 day) were stained 
with Martius scarlet blue. Bar represents 100 pm, original magnification 
x40.
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Figure 5.13 Reticulin staining demonstrated well defined reticular 
network in tumours. Thiaproline-treated AC29 tumours (section 2.7.3) 
were excised at 10 and 18 days and processed to paraffin sections. Control 
tumour (A; 10 day, C; 18 day) and treated tumour (B; 10 day, D; 18 day) 
were stained for reticulin (section 2.9.4). Bar represents 50 pm, original 
magnification x200.
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Immunohistochemical staining for different collagen types revealed unique 
distribution in each case, although no obvious differences between the thiaproline- 
treated and control tumours were apparent at either time point. Collagen type I 
exhibited a fibrillar pattern in the ECM within the tumour (figure 5.14), collagen type 
m  appeared to be much more diffuse with an amorphous distribution (figure 5.15) 
and basement membrane collagen type IV showed dense fibril-like staining (figure 
5.16). All collagen types were present in the tumour capsule encircling the periphery 
of the tumour.
Haematoxylin and eosin staining of 10 day (figure 5.17) and 18 day (figure 5.18) 
tumour sections demonstrated an amorphous and heterogeneous cell population with a 
large nucleus to cytoplasmic ratio, characteristic of tumour cells. The majority of 
blood vessels were located in the periphery of the tumour. An inflammatory infiltrate 
(predominately macrophages) was also localised to the periphery, penetrating 
approximately 50 -  100 cell layers into the tumour, regardless of tumour size (figures 
5.17 and 5.18). There were no observable differences in inflammatory cell or blood 
vessel number between the treated and control tumours.
5.5 Discussion
5.5.1 Murine models o f MM tumour growth
The i.p. injection of AC29 cells into syngeneic mice is an established model of MM 
(Bielefeldt-Ohmann et al., 1995a, Bielefeldt-Ohmann et al., 1995b). In these studies’ 
the extent of tumourigenicity was assessed using. scoring methods examining 
variables such as body weight, behaviour, and physical appearance over a period of 
up to 3 months. However, for the current study, at 18 days no observable symptoms 
of i.p. tumour inoculation were observed and so tumour extraction and weight were 
used (Lukacs et al., 1999). The i.p. tumours grew as an inseparable aggregation of 
tumour bulk and abdominal organs and thus the entire abdomen contents were 
removed and weighed (figure 5.1). Biological variation between abdominal weights 
in the control group mask the comparatively smaller differences in weight of the 
induced tumours and therefore made this model unsuitable for studying the effect of 
thiaproline on MM tumour growth. However, there was a trend towards a decrease 
with thiaproline treatment, the treated group having an approximate 5 % decrease in 
mean abdominal weight compared to the injected control group.
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Figure 5.14 Immunohistochemistry revealed fibrillar collagen type I distribution in AC29 solid tumours. Thiaproline-treated
induced AC29 tumours (section 2.7.3) were excised at 10 and 18 days, processed to paraffin sections and stained with a collagen type I
specific antibody (section 2.9.6). Bar represents 25 pm, original magnification x200.
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Figure 5.15 Immunohistochemistry revealed a large distribution of fibrillar collagen type III in tumour sections. Female CBA 
mice were inoculated subcutaneously with 106 AC29 mesothelioma cells. The control group had free access to drinking water. The 
treated group received water supplemented with thiaproline. The induced tumours were excised at 10 and 18 days, processed to 
paraffin sections and stained with a collagen type III antibody (section 2.9.6). Bar represents 25 pm, original magnification xlOO.
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Figure 5.16 Immunohistochemistry showed the presence of basement membrane collagen type IV in tumours. Thiaproline-
treated AC29 solid tumours (section 2.7.3) were excised at 10 and 18 days, processed to paraffin sections and stained with a collagen
type IV specific antibody (section 2.9.6). Bar represents 25 pm, original magnification xlOO.
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Figure 5.17 Haematoxylin and eosin staining revealed blood vessels close to the periphery of tumours at 10 days. Female CBA 
mice were inoculated subcutaneously with 106 AC29 mesothelioma cells. The control group had free access to drinking water. The 
treated group received water supplemented with thiaproline. The induced tumours were excised at 10 days, processed to paraffin 
sections and treated with Haematoxylin and eosin stain (section 2.9.5). Arrows mark areas of vasculature, circles highlight 
macrophages. Bar represents 25 jam.
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Figure 5.18 Haematoxylin and eosin staining showed established vasculature in 18 day tumour sections. Thiaproline-treated
induced AC29 tumours (section 2.7.3) were excised at 18 days, processed to paraffin sections and treated with Haematoxylin and eosin
stain (section 2.9.5). Arrows indicate vessels, circles surround macrophages Bar represents 25 pm.
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The s.c. injection of MM cells into syngeneic mice is an alternative model of MM 
growth (Davis et al, 1992). This model has been demonstrated to be consistent with 
the human disease in almost every aspect, in terms of histology, ultrastructure, 
growth, morphology and tumourigenicity. The s.c. model was more amenable for 
tumour studies than the i.p. model as s.c. induction of MM enabled the assessment of 
tumour growth externally without the need to sacrifice the animal, as well as 
generating a single defined tumour mass which was convenient for analysis.
Tumour growth was initially measured by obtaining two perpendicular measurements 
on the excised tumour using microcallipers at the time of sacrifice. Figure 5.2 shows 
that AC29 had the fastest rate of growth between 18 and 25 days, producing larger 
tumours than AB1 or AB22. Other studies assessed rate of growth by measuring 
tumour dimensions whilst still in vivo through the skin (Hwang et al., 1995, Leong et 
al., 1997, Caminschi et al, 1999). However, these methods could be considered to be 
imprecise. Skin thickness influenced size measurements, and given the irregular 
nodular shape of the tumours (figure 5.3) it was not an accurate reflection of tumour 
size using measurements in two dimensions and calculating volume. Due to these 
concerns weight was measured as an assessment of tumour growth (figure 5.4). The 
surgical removal and weighing of the tumours allowed a more precise measurement of 
tumour growth from an earlier time-point than measuring tumour dimensions 
externally through the skin. Subsequent in vivo studies used weight as a measure of 
tumour growth.
5.5.2 Administration o f thiaproline in vivo delayed tumour growth
Previous in vivo studies have shown a range of doses of thiaproline that are non-toxic 
when given orally to mice. Lubec et al. (1994) observed a reduction in glomerular 
basement membrane thickening in the diabetic db/db mouse following treatment with 
thiaproline at 30 mg/kg/day for 12 weeks. Correa and associates (1999), studying the 
effect of thiaproline on macrophage function, fed mice thiaproline at 0.1% w/w in 
food for 5 weeks without any toxicity. In this study, mean animal body weight was 
measured over the course of thiaproline treatment with no difference seen between the 
treated and untreated groups (figure 5.7A). Body weight increased as expected from 
the supplier’s growth curves. To demonstrate that thiaproline was not affecting water 
intake, and that animals in treatment groups received equal doses, the volume of
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drinking water was measured daily (figure 5.7B). There was no significant difference 
in the mean daily water consumption per animal between the treated and untreated 
groups. No observable difference in the behaviour or appearance of treated and 
untreated animals was noticed, confirming previous studies (Lubec et al., 1994).
In order to be confident that thiaproline was reaching the tumours in the animal model, 
an attempt was made to measure the circulating level of thiaproline in the blood 
plasma of control and treated animals. Figure 5.8 demonstrates that thiaproline could 
be measured from a concentration of 0.05 mM in standard solutions, and that 
thiaproline concentration was strongly correlated with peak area. However, when 
measuring thiaproline in extracted plasma, there was an unidentified peak present at 
the same position as thiaproline in the standards (figure 5.9). This unidentified peak 
masked the thiaproline peak making quantification impossible.
Pine et al. (1983) previously demonstrated that thiaproline could be detected in mouse 
blood plasma at a circulating concentration of 77 nmol/ml when given orally in 
drinking water at 8 mg/ml. At lower doses they were unable to detect circulating 
thiaproline. In the current study, thiaproline was given to mice at a dose of 0.4 mg/ml 
of drinking water, equivalent to a concentration of ImM, which has been demonstrated 
to be effective in reducing collagen production (figure 4.7) and cell proliferation 
(figure 4.9) whilst not being toxic (figures 4.3 -  4.6). Therefore, at this concentration 
thiaproline was too dilute to be detected and measured in blood plasma using the 
method of Pine and colleagues.
A possible solution to detect blood plasma thiaproline would be to employ the use of 
high-resolution NMR spectroscopy, which is able to detect compounds at parts per 
million sensitivity, which equates to pM concentrations. Recent publications 
investigating metabonomics demonstrated the sensitivity of this system using plasma 
and urine samples (Tate et al., 200i; Sidelmann et al, 2001; Nicholls et al., 2001).
In this study at 10 days, oral administration of thiaproline at a dose of 100 mg/kg/day 
significantly lowered AC29 median tumour weight by approximately 85% compared 
with the control group (figure 5.5). There was no overlap of tumour weights from one 
group to another, and within the thiaproline treated group there was a minimal spread
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of weight. Collagen analysis of the tumours revealed that there was a significantly 
lower concentration of collagen per tumour in the thiaproline treated group compared 
with the control group (figure 5.1 IB). When collagen content was expressed with 
respect to tumour weight there was a strong correlation between tumour weight and 
collagen content (figure 5.11 A). This showed that an increase in tumour weight was 
associated with an increase in collagen content and that the greater tumour mass seen 
in the control group was not only due to an increase in tumour cells or fluid retention. 
These data demonstrated that the use of thiaproline resulted in significantly smaller 
tumours with a significantly lower concentration of collagen, whereas in untreated 
animals, tumours were larger with a higher concentration of collagen.
The in vitro studies from chapter 4 demonstrated that AC29 had an enhanced rate of 
proliferation on a collagen type I substrate (figure 4.1), that thiaproline inhibited AC29 
collagen production (figure 4.7) and that thiaproline also reduced AC29 proliferation 
(figure 4.9). These data are consistent with the hypothesis that collagen production 
stimulates MM proliferation. Together, the in vitro (chapter 4) and in vivo data clearly 
demonstrate that thiaproline inhibited collagen production, which correlated with a 
reduced rate of tumour growth up to 10 days post transplantation.
At 18 days there was no significant difference in tumour weight between the treated 
and untreated groups (figure 5.6). Therefore, for the tumour size to be the same in 
both groups either the treated tumours increased their rate of growth, growth of 
control tumours slowed, or a combination of both occurred. The reasons for this are 
unclear. It is possible that between 10 and 18 days the control tumours reached a peak 
in their rate of growth, with the tumours being unable to support a higher rate of 
growth due to insufficient vasculature. Areas of necrosis at the core of several 
tumours were seen at 10 and 18 days (data not shown), these could have been due to 
insufficient vasculature leading to cell death. However, the median tumour weight of 
the control group approximately doubled between 10 to 18 days showing that an 
attenuation of control tumour growth did not occur. It is also possible that at 10 days 
in the treated group there were insufficient collagen producing cells to sustain a rapid 
rate of growth, or that a critical amount of collagen was required to be produced 
before the rate of growth increased. During 10 to 18 days a critical number of cells 
may have been reached that could produce the required quantities of matrix
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components and cytokines allowing the tumour to grow at a faster rate. The integrin 
family of receptors mediates the interaction between cells and the ECM. After being 
activated by an ECM ligand, integrins stimulate intracellular signalling and can 
promote cell-cell aggregation and adhesion to ECM components (Sethi et al., 1999). 
The lower concentration of collagen at 10 days in the thiaproline treated group 
potentially provides less ligand for the integrins to bind resulting in slower growth. 
This may be overcome as sufficient ECM is produced between 10-18 days.
Administration of higher doses of thiaproline may have had a greater effect in 
delaying tumour growth, however there was concern regarding its in vivo toxicity. 
Toxicity has been observed at different concentrations in various species when given 
orally and intraperitoneally (Nasca et al., 1981, Newman et al., 1980). It has been 
reported that the most toxic route of thiaproline administration is that given orally 
(Gosalvez et al., 1980). Therefore doses of thiaproline above the 100 mg/kg/day 
reported here were not investigated.
A similar delay in tumour growth to that demonstrated in this study has been observed 
in several other in vivo studies of mesothelioma. Leong et al. (1994) have shown that 
AC29 cells transfected with allogenic MHC genes were able to retard, but not inhibit, 
the growth of parental AC29 cells injected into the same animal. AC29 cells 
transfected with the T-cell costimulator B7-1 had a delayed ability to grow in vivo, 
although all eventually formed tumours (Leong et al., 1996). Mukherjee et al. (2001) 
established that a combination of surgical debulking and transfection of AC29 cells 
with B7-1 or GM-CSF resulted in a delay of tumour growth.
Fitzpatrick et al. (1994) and Marzo et al. (1997) demonstrated that antisense 
oligonucleotides to TGF-P2 delay AC29 tumour development compared to controls. 
However, once the treated tumours became palpable they exhibited similar growth 
kinetics compared to the control groups. A possible explanation for this delay in 
tumour growth at earlier time points and subsequent ‘catch up’ growth in the treated 
group at a later stage may be due to the incomplete suppression of TGF-P2 (Marzo et 
al., 1997). At early stages of tumour growth the level of inhibition may be sufficient 
to restrict growth, however once the tumour reaches a certain size this level of
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inhibition is no longer strong enough to slow growth due to the greater cell number 
within the tumour. This thesis has demonstrated that at a concentration of ImM 
thiaproline inhibits collagen production by approximately 20% in vitro (figure 4.8) and 
other studies have demonstrated that similar concentrations of thiaproline reduce 
collagen accumulation in vivo (Lubec et al., 1994, 1997). At a concentration of ImM 
thiaproline decreased tumour size compared to untreated controls at 10 days (figure 
5.5). However, the remaining 80% of collagen production may have been sufficient to 
promote tumour growth between 10 -  18 days resulting in the similar sized 
thiaproline-treated and control tumours observed (figure 5.6).
A delay in tumour growth has been apparent in several clinical studies of MM where 
chemoimmunotherapeutic methods have been used to try and improve patient survival. 
Trials involving the use of interferon-a in combination with other chemotherapy 
agents (Upham et al, 1993, Ardizzoni et al, 1994, Fizazi et al, 2000) increase the 
median survival of patients marginally. These studies show partial responses in some 
patients suggesting that these treatments are delaying tumour growth slightly, but that 
the disease is still fatal.
Martius scarlet blue (figure 5.12) and haematoxylin and eosin staining (figures 5.17 
and 5.18) demonstrated an amorphous and. heterogeneous cell population with a large 
nucleus to cytoplasm ratio, characteristic of malignant cells. Histological assessment 
of tumours did not show differences between treated and control sections (figures 5.12 
-  5.18). There was a very similar pattern of matrix distribution and intensity of 
staining for collagen and reticulin, both of which contributed to the body of the tumour 
and occurred as part of the surrounding tumour capsule. Reticulin staining (figure 
5.13) demonstrated less mature reticulin around the periphery of the tumours 
suggesting that the matrix around the tumour edges was laid down later and tumour 
growth occurred outwards.
The apparently similar collagen distribution shown in figures 5.14 -  5.16 is 
contradictory to figure 5.1 IB which demonstrated a lower concentration of collagen in 
the thiaproline treated group when compared with the control group at 10 days. The 
difference could be attributed to the fact that histology is a 2-dimensional
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representation of 3-dimensional tissue and there could have been uneven collagen 
deposition across the tumour mass. Collagen analysis by HPLC sampled the entire 
tumour collagen content and would therefore give a better indication of the actual 
overall collagen content.
Specific immunohistochemical staining revealed the presence of fibrillar collagens 
type I and type HI (figures 5.14 and 5.15). Collagen type I had a fibrillar network 
pattern, collagen type DI a more amorphous distribution than type I. However, the 
collagen type ID antibody exhibits a 70% cross-reactivity with type I collagen 
(manufacturer’s data) and therefore shows the distribution of collagen type I and type 
HI. The basement membrane collagen type IV was also found distributed in the 
tumour stroma in a dense fibrillar pattern (figure 5.16). This has also been observed 
in gastric and bile duct carcinomas immunohistochemically and by in situ 
hybridisation (Chen et al., 2000b). The authors suggest that stromal collagen type IV 
deposition may increase the extent of desmoplasia in these tumours. MM has been 
shown to adhere and migrate to collagen type IV (Klominek et al., 1997), and 
collagen type IV has been implicated in breast carcinoma growth (Lewko et al., 
1981). Reduction of tumour growth by proline analogues inhibiting collagen 
production has been found to be most effective in tumours that synthesise collagen 
type IV (Klohs et al., 1985). The data presented here demonstrating enhanced 
proliferation of MM cells on collagen substrates (figures 4.1 and 4.2), the abundance 
of collagen in MM, and the inhibition of tumour growth with thiaproline supports a 
role for collagen in MM tumour growth. The decrease in proliferation observed with 
thiaproline (figure 4.9), an inhibitor of collagen production (figure 4.7), provides 
further evidence for the importance of collagen in MM growth.
Haematoxylin and eosin staining (figures 5.17 -  5.18) revealed that the majority of 
blood vessels were located close to the periphery of the tumour. There were no 
apparent differences in the number of vessels or inflammatory cell numbers between 
groups.
5.5.3 Non-collagen related effects o f thiaproline
Several studies suggest that thiaproline has other effects apart from inhibition of 
collagen production, and these may influence tumour growth. The inhibition of
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angiogenesis and the regression of growing capillaries in the chick chorioallantoic 
membrane were observed with thiaproline treatment (Ingber and Folkman, 1988). 
Angiogenesis is essential for tumour growth beyond 1 - 2  mm in diameter and there 
are studies which demonstrate that inhibiting angiogenesis may be a suitable strategy 
for treating cancer growth (Riedel and Hormann, 2001, Rozic et al, 2001, Katzenstein 
et al, 2001). Therefore, thiaproline may have at least partly delayed tumour growth 
through inhibition of angiogenesis. However, histologically there didn’t appear to be 
any difference in the number or structure of vessels within the tumours (figures 5.17 -  
5.18) although further studies with markers specific to endothelial cells to enable 
quantification are required to confirm this.
The ability of cancer to evade the host immune system allows unchecked tumour 
growth. A possible control of MM would be to stimulate local and systemic anti­
tumour immune responses. Bielefeldt-Ohmann et al (1995a) have shown that the 
treatment of MM bearing mice with recombinant human interferon-a (rhuINFa) 
curtailed the clinical symptoms of the disease accompanied by improved lymphocyte 
activity and an enhanced number of tumour-infiltrating lymphocytes and 
macrophages. Therapy with rhuINFa has also been demonstrated to have stimulatory 
effects on immune cells with a decreased rate of MM tumour growth in vivo 
(Bielefeldt-Ohmann et a l 1995b).
There are several studies suggesting that murine immune functions can be improved 
by thiaproline, both in vitro and in vivo. The lymphoproliferative response, 
lymphocyte motility and the natural killer activity of leukocytes in mice were all 
significantly stimulated by ingested thiaproline (De la Fuente et al, 1993, 1998). It is 
also suggested that thiaproline may enhance murine macrophage function (Correa et 
a l , 1999). As the range of concentrations of thiaproline used in these studies were 
similar to those used in this study, an improvement in immune function by thiaproline 
may have contributed to the delayed tumour growth at 10 days. However, 
haematoxylin and eosin staining revealed no differences in inflammatory cell influx 
between treated and control sections at 10 days (figures 5.17 -  5.18). Further studies 
to quantify inflammatory cells are required to confirm this.
162
Thiaproline given orally is metabolised in the liver to cysteine and formaldehyde 
(Grier et al., 1984, Zhao et al., 1995). Formaldehyde release leads to cytotoxic 
damage, which would limit tumour growth. There have been several reports 
documenting the effect of aldehydes on inhibiting tumour growth (Schauenstein and 
Esterbauer, 1978, Gescher et al., 1982). However, ingested thiaproline is probably 
partially removed in the portal circulation (Pine et al., 1983) and at the dose used in 
this study, mice exhibited no toxic or behavioural problems associated with aldehyde 
poisoning.
The non-collagen related effects of thiaproline described above may have contributed 
to the lower tumour mass seen in the thiaproline-treated group. However, collagen 
analysis revealed a lower concentration of collagen per mg of tumour in the 
thiaproline-treated group compared with the control group (figure 5.1 IB). This 
observation suggests that despite the other effects of thiaproline, decreased collagen 
production was associated with delayed tumour growth. This is consistent with the 
observation in the previous chapter that inhibition of collagen production with 
thiaproline decreased AC29 cell proliferation (figure 4.9).
5.6 Summary and conclusions
The experiments described in this and the previous chapter demonstrate that MM cells 
produce collagen and furthermore proliferate at a significantly faster rate when grown 
on a collagen matrix. Inhibition of collagen production with thiaproline significantly 
reduced cell proliferation in vitro and tumour weight and collagen concentration at 10 
days but not 18 days of treatment in vivo. These novel findings demonstrate that 
inhibition of collagen production delays MM tumour growth. The use of thiaproline in 
the treatment of human MM would not be feasible due to the cytotoxic nature of this 
compound. However, this study has clearly shown that therapeutic agents capable of 
inhibiting collagen production at non-toxic doses could be effective in the treatment of 
MM. A multimodal approach combining surgical debulking of the tumour followed 
by the use of an inhibitor of collagen production may prove to be a viable therapeutic 
strategy for the treatment of this disease.
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This thesis has demonstrated that collagen production is potently stimulated by TGF-P 
(table 3.1) and that TGF-P is at elevated levels in MM (figure 3.3). The effect of the 
different TGF-p isoforms on MM collagen production and cell proliferation have not 
previously been determined. Therefore, the next chapter investigates the role of 
different exogenous TGF-P isoforms on MM cell proliferation and the effect of 
specifically neutralising TGF-P isoforms on proliferation and collagen production in 
vitro.
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Chapter Six 
The role of exogenous and 
endogenous Transforming Growth Factor 
on mesothelioma cell proliferation 
and collagen production in vitro
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6.1 Introduction
Chapters 4 and 5 demonstrated that inhibition of procollagen production in MM cells 
reduced their proliferation in vitro and delayed tumour growth in vivo, suggesting an 
important role for collagen in MM growth. Also, levels of transforming growth 
factor-beta (TGF-pi.3), key regulators of cell proliferation and potent stimulators of 
collagen production, are increased in MM. Compared to normal mesothelial cells, 
MM produces elevated levels of TGF-p at the RNA and protein level (Fitzpatrick et 
al., 1994, Kuwahara et al., 2001), and in pleural effusions from MM patients TGF-P 
is present at 3 -  6  times the levels found in other primary lung cancers (Maeda et al, 
1994). Increased levels of TGF-p have also been demonstrated in MM cells 
compared with normal mesothelial cells in this study, and exogenous TGF-P 1 shown 
to stimulate MM cell procollagen production in a dose dependent fashion in vitro 
(chapter 3). The following two chapters test the hypothesis that autocrine TGF-p 
production by MM promotes cell proliferation and tumour growth through the 
enhancement of collagen production. A comparison of the specific endogenous TGF- 
P isoforms produced by normal mesothelial cells and MM has not previously been 
performed and TGF-P isoform specific effects on MM cell proliferation and collagen 
production have not been assessed. The aims of this chapter are to:
1. determine the effect of exogenous TGF-p isoforms on MM cell proliferation,
2. quantitate TGF-P isoform production at the protein level,
3. and examine the effect of inhibiting specific TGF-p isoforms on cell
proliferation and procollagen production.
6.2 The effect of exogenous TGF-pi, -p2 and -p3 on mesothelioma cell
proliferation
DNA synthesis in AC29 cells in response to 24 hr incubation with a range of 
concentrations of TGF-Pi, -p2 and -p3 (0 -  10 ng/ml) was assessed by 3H-TdR 
incorporation studies. Data was presented as percentage change from the medium 
control (figure 6.1). All three isoforms of TGF-p had a similar effect, reducing 
thymidine incorporation with increasing concentrations of TGF-P in a dose-dependant 
manner. At a concentration of 100 pg/ml TGF-p 1 significantly decreased AC29 
thymidine incorporation compared with the medium control by approximately 15%
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Figure 6.1 Exogenous TGF-p,, -P2 and -P3 inhibited AC29 DNA synthesis. AC29 cells were incubated with increasing 
concentrations of TGF-P,_3 for 24 hr and DNA synthesis measured via tritiated thymidine incorporation. Data are expressed 
as percent change from medium control. *p<0.05, **p<0.01 vs. medium control. The results are representative of three 
repeat experiments.
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(TGF-pi-treated 26380 ± 730 d.p.m. / well, medium control 36980 ± 530 d.p.m. / 
well; p<0 .0 1 ). Incubation with 2 0 0  pg/ml TGF-p2 significantly reduced thymidine 
incorporation by approximately 30% (TGF-p2-treated 18750 ± 1460 d.p.m / well, 
medium control 26200 ± 1650 d.p.m. / well; p<0.05). Thymidine incorporation was 
also reduced by approximately 15% with 50 pg/ml TGF-p3 (TGF-P3-treated 52660 ± 
1190 d.p.m / well, medium control 61200 ± 1140 d.p.m. / well; p<0.01). Further 
inhibition of thymidine incorporation occurred with increasing concentrations of all 
TGF-P isoforms, with a maximal inhibitory effect seen at a concentration of 
approximately 1 ng/ml TGF-p.
6.3 Characterisation of isoform-specific TGF-p neutralising antibodies
To examine the amount of TGF-P protein secreted by cell lines into conditioned 
medium a panel of TGF-p antibodies were firstly characterised for their potency and 
selectivity towards the different TGF-p isoforms. The ability of the antibodies to 
neutralise 0.1 n g / m l  TGF-P i, -P2 and -P3 was assessed using a MLEC TGF-P 
bioassay. All of the antibodies were used at the manufacturers recommended 
concentrations.
The effectiveness of the R & D Systems TGF-p antibodies in neutralising TGF-p 1, -p2 
and -p3 are shown in figure 6.2. The pan-specific TGF-P antibody was extremely 
potent, completely neutralising the activities of all three TGF-p isoforms, whilst the 
control antibodies had minimal effects. The TGF-p 1 and TGF-p2 neutralising 
antibodies specifically blocked their respective isoforms with minor effects on the 
other TGF-p isoforms. TGF-pi antibody reduced TGF-pi activity by 100%, TGF-p2 
neutralising antibody decreased the activity of TGF-p2 by 95%. The TGF-p3 antibody 
neutralised TGF-p3 activity by 95% compared to the control antibody. However, 
cross-reactivity was observed (as stated on the manufacturer’s datasheet), as the TGF- 
p3 antibody also decreased TGF-p2 activity by approximately 65% compared to the 
antibody control.
Neutralising antibodies against TGF-p isoforms supplied by Cambridge Antibody 
Technology (CAT) for in vivo studies (chapter 7) were also characterised (figure 6.3).
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The pan-specific TGF-p antibody was also highly potent, with 100% neutralisation of 
all three TGF-P isoforms. The TGF-pi antibody exhibited poor neutralisation of 
TGF-P i, reducing activity by approximately 25% compared with the control antibody. 
There was a similar degree of cross-reactivity with TGF-p3 with the TGF-pi antibody 
decreasing TGF-P3 activity by approximately 2 0 %. The TGF-p2 antibody completely 
neutralised TGF-p2 activity, although there was cross-reactivity with TGF-p3, 
showing a reduction in activity of approximately 15%.
The CAT TGF-p 1 antibody becomes more potent in vivo due to unknown 
mechanisms, and this can be mimicked in vitro by the acid-activation of the antibody 
(personal communication from Dr Matthew McCourt, CAT). A titration of acidified 
TGF-p 1 antibody, supplied by CAT, was performed (figure 6.4A) to determine the 
optimal concentration for use in vitro. Increasing concentrations of antibody resulted 
in a dose-dependent decrease in TGF-pi activity, however this was also observed with 
the control antibody. At a concentration of 150 ng / ml the acidified TGF-p 1 antibody 
decreased TGF-P 1 activity by approximately 40% (p<0.05 compared with 0.1 ng / ml 
TGF-P 1 control group) whilst the control antibody was not significantly different from 
the control group (decrease of approximately 10%). Higher concentrations of 
antibody caused a further reduction in TGF-Pi activity in both TGF-pi and control 
antibody treatments. Therefore, a concentration of 150 ng / ml was chosen to perform 
subsequent characterisation studies (figure 6.4B). At this concentration the acidified 
TGF-p 1 antibody decreased TGF-P 1 activity by approximately 35% compared to the 
control antibody, whilst having no neutralising effect on either TGF-P2 or -p3 .
6.4 Determination of endogenous active and latent TGF-p isoforms produced in 
the conditioned media of normal mesothelial and AC29 cells in culture
Due to their efficiency and low cross-reactivity, the TGF-p 1 and -P2 neutralising 
antibodies purchased from R & D Systems were used to quantitate the different TGF- 
P isoforms present in conditioned media collected from normal mesothelial and AC29 
cell lines (figure 6.5). Conditioned media were heated to activate latent TGF-p 
present in the samples (section 2 .6 .1).
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As previously demonstrated in figure 3.3, AC29 cells produced elevated levels of 
TGF-P, the total amount over 12 times that of normal mesothelial cells (figure 6.5 A). 
There was a shift in the proportion of TGF-p isoforms produced comparing the 
control cells to the malignant cells. Figure 6.5B demonstrates that the majority of 
active TGF-p produced by the normal control cells was th /  -pi isoform (53%) 
whereas the malignant cells produced predominantly TGF-p^ (76%). This trend was 
also observed with total TGF-p production (figure 6.5C), the control cells produced 
TGF-Pi as 73% of the total, whilst the malignant cells produced TGF-p2 as 74% of the 
total.
6.5 The effect of neutralising specific endogenous TGF-p isoforms on AC29 cell 
proliferation and collagen production
Following the determination of the TGF-P isoforms produced by AC29 cells, the 
effect of inhibiting specific isoforms with neutralising antibodies on cell proliferation 
and collagen production was examined. Figure 6.6 demonstrates that R & D TGF-p 
antibodies had no effect on AC29 3H-TdR incorporation, with no significant changes 
observed between any of the treatment groups. The CAT TGF-p neutralising 
antibodies (figures 6.7A and 6.7C) and the acidified TGF-pi antibody (figure 6.7B) 
also had no effect on AC29 thymidine incorporation.
Basal AC29 procollagen production was assessed after incubation with R & D TGF-p 
neutralising antibodies (figure 6.8). Apart from the pan-specific TGF-p control 
antibody stimulating procollagen production, there were no significant differences 
between any of the treatment groups (pan-specific control antibody 9.90±0.11; pan­
specific TGF-P neutralising antibody 8.28+0.24; medium control 6.98±0.60 nmol hyp 
/ 106 cells / 24 hr, p<0.05 compared to TGF-p neutralising antibody and medium 
control). The effect of CAT TGF-p neutralising antibodies on AC29 procollagen 
production was also assessed (figure 6.9). There was no significant effect on the basal 
level of procollagen production with any of the treatments. However, there appeared 
to be a trend towards lowered procollagen production with TGF-P2 neutralising 
antibody treatment.
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synthesis. AC29 DNA synthesis was assessed 24 hr after incubation with TGF-P neutralising antibodies. Results are 
expressed as disintegrations per minute (d.p.m.). Each bar represents the mean + SEM for six replicate cultures. Similar 
data was obtained in six repeat experiments.
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Figure 6.7 Cambridge Antibody Technology TGF-P antibodies did not affect 
AC29 DNA synthesis. AC29 DNA synthesis was assessed 24 hr after incubation 
with TGF-p neutralising antibodies. Results are expressed as disintegrations per 
minute (d.p.m.). Each bar represents the mean + SEM for six replicate cultures. 
Similar data was obtained in three repeat experiments.
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Figure 6.8 AC29 basal procollagen production was not affected by neutralising TGF-p with R & D antibodies. R & D
TGF-P neutralising antibodies were applied to confluent cultures of AC29 cells for 24 hr. Values were corrected for cell 
number and procollagen production expressed as nmol hyp / 106 cells / 24 hr. Each bar represents the mean ± SEM for four 
replicate cultures. * denotes a significant difference of p<0.05 compared with both the medium control group and the pan­
specific TGF-P antibody treated group. Data representative of two independent experiments.
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Figure 6.9 Neutralising TGF-P with CAT antibodies did not alter AC29 basal 
procollagen production. Confluent cultures of AC29 cells were incubated with 
CAT TGF-p neutralising antibodies with and without 1 ng/ml TGF-P! in DMEM 
supplemented with 1% FCS for 24 hr. Values were corrected for cell number and 
procollagen production expressed as nmol hyp / 106 cells / 24 hr. Each bar 
represents the mean ± SEM for six replicate cultures. Data representative of two 
independent experiments.
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6.6 Discussion
6,6.1 Exogenous TGF-/3i, -p2 and, -/?j inhibited mesothelioma cell proliferation 
TGF-(3 is generally considered a tumour suppressor. In the early stages of 
tumourigenesis TGF-p inhibits cell proliferation, but as the disease progresses, 
mutations are gained in the TGF-p signalling pathway and TGF-p is no longer able to 
inhibit, in some cases stimulating tumour growth (section 1.3.3). To test the 
hypothesis that this switch has occurred in MM, exogenous TGF-p 1.3 was applied to 
AC29 cells in an increasing concentration. Unexpectedly, proliferation was inhibited 
with all TGF-p isoforms in a dose responsive fashion (figure 6.1). All three isoforms 
of TGF-p had a virtually identical effect on inhibiting AC29 cell proliferation. 
Cordeiro et al. (2000) also observed no differences between the effect of different 
exogenous TGF-p isoforms in vitro on human ocular fibroblast proliferation, collagen 
gel contraction or cell migration.
Autocrine TGF-p levels are highly elevated in MM (figures 3.3 and 6.5) suggesting a 
role for TGF-p in MM biology. However, an in vitro study of MM showed that 
exogenous TGF-Pi (0 -  10 ng/ml) had no effect on rat MM cells whilst stimulating 
normal mesothelial cells to proliferate (Kuwahara et al., 2001). The rat MM cell lines 
produced 30 -  70 times more TGF-p than the control cells, and it was hypothesised by 
the authors that the high autocrine production of TGF-p had maximally stimulated the 
MM cell lines, and therefore further TGF-p application had no effect.
TGF-P is known to have biphasic effects on other cell types. For example, at low 
concentrations TGF-p stimulates fibroblast proliferation, but at higher concentrations 
inhibits proliferation (McAnulty et al, 1997, Cordeiro et al, 2000). It is possible that 
TGF-p has biphasic effects on AC29 cell proliferation, the high levels of endogenous 
TGF-p production are sufficient to stimulate proliferation, and application of further 
TGF-P increases the local concentration to levels resulting in inhibition.
TGF-p has been shown to reduce cell proliferation in other tumour settings whilst 
simultaneously enhancing other aspects of tumour growth. For example, TGF-p 1 
inhibits the in vitro proliferation of human oral carcinoma cell lines, but also in some
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of the same cell lines has a stimulatory effect on invasion (Hsu et al, 2002). In 
another study of human oral squamous cell carcinoma it was demonstrated that TGF- 
pi increased cell migration whilst inhibiting cell proliferation (Hasina et al, 1999). 
These studies provide evidence that TGF-p-induced cell migration and invasion may 
contribute to the tumour enhancing effects of TGF-p, and that cell proliferation may 
play a less important role. TGF-p has been shown to enhance MM tumour growth in 
vivo (Fitzpatrick et a l, 1994, Marzo et a l, 1997). The stimulatory effect of 
exogenous TGF-P on MM collagen production was shown in chapter 3 (table 3.1). 
Additionally, cell proliferation in vitro and tumour growth in vivo was stimulated by 
collagen (chapters 4 and 5). Therefore, as TGF-P promotes MM growth in vivo, the 
inhibitory effect of TGF-p on cell proliferation (figure 6.1) may be negated by the 
protumourigenic properties of TGF-P, such as enhanced collagen production, immune 
suppression and the stimulation of angiogenesis (section 1.3.2, figure 8.1).
Although exogenous TGF-P did not stimulate MM cell proliferation, it was 
hypothesised that inhibition of the elevated levels of endogenous TGF-p would 
reduce AC29 proliferation. In order to determine the relative contributions of specific 
TGF-p isoforms to AC29 cell proliferation and collagen production a panel of TGF-p- 
neutralising antibodies were characterised to determine their specificity and potency.
6.6.2 TGF-p neutralising antibody characterisation
TGF-p neutralising antibodies from two separate sources were characterised for their 
ability to neutralise porcine TGF-pi and -P2 and recombinant human TGF-P3 . These 
isoforms of TGF-p were also used as the standards in the MLEC TGF-p bioassay to 
determine the different TGF-P isoforms produced in MM conditioned media.
When determining the ability of the TGF-p antibodies to bind and neutralise TGF-p 
isoforms, comparisons were made with the control antibodies rather than to a set 0 . 1  
ng / ml concentration of TGF-p. TGF-p has an affinity for binding to plasticware 
used in tissue culture (Reisenbichler and Jirtle, 1994) and this could affect the 
retrieval of TGF-p and it’s measurement. The ‘sticky’ nature of TGF-p probably 
accounts for the differences seen in the remaining TGF-p concentration of the same
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control antibodies with different TGF-P isoforms (figures 6.2 -  6.4). Therefore, 
comparisons between control and neutralising antibodies were chosen as an indication 
of the potency of the antibody as both groups were treated in an identical fashion.
The R & D Systems TGF-p antibodies were highly potent, although the TGF-p3 
antibody cross-reacted with TGF-p2, neutralising activity by 65% (figure 6 .2 ). The 
cross-reactivity of the TGF-P3 antibody made it unsuitable for characterising isoform 
production in conditioned media. However, the specificity of the other antibodies 
enabled the determination of TGF-P 1 and TGF-p2 activity, and by the subtraction of 
these from the total, TGF-P3 activity could also be assessed (figure 6.5).
The CAT TGF-pi neutralising antibody was not as potent as the R & D Systems 
antibody, with the CAT TGF-Pi neutralising antibody there was a 25% neutralisation 
of TGF-P 1 activity, although a similar degree of neutralisation was observed with 
TGF-p3 (figure 6.3). Acid-activation of the antibody increased specificity, the 
antibody only neutralising TGF-p 1 (figure 6.4B), and improved potency (35% TGF-p 1 
neutralisation compared to control antibody). However, even with this degree of 
neutralisation, there is evidence suggesting that the CAT TGF-p 1 neutralising 
antibody has an effect in vivo. Administration of the same TGF-p 1 antibody into a 
murine model of asthmatic airway remodelling showed almost a complete block of 
the remodelling process with a significant reduction in the amount of subepithelial 
airway collagen deposition (Dr Alistair Reinhardt, personal communication). 
Additionally, other studies have demonstrated that TGF-p 1 is the predominant isoform 
upregulated in human fibrosis and in experimental fibrosis models (Coker et al, 1997, 
2001). The CAT pan-specific TGF-p antibody and TGF-pi neutralising antibody had 
a very similar effect in significantly reducing murine bleomycin-induced lung fibrosis 
(Carruthers et al., 2002). Therefore, for the TGF-p 1 neutralising antibody to have a 
similar neutralising effect to the pan specific TGF-p antibody in vivo, activation of the 
antibody is likely to be occurring.
Although the R & D Systems antibodies were more potent, CAT generously supplied 
sufficient pan-specific, TGF-p 1 and -P2 antibodies with relevant controls for in vivo
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experiments and therefore animal studies were conducted with these antibodies 
(chapter 7). Both panels of antibodies were used for in vitro studies on cell 
proliferation and collagen production.
Once the antibodies were characterised, the relative amounts of TGF-P isoforms 
produced by normal and malignant cells at the protein level were assessed.
6.6.3 Endogenous TGF-fcproduction was increased in AC29
Figure 6.5 compared TGF-p isoform production at the protein level by MM and 
normal mesothelial cell lines. The malignant cells produced a higher overall 
concentration of TGF-p than the normal mesothelial cells (figure 6.5A), confirming 
the previous results observed in figure 3.3. There were differences in the relative 
proportion of TGF-P produced by malignant and normal cells. AC29 produced a 
higher proportion of TGF-p2 compared to normal cells, which were producing mainly 
TGF-pi. This suggested that elevated TGF-p2 production may be characteristic of the 
malignant process, and that TGF-P2 may be the TGF-p isoform most important in 
MM biology. Other studies support this concept; Marzo et al. (1997) demonstrated 
that antisense oligonucleotides (ODNs) to TGF-p2 inhibited AC29 in vitro 
proliferation and reduced tumour growth in a flank model of MM. Fitzpatrick et al. 
(1994) used TGF-pi and TGF-p2 ODNs to similar effect, although the ODNs cross­
reacted with each other. The TGF-p 1 ODN inhibited TGF-p2 and vice versa, 
therefore any inhibitory effects observed on tumour growth may well have been due 
to the inhibition of TGF-p2 alone.
6.6.4 Specific inhibition o f endogenous TGF-P isoforms did not alter cell 
proliferation or procollagen production
The effect of neutralising specific TGF-p isoforms on AC29 proliferation and 
collagen production was examined. The antibodies were used at concentrations in 
excess of those required to neutralise the TGF-p produced by the cells over the course 
of the experiments. The characterisation experiments used concentrations of antibody 
sufficient to neutralise 0.1 ng/ml of TGF-p (figures 6.2 -  6.4). Figure 6.5 shows that 
over 24 hr 106 AC29 cells produce 0.03 ng of active TGF-pi, 0.11 ng of active TGF-
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p2 and 0.01 ng of active TGF-P3 (a total of 0.15 ng active TGF-P for all isoforms). 
Cell proliferation assays were conducted at 4,000 cells / well which were left to 
adhere for 24 hr before applying the treatment conditions (section 2.2.1). AC29 has a 
cell doubling time of 27 hr (Davis et al, 1992). Thus, by the time of treatment there 
would be approximately 8 , 0 0 0  cells, which would produce a total concentration of 8  
pg/ml of all active isoforms of TGF-p. Therefore, at the concentration used, the 
antibodies were more than adequate to neutralise all the TGF-P produced by the cells. 
Considering the collagen assays, figure 3.4A shows that 6  x 105 cells in 1 ml were 
present at to. Therefore, the maximum active TGF-P production would be 0.06 ng/ml, 
again at a low enough concentration for the antibodies to fully neutralise all TGF-p 
activity.
Surprisingly, no changes in proliferation (figures 6 . 6  and 6.7) were observed. 
Fitzpatrick et a l (1994) demonstrated that the anchorage-dependent growth of MM 
cell lines (including AC29) was not affected by the ODN inhibition of TGF-P2 , 
although anchorage independent growth in soft agar and in vivo tumour growth were 
inhibited. A wider range of in vitro assays, such as growth in soft agar, would need to 
be performed to assess the effect of neutralising TGF-p isoforms on AC29 in tissue 
culture. As discussed in section 6.6.1, it is possible that no differences would be 
observed in proliferation, and that other tumour cell properties such as migration and 
invasion would be affected.
However, Marzo et a l (1997), observed a decrease in anchorage-dependent AC29 cell 
proliferation with ODNs to TGF-pi and -P2 , although the same group had not 
managed to obtain these results previously (Fitzpatrick et al, 1994). Also, Kuwahara 
et a l (1997) obtained a decrease in both anchorage-dependent and -independent 
growth using ODNs to TGF-P2 (although rat cell lines were used rather than murine). 
There is controversy over how representative of an in vivo tumour an in vitro cell 
monolayer is. Recent studies are using new techniques such as tumour cell spheroids 
to create cell-cell interactions in a 3D setting to model the in vivo environment more 
accurately (Guirado et al, 2003). Differences observed in the studies cited above 
may well be due to the limitations of using a cell monolayer for proliferation studies.
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Minor effects were observed on procollagen production (figures 6 . 8  and 6.9), 
although these were most likely non-specific effects as the control antibodies were 
also affecting procollagen production. Due to the lack of specificity, the effect of 
TGF-P3 neutralising antibody on AC29 collagen production was not examined (figure 
6 .8 ). There is evidence in the literature to suggest that TGF-p3 acts as an anti-scarring 
agent and prevents ECM formation (Shah et al., 1995). With this observation it 
would be expected that TGF-p3 neutralising antibody would increase collagen 
production. Although this was not investigated, exogenous TGF-p3 had an identical 
effect to the other isoforms on proliferation (figure 6.1) and inhibition of TGF-p3 also 
had a similar effect to neutralisation of other TGF-p isoforms (figure 6 .6 ).
The lack of effect on cell proliferation and collagen production in response to the 
TGF-p antibodies was not due to incomplete neutralisation of TGF-p as sufficient 
concentrations of antibody were used. It is possible that endogenous TGF-p\may not 
be important for AC29 cell proliferation or collagen production, and therefore TGF-P 
inhibition had no effect on either. However, exogenous TGF-P stimulated collagen 
production (figure 3.5), and collagen was shown to enhance cell proliferation (figures
4.1 and 4.9) and tumour growth (figures 5.5 and 5.11). Collectively, these data 
strongly suggest a role for TGF-p-induced collagen production in MM growth. 
Alternatively, the TGF-P antibodies mav not have been able^to neutralise J b e 
endogenous TGF-p before it bound to its receptor and generated a response. This 
hypothesis~could belested by blocking TGF-p production at the mRNA level, using 
specific ODNs to all three TGF-P isoforms. Inhibiting mRNA production would 
prevent any TGF-p protein being translated and the effect on cell proliferation and 
collagen production could be examined.
6.7 Summary and conclusions
At concentrations that promoted collagen production (figure 3.5), exogenous TGF-P 
decreased cell proliferation. However, endogenous levels of TGF-p were raised in the 
malignant cells, with increased TGF-P2 protein production compared to normal cells. 
Inhibiting specific TGF-P isoforms had no effect on proliferation or collagen 
production.
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Although unexpected results were obtained in vitro, TGF-p could possibly still 
enhance tumourigenesis in vivo. Tobin et al. (2002) over-expressed TGF-p i by stable 
transfection in human breast carcinoma and found seemingly contradictory results in 
vitro and in vivo. It was observed in vitro that TGF-pi over-expression lowered the 
rate of proliferation, although no alteration on invasion through a collagen type I 
coated membrane was seen. However, in an in vivo murine flank model, TGF-pi 
over-expression enhanced tumour growth and increased tumour invasion into local 
tissue and metastasis to distant organs. The authors suggest that the tumour 
enhancing effects of TGF-Pi in vivo may be in part due to paracrine effects on other 
cells present in the tumour environment (figure 8.1). Also, TGF-p can enhance 
tumourigenesis in vivo through the stimulation of angiogenesis and suppression of the 
host immune response (section 1.3.2). In addition, TGF-p is a potent stimulator of 
collagen production and, as demonstrated in chapters 4 and 5, collagen stimulates 
MM cell proliferation and tumour growth. Therefore, although the results in this 
chapter demonstrated the inhibition of proliferation in culture with TGF-p, in vivo 
TGF-p may exert a stimulatory effect on MM tumour growth, possibly through an 
enhancement of collagen production. This was investigated in the final results 
chapter, by inhibition of TGF-p in vivo with the systemic administration of the 
neutralising antibodies characterised in this chapter to an animal model of MM.
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Chapter Seven
Transforming Growth Factor-p antibody 
in vivo studies
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7.1 Introduction
There is strong evidence to suggest a role for TGF-P in the promotion of 
tumourigenesis through stimulation of ECM production. Human melanoma cell lines 
transfected with TGF-p i adenoviral vectors induced more stroma in and around the 
tumour than control cells (Berking et al., 2001). The TGF-pi-induced increase in 
ECM (predominantly collagen and fibronectin) conferred a survival advantage 
protecting cells against apoptosis and enhancing melanoma growth in vivo. The 
occurrence and size of metastases were also increased. In another study, the stable 
transfection of human pancreatic carcinoma cells with TGF-pi led to the induction of 
desmoplasia in vivo by tumour derived TGF-pi which was not seen in control tumours 
(Lohr et al., 2001). The authors suggested that tumour stroma may be beneficial for 
tumour growth. Based upon the observations above as well as the previous 
experiments in this thesis, the hypothesis for this chapter was constructed:
tumour-derived TGF-P induces ECM, which promotes in vivo tumour growth
This hypothesis was tested using the TGF-P neutralising antibodies characterised in 
the previous chapter in the animal model of MM described in chapter 5. The use of 
antibodies in cancer treatment is widespread, and monoclonal antibodies have been 
likened to “magic bullets”, being able to specifically neutralise proteins involved in 
disease (Gura, 2002). The systemic administration of TGF-p antibodies to animal 
models is an established procedure, and a demonstrated reduction in ECM production 
has been observed. Pan-specific neutralising antibodies have been shown to reduce 
rat renal atrophy (Miyajima et al., 2 0 0 0 ), and the same TGF-p2 antibodies used in 
vivo in this chapter (figures 7.3 and 7.4) have been shown to reduce diabetic rat 
kidney fibrosis (Hill et al., 2001). In addition, antibodies to TGF-pi and -p2 have 
been shown to reduce the lung collagen accumulation associated with murine 
bleomycin-induced fibrosis (Giri et al., 1993). The importance of collagen production 
to MM growth was established in chapters 4 and 5, and this chapter investigated the 
effect of inhibiting the elevated levels of TGF-p in MM on tumour growth and tumour 
collagen production. More specifically to:
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1. determine the effect of TGF-P antibodies on MM tumour growth in vivo,
2 . establish whether histological differences between the treatment groups exist,
3. and to quantitate the collagen content of antibody treated tumours by HPLC.
7.2 The effect of TGF-p neutralising antibodies on tumour growth in vivo 
The in vivo relevance of different TGF-P isoforms on MM tumour growth was 
investigated by the i.p. administration of CAT TGF-p neutralising antibodies to the 
s.c. murine model of MM. The tumours were harvested at several time-points (10, 14, 
15 and 19 days), the later time-points dependent upon tumour size and the ulceration 
of the subcutaneous tumours through the skin. Figure 7.1 shows the effect of TGF-p i 
neutralising antibodies on median tumour growth at 4 different time-points. Each 
group demonstrated a steady increase in median tumour weight over the course of the 
experiment, although considerable variation was observed within each group (figure 
7. IB). A representative experiment demonstrating the spread of tumour weights at 14 
days is shown in figure 7.2. There were no significant differences between any of the 
groups at any of the times examined.
Due to tumour ulceration through the skin, experiments with TGF-P2 neutralising 
antibodies were unable to be continued beyond the 15 day time-point. However, 
administration of TGF-p2 antibody significantly reduced median tumour weight at 15 
days (figures 7.3 and 7.4). The TGF-p2 antibody treated tumours exhibited more than 
a 50% reduction in median tumour weight compared with the PBS and IgG control 
groups, p<0 . 0 0 1  in both cases.
Pan specific neutralisation of all three TGF-p isoforms (figures 7.5 and 7.6) decreased 
median tumour weight compared to PBS control at 14 days (pan-specific TGF-p 
antibody 30 (14 -  6 6 ); PBS control 46.5 (25 -  109), p<0.05). However, at earlier and 
later time-points there were no differences between any of the treatment groups.
The weights of the animals were monitored at regular intervals over the course of the 
experiment, to ensure that antibody administration was not deleterious to animal 
health. Figure 7.7 shows the effect of antibody administration over 19 days. All of
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Figure 7.1 The effect of TGF-P, neutralising antibodies on AC29 tumour growth. Mice 
were inoculated subcutaneously with 106 AC29 cells. Animals were injected intraperitoneally 
with 5 mg/kg (in 100 pi) of TGF-P, neutralising antibody, irrelevant IgG control antibody and 
lOOpl of PBS thrice weekly. Groups of animals were sacrificed at 10, 14, 15 and 19 days and 
the induced tumours surgically excised. A compares the median tumour growth of the treatment 
groups over time, B demonstrates the median tumour weight (mg) with the range in parentheses.
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Figure 7.2 TGF-p, neutralising antibody did not affect tumour weight at 14 days. Female CBA mice were injected 
subcutaneously with 106 AC29 cells in 100 pi of DMEM. Animals were injected intraperitoneally with 5 mg/kg (in 100 pi) 
TGF-p, neutralising antibody, irrelevant IgG control antibody and lOOpl of PBS thrice weekly. The animals were sacrificed 
after 14 days and the induced tumours surgically removed and weighed. The horizontal bar represents the median tumour 
weight. Results are representative of two repeat experiments.
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Figure 7.3 TGF~P2 neutralising antibodies decreased AC29 tumour growth. TGF-|32 
neutralising antibody and irrelevant IgG control antibody (administered at 5 mg/kg in 100 jul) 
and lOOpl of PBS were injected intraperitoneally into AC29 tumour bearing mice thrice weekly. 
Groups of animals were sacrificed at 10 and 15 days and the induced tumours surgically excised. 
A evaluates the median tumour growth of the treatment groups over time, B shows the median 
tumour weight (mg) with the range in parentheses. *p<0.001 compared to PBS and IgG control.
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Figure 7.4 TGF-P2 neutralising antibody decreased tumour weight at 15 days. Animals inoculated with AC29 tumour 
cells in the flank were injected intraperitoneally with 5 mg/kg (in 100 pi) TGF-P2 neutralising antibody, irrelevant IgG 
control antibody and lOOpl of PBS thrice weekly. The animals were sacrificed after 15 days and the induced tumours 
removed and weighed. The horizontal bar represents the median tumour weight.
192
PBS
WDs'—/
JS
S i
‘3
*h.so
S
2
§
■§
100
80
60
40
20
L / /
10 15
Time (days)
20
TGF-P
pan-specific
antibody
IgG control
B Antibody treatment 
Median tumour weight (mg)
Time (day) PBS control Pan-specific IgG control
10 24.5 (10-85) 15.5 (4-76) 26 (5-79)
14 46.5 (25-109) 30(14-66)
*
36 (19-107)
19 70 (22-253) 90 (47-242) 52 (6-200)
Figure 7.5 The effect of pan-specific TGF-p neutralising antibodies on AC29 tumour 
growth. Mice seeded subcutaneously with 106 AC29 cells in each flank were injected 
intraperitoneally with 5 mg/kg (in 100 jul) of pan-specific TGF-P neutralising antibody, 
irrelevant IgG control antibody and lOOpl of PBS thrice weekly. Groups of animals were 
sacrificed at 10, 14 and 19 days and the induced tumours surgically excised. A compares the 
median tumour growth of the treatment groups over time, B demonstrates the median tumour 
weight (mg) with the range in parentheses. *p<0.05 compared to PBS control
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Figure 7.6 Pan-specific TGF-p neutralising antibodies reduced tumour weight at 14 days. Mice seeded with 106 AC29 
cells in each flank were injected intraperitoneally with 5 mg/kg pan-specific TGF-P neutralising antibody, irrelevant IgG 
control antibody and PBS thrice weekly. The animals were sacrificed after 14 days and the induced tumours removed and 
weighed. The horizontal bar represents the median tumour weight.
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Figure 7.7 Administration of intraperitoneal TGF-P neutralising antibodies did not alter animal weights. The weight 
of the animals used in the antibody studies was monitored over the course of the experiments. The animals were weighed at 
regular intervals (4-5 days). Each point represents the mean weight of 5 animals ± SEM.
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the groups had a similar increase in mean animal weight (approximately 5 -  10%) 
from the start of treatment.
7.3 Histology of tumour sections
Antibody treated and control tumours were processed to paraffin wax and sections cut 
for histological examination. To confirm the presence of TGF-p in the tumour 
samples, immunohistochemical staining with the R & D TGF-pi antibody was 
performed (figure 7.8). No positive staining resulted with the isotype control 
antibody. Dense TGF-p i staining was observed in the ECM of the tumour samples, 
equally distributed in the section. The different antibody treatments of the tumours 
resulted in no observable differences in TGF-pi distribution amongst the tumour 
groups.
To establish whether any differences in collagen distribution were evident 
histologically, the Martius scarlet blue stain for collagen was used. Figure 7.9 shows 
collagen staining for animals treated with TGF-P i, TGF-p2 and pan-specific 
neutralising antibodies (A, B and C respectively), with their control antibodies. Thick 
blue fibrils were observed within the tumours, indicative of a dense collagen network. 
There were no apparent differences between any of the antibody treatment groups and 
their controls. Also, as in the thiaproline studies (figures 5.17 and 5.18), 
inflammation was limited to the periphery of the tumour with virtually no infiltrate 
seen within the bulk of the tumour. From visual analysis the main inflammatory cells 
appeared to be macrophages.
7.4 Collagen analysis of tumour tissue
Tumour tissue from the 14/15 day in vivo experiments in this chapter was crushed and 
the collagen content assessed. This time-point was chosen as significant differences 
in tumour weight between treatment groups were observed at 14 - 15 days (figures 7.3 
-  7.6). Collagen content was represented as total nM hyp / tumour and as a 
concentration per mg of tumour weight (nM hyp / mg tumour).
Treatment of animals with TGF-P i or TGF-p2 antibodies did not alter the tumour 
collagen concentration (figure 7.10A). Correlation (r = 0.47) was found between
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Figure 7.8 Immunohistochemistry for TGF-P, distribution in AC29 solid tumours. Female CBA mice were inoculated 
subcutaneously with 106 AC29 mesothelioma cells. Animals were injected intraperitoneally with 5 mg/kg (in 100 pi) TGF-p, 
neutralising antibody, irrelevant IgG control antibody and lOOpl of PBS thrice weekly. The induced tumours were excised at 15 days, 
processed to paraffin wax and sections stained with a TGF-P, specific antibody. Bar represents 25 pm, original magnification X200.
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Figure 7.9 Martius scarlet blue staining revealed abundant collagen deposition in 
TGF-p antibody treated tumour sections. Female CBA mice were inoculated 
subcutaneously with 106 AC29 cells and groups treated with TGF-P, neutralising antibody 
(A), TGF-P2 neutralising antibody (B), pan-specific TGF-p antibody (C), IgG control or 
PBS. The induced tumours were excised at 15 days, processed to paraffin wax and 
sections stained with Martius scarlet blue. Magnification xlOO.
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Figure 7.10 Administration of TGF-p, or TGF-P2 neutralising antibodies had no effect on tumour collagen 
concentration at 15 days. Antibody treated and control tumours were analysed for hyp content using HPLC following 
excision at 15 days. The concentration of collagen per mg of tumour tissue was measured (A), the horizontal black bar 
indicative of mean collagen concentration. Also, tumour collagen content was plotted against tumour weight (B) and the 
correlation coefficient (r) calculated. Results are representative of two repeat experiments.
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tumour weight and the total collagen content (figure 7.10B), an increase in tumour 
weight matched by an increase in total tumour collagen. Interestingly, the TGF-p2  
antibody treated group had a limited total collagen content, all tumours containing 
under 1000 nM hyp.
As shown in figure 7.11 A, the neutralisation of all TGF-p isoforms with the pan­
specific antibody reduced the concentration of collagen significantly compared to the 
PBS control group (pan-specific treated 4.03±0.68, PBS 9.11±0.76; p<0.0001). 
However, the IgG control antibody treated tumour group also demonstrated a lower 
collagen concentration compared to the PBS control group (control IgG treated 
6.28±1.02; p<0.05 compared with PBS), although to a lesser extent. A strong 
correlation (r = 0.78) existed between tumour weight and collagen content (figure
7.1 IB), an increase in collagen related to an increase in tumour weight. The pan­
specific antibody treated tumours were clustered in a group localised close to the y- 
axis, demonstrating that this group had a low total collagen content which was 
associated with a low tumour weight.
7.5 Discussion
7.5.1 In vivo administration o f TGF-p neutralising antibodies
Tumour growth was not affected by TGF-pi neutralising antibody (figures 7.1 and 
7.2). This could be due to the poor ability of the antibody to neutralise the substrate 
(figures 6.4 and 6.5). However, the same TGF-p \ antibody reduced collagen 
accumulation in a murine model of asthmatic airway remodelling (Dr Alistair 
Reinhardt, personal communication), suggesting in vivo activity. Additionally, 
Carruthers et al. (2002) demonstrated an in vivo effect; the same TGF-pi antibody 
showed activity in a murine model reducing bleomycin-induced lung fibrosis. 
Therefore, the antibody is likely to be active in vivo and the lack of response seen is 
more likely due to the fact that TGF-p i neutralisation did not affect tumour growth. 
The lack of effect with TGF-pi neutralisation is consistent with the previous 
observation that the majority of active TGF-p produced by AC29 cells is TGF-p2 
(figure 6.5), and not TGF-Pi.
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Figure 7.11 Administration of intraperitoneal pan-specific TGF-f) neutralising antibodies reduced tumour collagen 
concentration at 14 days. Antibody treated and control tumours were analysed for hyp content using HPLC following 
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Fitzpatrick et al. (1994) observed decreased AC29 solid tumour growth with ODNs to 
TGF-pi. However, the authors state that the ODN was not specific and also decreased 
TGF-p2 mRNA levels. Therefore the effects observed may have been solely due to 
the neutralisation of TGF-P2. Also, Shinozaki et al. (1997) observed that the injection 
of recombinant TGF-P isoforms into the subcutaneous tissue of newborn mice caused 
differing states of fibrosis depending on the isoform used. The level of fibrosis 
induced with TGF-p 1 was less when compared to injections of TGF-p2 or TGF-P3. 
This suggests that in vivo TGF-p 1 may be less important that the other TGF-P 
isoforms in matrix elaboration.
TGF-P2 neutralising antibodies reduced tumour growth at 15 days compared to the 
PBS and IgG controls (figures 7.3 and 7.4). The experiments were unable to be taken 
to later time-points as the antibody treated tumours were extremely invasive through 
the skin and began to ulcerate by 15 days (figure 5.3A). Interestingly, TGF-p2 was 
highly upregulated in MM compared to NM (figure 6.5) and inhibition of TGF-P2 
resulted in the decreased tumour growth observed, suggesting an important role for 
TGF-p2 in MM biology. This supports previous studies (Fitzpatrick et al., 1994, 
Marzo et al., 1997) which also demonstrated a reduction in AC29 tumour growth by 
neutralisation of TGF-p2 . In another study examining eye development using TGF-p 
knockout mice, loss of expression of TGF-p 1 or TGF-p3 had no effect on eye 
morphology whereas lack of TGF-p2 expression resulted in decreased deposition of 
corneal stroma (Saika et al., 2001). This observation is consistent with an important 
role for TGF-P2 in ECM deposition.
However, TGF-p2 antibody treated MM tumours did not contain a significantly 
lowered concentration of collagen (figure 7.10), and therefore it is likely that 
inhibition of TGF-P2 reduced tumour size by other means. TGF-p promotes 
angiogenesis and host immune suppression (section 1.3.2), which are both crucial to 
successful tumour growth. Removal of TGF-p would possibly decrease angiogenesis 
and increase the inflammatory infiltrate into the tumour restricting growth. Specific 
staining for vascular and inflammatory markers on tumour tissue sections is required 
to confirm this. Additionally, the treatment of AC29 tumours with ODNs to TGF-P2
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resulted in reduced growth, with an increase in T cell lymphocyte infiltration into the 
tumours (Fitzpatrick et al., 1994). This suggests that the mechanism of decreased 
tumour growth mediated by TGF-P2 may be due to an increase in inflammatory cells, 
rather than the attenuation of collagen production.
Neutralisation of all TGF-p isoforms reduced tumour weight at 14 days compared 
with the PBS control (figures 7.5 and 7.6). Although tumour weight was not 
significantly reduced with pan-specific TGF-p neutralisation when compared with the 
IgG control treatment, there was a trend towards decreased tumour weight (figure
7.6). This result corresponds with the effect of specifically neutralising TGF-p2. The 
effect of neutralising TGF-p3 alone could not be examined as the antibody was not 
specific, showing 65% cross-reactivity with TGF-P2 (figure 6 .2 ). AC29 cells produce 
more TGF-p3 than TGF-p 1 (figure 6.5) which suggests a possible role for TGF-P3 in 
the tumourigenicity of MM. However, the neutralisation of all TGF-P isoforms with 
the pan-specific antibody did not have a more pronounced effect than specific 
neutralisation of TGF-p2 alone, and therefore it could not be concluded that TGF-P3 
significantly influenced MM growth.
Reduced tumour growth was observed with the TGF-p2 and pan-specific neutralising 
antibodies at the middle time-point of 14 -  15 days, which was not seen at 10 days 
(figures 7.4 and 7.6). However, with all the antibody treatments at 10 days the 
median value for the antibody group was lower than the PBS or IgG control groups, 
although not significant, perhaps due to insufficient power to detect the differences. 
This may be due to the difficulties in dissecting out small tumours from the 
surrounding tissue at the early time-point leading to erroneous weight measurements. 
An increased number of animals per treatment group may reveal significant 
differences at the 10 day time-point. Alternatively, the delay before the effect of the 
antibodies became apparent may have been because sufficient time was required to 
increase the circulating concentration of TGF-p antibody to a level adequate for 
tumour TGF-p neutralisation.
In the pan-specific antibody treated tumours, the reduction in growth was lost by 19 
days (figure 7.5), with no difference apparent between the treated and untreated
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tumours. Antibodies raised in one animal and then introduced into another animal 
will be recognised as foreign by the recipients’ immune system and illicit an immune 
response, even if from the same species (Kunkel et al, 1963). It is likely that in 
response to the introduced TGF-p neutralising antibodies the mice produced anti­
idiotype antibodies. With repeated dosing, high affinity neutralising antibodies 
become apparent to the immune system between 1 4 - 2 1  days (Dr Ken Smith, 
personal communication). Therefore, in this study, by 19 days the introduced 
antibodies may have been neutralised by anti-idiotype antibodies and no longer had an 
effect. In addition to this, it is also possible that by the later time point a sufficient 
amount of time had elapsed to allow ECM deposition to occur, especially collagen 
production, further enhancing tumour growth (as demonstrated in figures 4.1 and 4.9). 
It is interesting to note that in another study using the same TGF-P2  antibody 
delivered systemically in vivo, a time-point of 14 days was chosen to observe the 
results (Hill et al, 2001). This suggests that the most potent effects of the antibodies 
may be elicited during the first two weeks of administration.
The same dose of antibodies used in these studies has been used in other in vivo 
experiments without detrimental effects to the animals (Cordeiro et al, 1999, Hill et 
al, 2001, Dr Alistair Reinhardt, personal communication). Also, in a murine breast 
cancer model, transgenic mice expressing a TGF-p antagonist over their entire 
lifetime had decreased levels of TGF-p and associated metastases without the 
regulatory roles of TGF-p in normal tissues being affected (Yang et al, 2002). In this 
study animal weight was measured over the course of antibody administration (figure
7.7) and the unaltered animal weight observed was taken to show that the antibodies 
were not affecting animal health.
7.5.2 Histological and biochemical analyses o f 14 -1 5  day solid tumours 
It was demonstrated histologically that TGF-P 1 was present in solid AC29 tumours 
(figure 7.8). The TGF-p antibodies administered in vivo neutralised activity by 
binding to the active site of TGF-p, thus preventing TGF-p binding to its receptor. 
The same antibody was used for TGF-p 1 immunohistochemistry on tumour tissue 
sections, and therefore any TGF-P inactivated by the in vivo antibody treatment 
should not be detected by histology due to a blocked active site. It was predicted that
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the antibody treated tumour sections would stain less intensely for the presence of 
TGF-pi. However, no differences were seen between the different antibody treatment 
groups. This could be due to the fact that a 2-dimensional tissue section may not be 
representative of an entire 3-dimensional structure. Further analysis of the whole 
tumour tissue may have revealed differences between treated and untreated tumour 
TGF-P content. For example crushing and homogenising entire tumours and assaying 
aliquots for TGF-p activity using the MLEC assay may have given a more accurate 
measure of active TGF-P content. However, all of the frozen tumour specimens 
obtained were used for collagen analysis. Staining for TGF-P2 , the predominant 
isoform produced by AC29 cells (figure 6.5), and TGF-P3 was not possible, as 
suitable antibodies were unavailable.
In addition, no differences were observed histologically for collagen deposition 
between antibody treatment groups (figure 7.9), perhaps for the same reason as given 
above. Also, in agreement with the histological assessment, HPLC analysis revealed 
no differences in the collagen content of TGF-P 1 antibody and TGF-P2 antibody- 
treated tumours (figure 7.10). As the TGF-p2 antibody-treated tumours were 
significantly growth inhibited compared to the controls (figure 7.4) another 
mechanism unrelated to decreased collagen deposition was required to explain this 
reduction. Previous studies have also demonstrated that inhibition of TGF-P2 in 
AC29 solid tumours reduced tumour growth (Fitzpatrick et al, 1994, Marzo et al., 
1997). In these studies an increase in tumour infiltrating lymphocytes into the tumour 
mass was observed, suggesting that removal of the inhibitory effect of TGF-p on the 
host immune system was responsible for decreased tumourigenicity. However, the 
authors did not examine the effect of inhibiting TGF-p2 on tumour stroma formation. 
In the current study, no gross differences in the inflammatory infiltrate were observed 
histologically in the tissue sections (figure 7.9). Further studies with markers specific 
to inflammatory cells are needed to investigate this in more detail. Interestingly, the 
TGF-p2 antibody treated tumours had the lowest collagen content (figure 7.10A) 
compared to the other treatment regimes, and as a group had the lowest total collagen 
content / tumour size. Although not significant, there was a trend towards a lowered 
collagen content in the TGF-p2 antibody treated tumours. Also, a trend towards 
reduced collagen production with TGF-p2 antibody treated MM cells was observed in
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vitro (figure 6.9). These data suggest that TGF-p2 may participate in collagen-driven 
MM tumour growth to a certain extent.
Pan-specific neutralisation of all TGF-p isoforms led to an associated decrease in 
collagen and a decrease in tumour weight (figure 7.11). This is consistent with the 
results observed in chapters 4 and 5, showing that inhibition of collagen production 
reduced tumour growth and that smaller tumours contained a lower concentration of 
collagen. The concentration of collagen (figure 7.11 A) followed the same trend as 
tumour weight (figure 7.6) suggesting a relationship between collagen and tumour 
growth, confirming the thiaproline in vivo studies (figure 5.5). Also, a strong 
correlation was found between tumour weight and total collagen content (figure
7.1 IB), providing further evidence for the importance of collagen to MM tumour 
growth. It is interesting to note that pan-specific neutralisation of all TGF-p isoforms 
had a more profound effect on tumour collagen content than inhibition of TGF-p2 
alone. Also, inhibition of TGF-pi had no effect on tumour collagen content (figure 
7.10), therefore the effect of the pan-specific antibody may be due to inhibition of 
TGF-p3. To test this hypothesis, the effect of exogenous application of the different 
TGF-P isoforms on MM collagen production needs to be investigated in vitro.
7.5,3 Non-ECM related effects o f TGF-p
As well as the induction of ECM production, which stimulates tumour growth 
(chapters 4 and 5), TGF-p has many other pro-tumourigenic properties, and it is likely 
that all of these effects working in concert contribute towards increased tumour 
growth (see figure 8.1). As mentioned above, TGF-p is a powerful suppressor of the 
immune system, and inhibition of TGF-p2 in MM has been demonstrated to increase 
the inflammatory infiltrate into tumours resulting in reduced tumour growth 
(Fitzpatrick et al., 1994, Marzo et al., 1997). However, evidence also exists 
supporting a role for collagen in reduced inflammatory infiltrate, as tumour stroma 
may form a barrier limiting inflammatory influx. Histological assessment of 
approximately 100 different cervical cancer sections revealed a significant correlation 
between TGF-p i production and the extent of tumour stroma, especially collagen type 
IV deposition (Hazelbag et al., 2002). In addition, TGF-pi expression and collagen 
deposition were inversely correlated with the extent of the inflammatory infiltrate,
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indicating that high levels of collagen and TGF-p have an inhibitory effect on 
inflammatory cell invasion. However, in the current study antibodies to TGF-P2 had 
the greatest effect on tumour growth (figure 7.4) but had little effect on tumour 
collagen concentration (figure 7.10). It is likely that the reduced tumour size that was 
observed with TGF-p2 neutralising antibodies may have been due to increased 
inflammation.
TGF-P is also a well-characterised stimulator of angiogenesis. For example, in a 
murine breast carcinoma model TGF-p 1 was demonstrated to increase blood vessel 
formation by the induction of VEGF (Breier et al, 2002). Inhibition of TGF-P in 
other tumours has been shown to decrease the extent of vascularisation and reduce 
tumour growth. Incubation of a human model of prostate cancer with TGF-P 1 
antibody or LAP resulted in smaller tumours with reduced surface vasculature 
(Tuxhom et al, 2002b). Additionally, histology revealed fewer blood vessels within 
the tumour mass compared to control tumours. The authors of this study suggested 
that a combination of TGF-p and stroma is required for tumourigenesis, with TGF-p 
acting in a paracrine manner on stromal cells to promote angiogenesis and tumour 
growth. Furthermore, in a study on colorectal cancer there was a significant 
correlation between TGF-p 1 and vessel density, depth of invasion, and the stage of 
disease (Xiong et al, 2002). Also, in non-small cell lung cancer, tumour tissue TGF- 
pi levels correlated with vascular density and disease stage (Hasegawa et al, 2001), 
and interestingly those patients with an elevated level of intratumoural TGF-p 1 had a 
trend towards decreased survival.
In the majority of tumours high TGF-p levels have been demonstrated to induce 
apoptosis. However, in a human breast cancer cell line inhibition of TGF-P signalling 
by expression of a soluble TGF-p type HI receptor increased the level of apoptosis in 
vitro and in vivo (Lei et al, 2002). This demonstrated that autocrine TGF-p 
production prevented apoptosis and promoted tumour growth in this model. Elevated 
levels of TGF-p are also observed in MM (figures 3.3 and 6.5), whilst no obvious 
areas of necrosis were observed within the tumour sections. It is possible that the
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high levels of TGF-P found in MM may be preventing apoptosis, although further 
studies with markers specific to apoptotic cells are required to confirm this.
In addition to autocrine effects, tumour derived TGF-P has paracrine effects on 
stromal cells with the tumour ECM, leading to enhanced tumour growth, invasion and 
metastasis (Berking et al, 2001, Tobin et al, 2002). TGF-p produced by human 
prostate carcinoma tumour cells can activate stromal fibroblasts to the myofibroblast 
phenotype resulting in an increase in collagen type I production (Tuxhom et al, 
2002a). Also, TGF-Pi induces the transformation of human mesothelial cells to a 
myofibroblastic phenotype with an increase in the amount of collagen type I 
synthesised (Yang et a l, 2003). An increase in collagen type I production has a 
potentially stimulatory effect on MM cell proliferation (figure 4.1). All isoforms of 
TGF-P are chemotactic for fibroblasts and strongly upregulate fibroblast procollagen 
production (Coker et al, 1997, Cordeiro et al, 2000). No quantitation of stromal 
cells within the solid tumours was performed in this thesis, therefore the extent of 
stromal cell involvement in MM tumourigenesis is unknown. However, around the 
periphery of the tumours there was an area of intense matrix deposition creating a 
capsule keeping the tumour discrete from the host tissue. The tumour capsule 
contained cells at the interface between tumour and host that appeared to be 
fibroblasts, raising the possibility that stromal cells could be involved in this response.
The histological assessment carried out on the tumour sections revealed no obvious 
difference between inflammatory influx, vascularisation, apoptotic bodies or any 
differences in stromal cells between the different treatment groups (figure 7.9). 
Further histological investigation is required with specific markers for each area of 
interest to elucidate their contribution to tumour growth in more depth. However, 
despite these other possible effects of TGF-P, there was a decreased concentration of 
collagen in the pan-specific TGF-P antibody treated group and a trend towards 
lowered collagen concentration in the TGF-P2 antibody treated group. These data 
demonstrated that inhibition of TGF-p was associated with an inhibition of collagen 
production, which may also have contributed to decreased tumour growth.
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7.6 Summary and conclusions
The presence of TGF-pi in solid tumours was confirmed by immunohistochemistry 
and TGF-Pi was found in abundance in the ECM within AC29 tumours. Inhibition of 
TGF-pi had no effect on tumour growth at any of the time points examined and did 
not alter tumour collagen content. However, neutralising TGF-P2 , the predominant 
TGF-p isoform produced by AC29, reduced tumour weight at 15 days, with a trend 
towards decreased collagen content. Evidence in the literature from other studies 
suggests that improved immune function may be responsible for the decreased tumour 
growth observed. Pan-specific neutralisation of all TGF-p isoforms reduced tumour 
weight at 14 days with an associated lower concentration of collagen in the treated 
tumours. These observations suggest that TGF-p-induced collagen production, at 
least in part, stimulated MM tumour growth. The importance of collagen production 
in MM cell proliferation and tumour growth was previously established in chapters 4 
and 5.
In summary, this thesis has clearly demonstrated that both collagen production and 
TGF-P production, especially the -p2 isoform, are important for MM growth, and 
inhibition of either collagen production or pan-specific TGF-P activity can delay MM 
tumour growth with a resultant decrease in tumour collagen content. The overall 
results and implications of this thesis are discussed in the following final chapter.
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Chapter Eight 
General Summary and Future Studies
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8.1 General Summary and Conclusions
To date, it is unknown whether the tumour stroma is beneficial for the tumour or 
represents a host defence mechanism to contain the tumour (Lohr et al., 2001). 
However, all solid tumours require ECM to grow beyond 1 - 2  mm2 and tumour 
growth has been likened to wound healing (Dvorak, 1986). Wound healing involves 
the formation of a provisional matrix and the emergence of blood capillaries, followed 
by fibroblasts that synthesise further ECM components. Eventually the vessels and 
fibroblasts clear and the wound resolves leaving a scar. Tumours appear to be 
‘unending wounds that do not heal’, and perhaps under the guise of a wound evade 
host rejection.
The first hypothesis of this thesis assessed the importance of collagen, a major ECM 
component of tumours and wounds, on MM tumour growth:
1) The ECM is vital to the progression of malignant mesothelioma with collagen 
production stimulating cell proliferation and tumour growth.
It was demonstrated in chapters 3 - 5  that MM tumour cells produced elevated levels 
of collagen compared to non-transformed mesothelial cells and that exogenous 
collagen stimulated MM cell proliferation. Inhibition of endogenous collagen 
production with thiaproline decreased MM cell proliferation dose-dependently. These 
observations indicated an important role for collagen in MM cell proliferation. This 
role was examined further by the in vivo inhibition of collagen production by 
thiaproline administration, and resulted in a delay in tumour growth at 10 days. The 
thiaproline treated tumours were smaller than the control tumours and contained a 
lower concentration of collagen. A very strong correlation was found between 
collagen content and tumour weight suggesting the two were closely linked. These 
novel data confirmed the above hypothesis and demonstrated for the first time that 
inhibition of MM collagen production could attenuate cell proliferation and tumour 
growth.
Levels of TGF-(3, a key regulator of cell proliferation and collagen production, are 
also elevated in MM (Fitzpatrick et al., 1994, Maeda et al., 1994). As collagen
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synthesis had been shown to be important in MM, the effect of TGF-p-induced 
collagen production on MM growth was investigated by testing the second thesis 
hypothesis:
2) Autocrine TGF-p production by MM promotes malignant cell proliferation 
and tumour growth by enhancing collagen production.
Experiments in chapters 3 and 6 confirmed that MM cells produce highly elevated 
endogenous levels of TGF-p compared to normal mesothelial cells. Additionally, it 
was shown that the exogenous application of TGF-pi to MM cell cultures highly 
stimulated collagen production in a dose-responsive fashion, although the same range 
of concentrations also reduced cell proliferation. These responses to TGF-P may 
explain the extremely fibrous nature of MM (high collagen production) and the long 
latency period from initial asbestos exposure to disease presentation (inhibition of cell 
proliferation).
Characterisation experiments reVealed that MM produced elevated levels of TGF-p2 
compared with normal mesothelial cells, although in vitro isoform specific effects of 
exogenous TGF-p on cell proliferation were not observed. No alteration in cell 
proliferation or collagen production was seen with neutralising antibodies to specific 
TGF-p isoforms. Interestingly, in vivo inhibition of TGF-P2 resulted in a highly 
significant decrease in tumour weight at 15 days, which was not seen with TGF-pi 
inhibition, suggesting an important role for TGF-P2 in MM tumour growth, 
confirming previous studies (Fitzpatrick et al., 1994, Marzo et al., 1997). However, a 
similar reduction in tumour weight was observed with pan-specific neutralisation of 
all TGF-p isoforms at 14 days, albeit not to the same extent. There was a trend 
towards decreased collagen concentration in the TGF-p2  antibody treated tumours, 
and this was also observed in the pan-specific TGF-p antibody treated tumours with a 
significant decrease compared to the PBS control tumours.
These novel data showed that in vitro exogenous TGF-p decreased cell proliferation 
and that inhibition of endogenous TGF-P did not affect collagen production or 
proliferation. However, in vivo TGF-p inhibition delayed tumour growth and reduced
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the collagen concentration of the treated tumours. These results clearly demonstrated 
the importance of collagen in MM solid tumour growth, and the in vivo pan-specific 
TGF-p neutralising experiments indicated that TGF-p-induced collagen production 
may play a crucial role in tumour growth.
There is an intertwined relationship between the ECM and TGF-P in tumourigenesis, 
TGF-P stimulates matrix production (Coker et al, 1997) and the matrix acts as a 
reservoir sequestering latent TGF-p within the vicinity of the tumour (Boudreau and 
Bissell, 1998). The ECM and TGF-P have multiple roles in the enhancement of 
malignant growth (summarised in figure 8.1). It has been demonstrated that ECM 
components are capable of stimulating tumour cell proliferation, migration, invasion 
and metastasis (Tobin et al, 2001) as well as protecting tumours from 
chemotherapeutic agents (Sethi et al, 1999). TGF-P suppresses the host immune 
response (Fitzpatrick et al, 1994) and may also be involved in the suppression of 
apoptosis (Lei et al, 2002). TGF-p also stimulates angiogenesis (Breier et al, 2002) 
and the recruitment of ECM-producing stromal cells (Berking et al., 2002). Thus, as 
figure 8.1 demonstrates, inhibition of both collagen and TGF-p production could be a 
powerful means of attenuating MM tumour growth.
Collectively, the data in this thesis have demonstrated that inhibition of either 
collagen or TGF-p reduces MM tumour size with an associated decrease in tumour 
collagen concentration. This clearly shows that collagen-mediated growth is 
important in MM tumourigenesis, although figure 8.1 demonstrates that this is only 
one of several interacting processes promoting malignant growth. The localised 
nature of MM makes it suitable for antibody and pharmaceutical therapies; the pleural 
membranes would potentially contain introduced agents in the vicinity of tumour. A 
multimodal approach combining a collagen inhibitor in association with TGF-p 
neutralisation may prove highly beneficial in the treatment of this disease.
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Figure 8.1 Pro-tumourigenic properties of TGF-p and collagen in the MM tumour 
microenvironment. The interaction of TGF-P and ECM proteins creates a favourable 
environment in which malignant cells proliferate whilst evading host detection.
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8.2 Further studies
To confirm the importance of ECM to tumour growth, inhibition of Pi integrin, a 
major cell - ECM attachment molecule, could be achieved with a function blocking 
antibody and the effect on in vitro cell proliferation and in vivo tumour growth 
observed (Sethi et al, 1999).
Having determined an important role for TGF-p induced collagen production in MM 
tumour growth, the contribution of the other possible effects of inhibiting collagen or 
TGF-p could be investigated in more detail (figure 8.1). The tissue sections generated 
from the in vivo studies could be analysed by immunohistochemistry, vascular 
development in the murine model compared by staining for endothelial cell markers 
(Edwards et al., 2001). Differences in the immune response between treated and 
control tumours could also be assessed histologically by using antibodies specific to 
inflammatory cells such as B-cells, T-cells and macrophages (Fitzpatrick et al., 1994).
Further in vitro studies to determine the effect of collagen and TGF-P on other aspects 
of tumour growth such as invasion and migration could be performed. Rather than 
using the cell monolayer, culture models more representative of in vivo cell-cell and 
cell-ECM interactions such as 3D gels and tumour spheroid models could be used to 
mimic the tumour more accurately (Green et al, 2002).
The combined effect of inhibiting both collagen and TGF-p on MM proliferation and 
tumour growth could be investigated with a combination of thiaproline and TGF-P 
antibodies. The importance of TGF-p-induced collagen production in the growth of 
other cell lines in the panel of MM lines characterised, especially the human cell lines 
in conjunction with nude mice, could also be assessed. Also, the effect of TGF-P 
antibodies and / or collagen inhibition on the ability of chemotherapeutic agents to 
induce MM cell apoptosis could be investigated (Sethi et al, 1999).
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